

NEXUS
Knowledge Publication
Imprint of AKT Multitask Consultancy

PRECISION ONCOLOGY

Innovations in Diagnosis, Drug Delivery, And Patient Care

EDITORS

Dr. Sanjeev Kumar
Dr. Sanjana Bhagat
Dr. Sumit Bhatt
Dr. Farah Deeba

PRECISION ONCOLOGY

Innovations in Diagnosis, Drug Delivery, And Patient Care

EDITORS

Dr. Sanjeev Kumar

Dr. Sanjana Bhagat

Dr. Sumit Bhatt

Dr. Farah Deeba

NEXUS
KNOWLEDGE PUBLICATION
Imprint of AKT Multitask Consultancy

Imprint of AKT Multitask Consultancy

NEXUS KNOWLEDGE PUBLICATION

All rights reserved

Administrative & Production Office

NEXUS KNOWLEDGE PUBLICATION,

Imprint of AKT Multitask Consultancy,

Near Satbahinia Mandir, Arvind Nagar, Sarkanda Bilaspur, Chhattisgarh, India, Pin- 495006

ISBN: 978-81-985724-3-1

PRICE: Rs. 499/-

Manuscript Formatting By **Gijeesh Nair**
FIRST PUBLISHED BY NEXUS KNOWLEDGE PUBLICATION IN **2025**
PRINTED & BOUNDED BY JEC PRINTING TECHNOLOGIES (JEC PRESS UNIT)

DOI 10.5281/zenodo.17199086

ACKNOWLEDGEMENTS

The successful completion of this work, *"PRECISION ONCOLOGY: INNOVATIONS IN DIAGNOSIS, DRUG DELIVERY, AND PATIENT CARE"*, would not have been possible without the guidance, support, and encouragement of many individuals and institutions. We are deeply grateful to our mentors and academic supervisors, whose expertise and insightful feedback have significantly shaped the direction of this research. Their continuous encouragement inspired me to pursue new perspectives and maintain the rigour necessary for a study of this nature.

We extend our sincere thanks to the faculty members, colleagues, and peers who provided constructive suggestions and shared valuable knowledge throughout the course of this work. Their collaboration and willingness to engage in thoughtful discussions enriched the quality of my analysis. They helped me address complex dimensions of precision oncology, including diagnostic advancements, innovative drug delivery systems, and holistic patient care strategies.

We are also indebted to the institutions, research centres, and libraries that provided access to essential resources, literature, and databases, without which this work could not have been completed. Their contributions ensured that we had the academic and technical support required to explore this evolving field in depth.

Finally, we express our heartfelt gratitude to my family and friends for their constant encouragement, patience, and moral support throughout this journey. Their unwavering belief in our abilities has been a source of strength and motivation, enabling us to persevere and complete this work successfully.

Thank You

Dr. Sanjeev Kumar

Dr. Sanjana Bhagat

Dr. Sumit Bhatt

Dr. Farah Deeba

PREFACE

The field of oncology is undergoing a paradigm shift, moving from conventional, one-size-fits-all treatments toward personalized and targeted therapeutic strategies. This work, *"PRECISION ONCOLOGY: INNOVATIONS IN DIAGNOSIS, DRUG DELIVERY, AND PATIENT CARE"*, seeks to capture the essence of this transformation by exploring the scientific advancements and clinical practices that are redefining cancer care. The aim is to present a comprehensive overview of how precision approaches are shaping diagnostic accuracy, enhancing therapeutic delivery, and prioritising holistic, patient-centred outcomes.

This study emphasises the integration of molecular profiling, biomarker-driven therapies, and state-of-the-art drug delivery systems that have enabled oncologists to tailor treatments to the unique genetic and clinical profiles of patients. It also highlights the growing importance of patient well-being, survivorship, and equity in access to innovative cancer care. By bridging research insights with clinical applications, the work aspires to contribute to the broader understanding of how innovations in precision oncology can transform healthcare delivery.

The preparation of this work has been both a challenging and rewarding journey. It required extensive engagement with interdisciplinary literature spanning molecular biology, pharmaceutical sciences, clinical oncology, and patient-care frameworks. I hope this contribution provides useful insights to researchers, practitioners, and students interested in the evolving landscape of precision oncology.

Finally, this preface reflects my aspiration to shed light on the potential of precision oncology not only as a scientific advancement but also as a patient-centric approach that holds promise for more effective, equitable, and compassionate cancer treatment in the future.

Thank You

Dr. Sanjeev Kumar
Dr. Sanjana Bhagat
Dr. Sumit Bhatt
Dr. Farah Deeba

ABOUT THE EDITORS

Dr. SANJEEV KUMAR

Dr. Sanjeev Kumar is a **Senior Resident** in the Department of Biochemistry at ESIC Medical College & Hospital, Bihta, Patna. He completed his **M.D. in Biochemistry (Gold Medalist)** and **MBBS** from IGIMS, Patna. He holds an **Advanced Certification in Dermatology** from the British Association of Dermatologists (NHS/HEE, UK) and a **Master Diploma in Dermatology** from MGBIMS, Delhi.

Dr. Kumar also pursued a prestigious **Post Graduate Certificate in Advanced Healthcare Management** jointly offered by **IIM Nagpur** and **AIIMS Nagpur.** Additionally, he has successfully completed the **ICMR-certified Basic Course in Biomedical Research** and **Clinical Laboratory Management** under ISO 15189:2022 standards.

With over seven years of diverse clinical and academic experience, he has served as a **General Duty Medical Officer (GDMO)** & In-charge at DOS/East Central Railway and as a **Nodal Medical Officer** at Sadar Hospital, Jamui, Bihar. He is the **first recipient from Bihar** of the prestigious **ICMR-STS Research Grant** for his pioneering work on ELISA-based serodiagnosis. His research focuses on clinical biochemistry, immune-dermatology, biomarker discovery, molecular diagnostics, and AI-driven medical device innovation.

Dr. SANJANA BHAGAT

Dr Sanjana Bhagat, working as Assistant professor & HOD in the department of Biotechnology, Govt. Nagarjuna PG College of Science, Raipur, Chhattisgarh with 12 years of research and teaching experience. Published Thirteen research articles in peer reviewed journals. Strong technical knowledge in Cell Biology, Immunology and Genetic Engineering. Thesis focus on molecular identification sickle cell disease haplotypes analysis. Good working knowledge of sickle haplotypes identification and bioremediation of environment pollutant. Many dissertation works supervised under her guidance. Expertized to work in research environment like environment biotechnology and molecular Biology.

Dr. SUMIT BHATT

Dr. Sumit Bhatt, an assistant professor and PhD Scholar in the department of oral and maxillofacial surgery at Rajasthan Dental College and hospital under Nirwan University Jaipur, completed his MDS (Gold Medalist) in 2022 and BDS (Topper) in 2016. He has earned 16 university awards, including the Pierre Fauchard Academy and International College of Dentistry honors. Recognized as the Best Undergraduate Student by Guident, Bitein, and Famdent journals, Dr. Bhatt won the Pepsodent quiz in 2013. He holds more than 25 patents and copyrights both national and international. Dr. Bhatt has authored more than 50 publications and also holds editorial board member's position in various journals.

Dr. FARAH DEEBA

Dr. Farah Deeba is an Assistant Professor of Pharmacology at the School of Pharmacy, Sharda University, Greater Noida. She holds a Ph.D. and M.Pharm in Pharmacology from Jamia Hamdard, a premier NIRF-ranked institution. With over seven years of teaching and four years of research experience, she has authored 15+ publications in reputed journals, including high-impact factor papers, and has participated in 50+ conferences nationally and internationally. Her work has earned her several awards, including the Highest Impact Factor Publication Award (2021), Best Poster Award (SNCI), and the Scholar Guidance Award (2023). She is actively involved in academic events, workshops, and industrial visits. Her research focuses on the endocannabinoid system in diabetes and therapeutic interventions.

TABLE OF CONTENTS

Chapter 1…

INTRODUCTION TO PRECISION ONCOLOGY

Dr. DIBYA FALGOON SARKAR
MDS (Oral and Maxillofacial Surgery),
Fellowship in Oral Oncosurgery,
Kolkata, West Bengal.
Email: drdfsarkar@gmail.com

Dr. APEKSHA GHATGE
BAMS, MSc Medical Pharmacology, PhD Scholar, Lecturer,
Yogita Dental College, Khed, Ratnagiri, Maharashtra.
Email: dr_apekshaghatage@rediffmail.com

Dr. MAHESH D R
Professor
Department of Oral Medicine and Radiology,
Dayananda Sagar College of Dental Sciences,
Shavige malleshwara Hills KS Layout,
Bangalore, Karnataka.
Email: maheshdr@dscds.edu.in

Dr. SHEETAL SANJAY CHAVAN
Assistant Professor
Department of Public Health Dentistry, SMBT Dental College & Hospital,
Sangamner, Maharashtra.
Email: drschavan02@gmail.com

Dr. SHIVANI KONDHALKAR
Tutor
Department of Periodontology, Sinhgad Dental College and Hospital,
Pune, Maharashtra.
Email: shivanikondhalkar9996@gmail.com

Precision oncology, or personalized or stratified oncology, is a paradigm shift of cancer therapy and understanding. In contrast to the traditional model of disease treatment, which was based on the tumor type, location, stage, and histological peculiarities as the main factors, precision oncology goes deeper into the molecular and genetic background of the disease. Transcriptomic, proteomic, immune signature, and other biomarkers analysis can give the clinician a detailed view of the unique biology that drives the tumor in each patient. Such a molecular-level understanding enables oncologists to determine targeted therapies, immunotherapies, and combination regimens that are most likely to be effective with a particular patient and avoid exposing them to treatment that would be ineffective or too toxic. It also transcends treatment into early detection, prevention and risk stratification which allows more active and personalized treatment of cancer.



Figure 1: Precision oncology

Source: (https://www.nature.com/articles/nrclinonc.2013.244)

The general objective of precision oncology is to optimize therapeutic efficacy and patient survival and limit avoidable toxicity, side effects and financial burden. It is a holistic and patient-centered approach that considers medical decisions with reference to both biological markers and patient-specifics: overall health, co-morbidities, and personal preferences. The strategy improves life quality by lowering the exposure to untested interventions and increasing the response rate to individual therapies. Moreover, accuracy oncology is cost-effective because it focuses on procedures with a greater probability of success, and avoids wasteful

spending on wide-spectrum treatment. With future developments in next-generation sequencing, big data analytics, and biomarker discovery, precision oncology is establishing itself as a foundation of contemporary cancer treatment and may offer a future in which cancer treatment is not only more scientifically accurate, but also more human and patient-centric.

1.1. HISTORICAL EVOLUTION: FROM TRADITIONAL TO PERSONALIZED MEDICINE

The history of oncology is marked by a gradual change towards highly personalized care as opposed to the generalized one. During the early-stage, treatment of cancer was depending on the location of the tumor, morphology and staging with surgery, radiation and cytotoxic chemotherapy as the main instruments. Effective in a few of the cases, these approaches were mean, non-selective, and did not always reflect the diversity of tumors. A discovery-based change came with the late 20 th century, with breakthroughs in molecular biology and high-throughput technologies revealing the genomic cancer nature. The discovery of oncogenes, tumor suppressor genes and molecular subtypes showed that tumors with common histology might be biologically different and formed the basis of precision oncology. Targeted treatments such as imatinib in chronic myeloid leukemia and trastuzumab in HER2-positive breast cancer, as well as biomarker-based diagnostics such as PCR, FISH, and next-generation sequencing, pointed to the possibility of matching therapies with a molecular profile of a tumor.

The development of immunotherapy became one of the principal ones, where checkpoint blockers (antiPD-1, PD-L1, and CTLA-4) re-initiate the immune system to combat cancer. This period broadened the use of biomarkers to PD-L1 expression, microsatellite instability, mismatch repair deficiency and tumor mutational burden, and the first histology-agnostic approvals, including pembrolizumab in MSI-high tumors. Multi-omic profiling, single-cell and spatial technologies, liquid biopsies, and adaptive clinical trial designs (basket, umbrella, and platform trials) are considered the drivers of precision oncology today. These advances do not only enhance our knowledge of tumor heterogeneity and resistance, but also increase the speed of drug development and more patients receiving targeted treatment. The specialty has therefore become a systems level, patient-centered model, with biology and not anatomy dictating cancer care.

❖ **Early era — histology and empiricism**

The early years of oncology were characterized by the initiation of treatment based on the same pattern largely determined by anatomical location of the tumor (e.g., lung, breast, colon) and microscopic characteristics (histology). Pathology reports of tumor morphology, grading and staging were used by clinicians to decide on treatment. The most powerful tools were surgery, radiation therapy and cytotoxic chemotherapy and each one of them was meant to eliminate or reduce the size of a tumor by blindly attacking rapidly growing cells. Although these approaches helped to save more lives of numerous patients, they were commonly characterized by toxicities, inconsistent efficacy, and the lack of personalization, as they failed to consider the biological differences in tumors. Basically, the model was a mass-market model, which was rooted in empiricism more than in molecular knowledge.

❖ **Discovery-driven transition**

The shift of the paradigm started with radical developments in the late 20 th century. Ongcology was redefined by two related revolutions:

1. **Molecular biology and cancer genetics -**The identification of oncogenes (e.g., RAS, MYC), tumor suppressor genes (e.g., TP53, RB1), and cell signaling pathways out of control showed that cancer was not merely a disease of uncontrolled cell proliferation but a genomic disease that was caused by particular molecular changes.

2. **High-throughput technologies -**With the introduction of DNA sequencing, microarray-based methods of gene expression and protein profiling, researchers could now examine thousands of genes and proteins at once. This demonstrated molecular heterogeneity of cancer: a tumor that appeared the same under the microscope could appear biologically distinct, and could have they own weaknesses to therapy. This awareness formed the basis of the idea of molecular subtyping, and the ultimate personalization of therapies.

❖ **Targeted therapy and biomarkers**

Targeted therapies, drugs that disrupt specific molecule drivers necessary to tumor growth and survival, were developed in the late 20 th and early 21 st centuries. Landmark examples include:

- BCR-ABL BCR-ABL inhibitors (imatinib/Gleevec) in chronic myeloid leukemia that turned the once terminal disease into a manageable one.

- HER2-targeted therapies (trastuzumab/Herceptin) in breast cancer with HER2-positive cancer, which enhanced patients' outcomes in a subset. These achievements highlighted the fact that the process of locating and addressing actionable changes could produce radically and lasting reactions.

Simultaneously, there were parallel developments in diagnostic methods (immunohistochemistry, fluorescence in situ hybridization [FISH], polymerase chain reaction [PCR], and subsequently targeted next-generation sequencing [NGS] panels) to enable clinicians to test tumors on a biomarker basis, and to be assured of giving therapies based on their molecular makeup.

❖ **Immunotherapy and biomarker expansion**

The second revolution was that of cancer immunotherapy particularly immune checkpoint inhibitors such as PD-1, PD-L1 and CTLA-4. These drugs did not affect tumor cells directly as targeted therapies would but instead restored the functioning of the immune system in the patient to recognize and destroy cancer. Their success brought in the necessity of new biomarkers other than the genetic mutations including:

- PD-L1 on tumor/immune cells.
- Instability of micro satellites (MSI-high) and lack of mismatch repair (dMMR).
- Tumor mutational burden (TMB), which is a measure of the general tumor genomic instability.
- Notably, a few immunotherapies received histology-agnostic approval, which implied that they could be used across the cancers based on their molecular characteristics, not the site of the tumor (e.g. MSI-high tumours with pembrolizumab). This was a huge leap in the development of a real personalized medicine.

The approval of pembrolizumab in MSI-high cancers of any anatomical origin was notably the first histology-agnostic approval- solidifying the transition of precision oncology to focus less on site and more on the mutations and mechanisms that drive oncogenesis.

❖ **Current era — multi-omics, liquid biopsy, and adaptive trials**

Precision oncology today is described as a combined, systems-level approach:

- Multi-omic profiling (genomics, transcriptomics, epigenomics, proteomics, metabolomics) offers a system-wide understanding of tumor biology, and can help better understand how resistance is formed and therapy vulnerable points.

- Single-cell sequencing and spatial technologies enable the resolution of tumor heterogeneity and tumor microenvironment at a new level.
- Liquid biopsies with circulating tumor DNA (ctDNA) and circulating tumor cell analysis provide non-invasive means to follow the progression of the disease, identify small residual disease, and make real-time changes to treatment options.
- Adaptive clinical trial designs, including basket trials (testing a therapy in many different types of cancers with a shared biomarker), umbrella trials (testing many different therapies in a single type of cancer with different subgroups), and platform trials (flexible, evolving trial designs) have enabled faster drug development, and increased patient access to novel therapeutic options, particularly in response to rare genomic alterations.

It was notable that the pembrolizumab approval in MSI-high cancers of any anatomical origin became the first histology-agnostic approval -finalizing the history of precision oncology transitioning to site-independent treatment based on mutations and mechanisms.

1.2. CORE PRINCIPLES AND OBJECTIVES OF PRECISION ONCOLOGY

The premise of precision oncology is to provide highly personalized cancer treatment through detailing both biological and molecular characterization of the tumors. The genetic, transcriptomic and immunologic profiling of each patient cancer is performed to discover specific alterations which may be mutations, gene fusions or immune signatures. Such data facilitates the choice of biomarker-based therapies, whereby the most likely treatment regimen with maximum minimal toxicity is given to patients. Dynamical monitoring techniques, such as circulating tumor DNA and minimal residual disease methods, enable clinicians to monitor the tumor evolution in real time, thereby enabling prompt corrective changes in treatment plans and overall clinical results.

Key to precision oncology is combined, multidisciplinary decision-making, using molecular tumor boards, in which oncologists, geneticists, pathologists, and other experts discuss complex data to formulate clinically actionable treatment courses. Patient-centricity has been a fundamental goal and treatment is designed to meet the specific tastes, quality-of-life, and economic realities. The continuous creation of evidence via adaptive trials, real-world data registries and learning health systems is used to ensure that clinical knowledge continually changes in accordance with new knowledge. Collectively, these principles render precision

oncology a dynamic, evidence-based and patient-centered paradigm, shifting cancer care away to a one-size-fits-all model, and instead to a precise, patient-centered model.

❖ ***Core principles***

Precision oncology aims to personalize cancer care by molecular profiling, biomarker-directed therapy, and dynamic monitoring with multidisciplinary decision-making, patient-centered care, and ongoing evidence generation through learning health systems.

- **Individualized biological characterization:** Precision oncology focuses on cancer molecular and genetic character, and not just histology or anatomical location. Tumors are profiled to reveal somatic mutations, gene fusions, copy-number changes, epigenetic modifications, expression signatures as well as immune microenvironment features. Such a personalized biological description enables clinicians to value the molecular fingerprint of each tumor and establish the basis of customized treatment.
- **Biomarker-based therapy choice:** Predictive biomarkers help clinicians to make the right drug choice on the right patient. Indicatively, EGFR mutations in lung cancer indicate predictable sensitivity to EGFR tyrosine kinase inhibitor, whereas ALK fusions indicate predictable benefit to ALK inhibitors. On the other hand, adverse biomarkers may prevent futile or toxic therapies. This concept optimizes the effectiveness of treatment in addition to minimizing unnecessary toxicity and expenditures.
- **Dynamic monitoring:** Precision oncology is not a single decision but a permanent journey. It is monitored by techniques like the circulating tumor DNA (ctDNA) assays, minimal residual disease (MRD), and serial imaging to determine tumor changes over time. Such dynamic monitoring would allow the early relapse to be detected, the emergent resistance mutations to be identified and the therapy adjusted promptly away from fixed treatment regimens towards the real-time personalization of treatments.
- **Multidisciplinary, integrated decision-making:** Molecular data is very complex and thus needs to be interpreted collaboratively. Molecular tumor boards (MTBs), which include oncologists, molecular pathologists, geneticists, bioinformaticians and pharmacists, are involved in the review of genomic reports, clinical setting and therapeutic options. Such boards make sure that the decisions are based on science, are relevant to clinical attributes, and are practical in the care environment of the patient.

- **Patient-centricity and shared decision-making:** Beyond biology, the patient-centric approach to oncology is based on the personal values and treatment preferences of the patient, as well as socio-economic realities. Topics that are discussed are toxicity tolerance, quality-of-life priorities, drugs accessibility, and monetary costs. This will make treatment decisions not only biologically correct, but also in accordance with the principles of patient-centered care.
- **The evidence and learning health systems:** A lot of the genomic changes are infrequent and not widely covered by the randomized trials. Precision oncology is thus based on adaptive clinical trials, registries and real-world evidence platforms to enable ongoing creation of knowledge. Learning health systems allow clinicians to input de-identified patient data and enhance evidence-generation around rare variants and novel drug combinations, plus a feedback loop around improved clinical practice.

❖ ***Primary objectives***

Precision oncology enhances by improving outcomes by matching therapy to tumor biology, decreasing toxicity, enable early detection of relapse and overcome resistance, and add therapeutic options to rare subtypes and increase cost-efficiency by directing resource utilization.

- **Enhance efficacy through tumor biology matching therapy:** Personalized therapies have ensured that therapies are matched to unique molecular weaknesses of a tumor of a patient. Such a fit increases the efficacy of treatment, leading to an increase in response rates, progression-free survival, and the overall outcome in comparison with other, more traditional, non-targeted methods.
- **Reduce toxicity and overtreatment:** Precision oncology can save a patient the hassle of being subjected to ineffective therapies by determining which therapies have little or no likelihood of benefiting the patient. This will minimize the number of adverse effects, hospitalizations, and overall burden of treatment, increasing the quality of life of patients.
- **Earlier detection of relapse or recurrence (MRD monitoring):** Molecular monitoring, like monitoring minimal residual disease (MRD), can help identify relapse or progression before it manifests in an imaging-based observation. Timely intervention enables clinicians to modify the treatment in a timely manner, which may enhance the

long-term results and even prevent the development of the full-scale disease development.

- **Prevent or overcome treatment resistance:** Clinical researchers can use insights into resistance mechanisms by secondary mutations, circumventing signaling pathways, and phenotypic plasticity to conduct therapies in a strategic manner or employ combination therapies. This preventive therapy has the power to stretch the length of treatment gain and postpone disease advancement.
- **Make rare molecular subtypes and histology-agnostic cases treatable:** Precision medicine has made available new targeted therapies to patients with unusual molecular alterations or histology-agnostic tumors, including tumors with NTRK fusions. This increases the scope of treatment among underserved patient groups in the past.
- **Cost-effectiveness:** Optimize the use of therapeutic resources: Precision oncology can help cut down painful spending on irrelevant treatments by directing therapeutic resources to interventions with the highest probability of success. The practice does not only improve patient outcomes but it promotes sustainable healthcare provision and use of clinical resources effectively.

❖ ***Typical clinical workflow***

Precision oncology is a step process, which involves collecting tumor or liquid biopsy samples, molecular testing and interpreting data supported by bioinformatics, which is followed by professional review of the tumor board. On this basis, patients are given customized therapies or trial alternatives, and continuing monitoring is done using imaging and biomarkers to make a dynamic adjustment to treatment.

1. **Sample & data acquisition:**

Precision oncology begins with the acquisition of high-quality biological material on which to run its analyses. In a traditional approach, this is done by means of tumor tissue biopsies, which allow direct access to cancer cells. Nevertheless, when insufficient tissues, inaccessible tissues, or repeated sampling is necessary, liquid biopsies- the analysis of the circulating tumor DNA (ctDNA) or circulating tumor cells (using blood plasma) are becoming more common. Also, the germline DNA samples (blood or saliva) can be provided when the hereditary cancer syndromes are suspected to separate between inherited and tumor-specific changes.

2. **Molecular testing:**

After samples are gathered, there are various molecular tests that can be used based on the clinical requirement and resources. This can be targeted next-generation sequencing (NGS) panels to measure actionable mutations; whole-exome or whole-genome sequencing to measure extensive genomic profiles; RNA sequencing to measure fusion detectors, expression patterns; immunohistochemistry (IHC) to measure protein expression (e.g., HER2, PD-L1); fluorescence in situ hybridization (FISH) to measure gene amplification or rearrangements; methylation profiling to measure epigenetic markers. This step produces an effective molecular dataset upon which precision treatment is based.

3. **Bioinformatic analysis & interpretation:**

The raw molecular information is subjected to sophisticated bioinformatics pipelines to determine genetic variations, structural rearrangements, and changes in expression as well as in epigenetics. Every change is marked with its pathogenic and therapeutic interest, and it is possible to distinguish between driver mutations, passenger mutations, and variants of uncertain interest. Analysis identifies actionable targets, prognoses sensitivity or resistance to particular therapies and produces a clinically interpretable report that oncologists can employ in decision-making.

4. **Molecular tumor board review:**

Due to the fact that the complexity of genomic data is often beyond the knowledge of individual clinicians, multidisciplinary molecular tumor boards (MTBs) are assembled. These are oncologists, molecular pathologists, geneticists, bioinformaticians, and pharmacists, with all of them consulting the genomic results and analysing them relative to the clinical history of the patient, the type of tumour, previous treatments and comorbidity. The agreement of the board makes sure that treatment recommendations are scientifically valid, clinical feasible, and in line with patient-specific requirements.

5. **Treatment selection & access:**

According to the recommendations of the MTB, patients are paired with specific-targeted therapies, immunotherapies, or applicable clinical trial opportunities. In the absence of approved options, off-label drug use can be an option provided that it is accompanied by molecular rationale and clinical evidence. Treatment may also imply a process of negotiating

regulatory approvals, insurance access, and pricing, and thus this step is an important interface point between science and the healthcare systems.

6. **Monitoring & adaptation:**

Precision oncology is not a static situation. Monitoring of treatment responses includes imaging studies, serum biomarker, and more recently, liquid biopsy assays that can follow ctDNA as a disease burden and resistance marker. Identifying minimal residual disease (MRD) or emerging resistance mutations at an early stage enables timely adjustment of treatment plans, including sequencing therapy, combination therapy, or trial alternative, such that treatment is adaptive and individualized over the course of the disease.

❖ ***Key practical concepts***

Limitations of clinical actionability of most variants, clonal heterogeneity within tumors, and resistance mechanisms are among the challenges that Precision oncology is facing. It also calls on the ability to differentiate between somatic and germline mutations that have consequences both in treatment and in hereditary risk management.

- **Actionability:** Not all genomic changes can be taken clinical action. Most of them are classified as variants of uncertain significance (VUS), which may only undergo additional research before they can be applied in treatment. The availability of therapies, the strengths of evidences, and approval status determine the clinical actionability.
- **Clonal heterogeneity:** Clonal heterogeneity is characterized by common occurrence of more than one subclone within a particular tumor with different genetic mutations. One biopsy might not reflect on this diversity resulting in incomplete molecular profiling. Efforts such as multi-region sampling or liquid biopsies are useful in overcoming this obstacle.
- **Cancers often resist in multiple ways (including, but not limited to):** secondary mutations of the target gene (e.g., T790M in EGFR), activation of bypass signaling pathway(s) (e.g., MET amplification), phenotypic changes (e.g., epithelial-to-mesenchymal transition), or immune evasion. Handling resistance involves sequential therapy, combination therapies that are rational and monitoring.
- **Germline vs somatic:** Precision oncology separates somatic mutations (only tumor cells have restricted sets of mutations) and germline mutations (inherited and found in

all cells). Germline discoveries, e.g. BRCA1/2 mutations, are information that has applications in hereditary cancer risk, family counseling and prevention measures, as well as determining treatment options (e.g., PARP inhibitors).

1.3. SCOPE ACROSS CANCER TYPES AND STAGES

Precision oncology is applicable to the whole range of cancer treatment, providing patient-centered interventions at all phases of the disease. Molecular profiling in early-stage cancers can inform adjuvant therapy with the aim to determine patients who may benefit most of the treatment after surgery. Further, the use of minimal residual disease (MRD)-centered approaches helps to identify microscopic disease that might persist after treatment and intervene at the earliest stage to minimize the probability of relapse. These methods do not only help in refining treatment selection but also reduce exposure to treatment that is not vital thus preventing toxicity and loss of quality life to patients.

In the locally advanced and metastatic cancers, precision oncology promotes the use of biomarker-guided combination therapy, which is created to ensure treatment efficacy and reduce adverse effects. In unusual, or hard-to-treat malignancies, molecular and immunologic profiling makes it possible to target therapies, immunotherapies, or participate in novel clinical trials previously unavailable. This population of patients with traditionally limited therapeutic options has better outcomes due to the combination of treatment with the unique genetic and immunological properties of tumors. All in all, precision oncology offers a dynamic model of individualized care, enhanced treatment response, and increased clinical opportunities in cancer types and stages.



Figure 2: The ABCs and 123s of Cancer Stages

Sources: (https://www.lanermc.org/community/lane-health-blog/the-abcs-and-123s-of-cancer-stages)

There is also a range of cancer types and patients where precision oncology can be applicable. Strategies are tailored to hematologic malignancies as opposed to solid tumors and to pediatric cancers, in which there are special considerations of genetic and developmental factors that determine the choice of therapy. In addition to treatment, precision oncology can be used in the prevention and risk stratification by performing germline tests and individualized screening programmes. The combination of molecular knowledge and aspects of the individual patient enables earlier interventions, more effective monitoring and more effective specific treatment approaches, thereby ensuring that cancer management is more accurate, proactive and personalized at all stages of the disease and in all its forms.

- ***Early-stage disease (curative intent)***

Oncology, Precision oncology in early-stage cancers, the aim is to cure, and precision oncology supports the refinement of perioperative and adjuvant approaches. The use of biomarker-guided escalation (including the addition of specific or immune-based treatment to high-risk patients) and de-escalation (preventing unnecessary treatment in the low-risk group) is increasingly embraced. E.g., in breast cancer, HER2 or hormone receptor status guides adjuvant therapy choice, and, in lung cancer, adjuvant EGFR inhibitors can be given to EGFR-mutated tumors following surgery. One of the significant emerging instruments is minimal residual disease (MRD) detection with ctDNA, which may identify microscopic disease post-operative or chemotherapy and subsequently customize the need, intensity, and period of adjuvant therapy.



Figure 3: Early-Stage Cancers

Sources: (https://www.researchgate.net/figure/A-visible-lesion-that-remained-an-early-stage-cancer-after-36-months-Left-picture-IIa_fig3_304630008)

- ***Locally advanced disease***

Precision oncology is used to inform combination strategies in cancers that are locally advanced but might be cured. Molecular profiling can support radio sensitization opportunities (e.g., repairing DNA repair pathways to boost the efficacy of radiotherapy) and allows the combination of targeted or immune agents with chemoradiation. In cancer types such as rectal or head-and-neck cancers, organ-specific biomarkers inform organ-preservation techniques and reduce morbidity with no harm to survival rates. Therefore, the decisions which are precision-guided moderate aggressive therapy and long-lasting functional outcomes.

- ***Metastatic disease (palliative/long-term control)***

Precision oncology has the most mature applications in advanced or metastatic cancers in which a treatment option is used to extend life and preserve quality of life. Targeted treatments (e.g., EGFR, ALK, ROS1 inhibitors in lung cancer; BRAF inhibitors in melanoma; PARP inhibitors in ovarian cancer) and immunotherapies (e.g., checkpoint inhibitors of PD-L1+ or MSI-high tumors) are being regularly paired with molecular changes. Notably, histology-agnostic approvals, including NTRK fusions or high levels of microsatellite instability have broadened the therapeutic potentials of patients with rare underlying genomic drivers, irrespective of the site of tumor origin.



Figure 4: Metastatic Cancers

Source: (https://www.cureus.com/articles/49635-cutaneous-metastatic-cancer-carcinoma-hemorrhagiectoides-presenting-as-the-shield-sign#!/)

Hematologic malignancies vs solid tumors

Hematologic malignancies are frequently associated with clear genetic drivers that render them highly susceptible to targeted therapies. As an example, in chronic myeloid leukemia (CML) BCR-ABL fusion protein can be blocked successfully by tyrosine kinase inhibitors, in acute myeloid leukemia (AML) FLT3 mutations can dictate the use of specific FLT3 inhibitors, and in some lymphomas, BTK dependency can be used to precisely block B-cell receptor signaling. The comparative genetic ease and accessibility of these cancers in the blood or bone marrow allow rapid application of molecular targeted interventions, which in most cases produce impressive clinical effects and better survival rates.

By contrast, solid tumours are more complex biologically in terms of space heterogeneity, tumor microenvironmental effects, and subclonal diversity within tumour lesions. These aspects are problematic to the process of recognizing and taking advantage of actionable molecular targets. However, precision oncology methods are finding greater application to solid tumors, with thorough profiling of diverse mutations, amplifications, or pathway dependencies that can be therapeutically exploited, possible via next-generation sequencing (NGS) and other molecular profiling techniques. Although approach to targeted strategies varies with the biology of tumors and accessibility to the tissues, the overall objective is the same: to pair the appropriate therapy with the individual molecular features of the patient, enhancing specificity of therapy, its effectiveness, and overall outcomes.

Pediatric cancers

In contrast to the situation with adult cancers, the burden of mutation and driver patterns in pediatric tumors vary dramatically. The number of somatic mutations is usually lower in pediatric cancers, however, these cancers can have highly specific genetic changes that propel tumor progression. Such examples are ALK mutations in neuroblastoma and fusion-driven events in other sarcomas, which can be addressed as actionable targets of therapy. Due to this unique molecular profile, accurate oncology in children needs to identify these essential changes with special attention to maximize the results and create a treatment choice. More sophisticated methods of sequencing and molecular profiling technologies are finding their way into pediatric oncology, with the ability to offer more personalized and precise treatment.

The application of precision oncology in pediatric clinical trials is increasingly possible, and programs such as the Pediatric MATCH trial indicate that it can be feasible to assign biomarker-guided therapies. Nevertheless, pediatric patients are vulnerable and require special

considerations because of the unique vulnerabilities. Targeted and immune-based therapies are of special interest in long-term toxicities, which may affect growth, development, and general quality of life. Decisions about treatment in children are thus a balance between the possible survival advantage and the risks of adverse effects and effective monitoring and long-term follow-up of treatment are key elements in pediatric precision oncology programs.

- ***Rare cancers & tumor-agnostic indications***

In the past, in most rare cancers patients have had scarce therapeutic options because of low trial enrolment and little commercial interest in drug development to treat these rare cancerous diseases. Traditional methods tended to produce an inferior result, which meant that these groups were under-served. The introduction of precision oncology has changed this situation to allow the use of molecularly guided treatment strategies even in low-incidence cancers. Basket trials, where patients are recruited on the basis of common molecular changes and not on tumor type, and platform studies have paved the way to assess targeted therapy in these hitherto neglected patient groups. These new trial designs enable the researchers to study the effectiveness of drugs on several types of cancer at once, speeding up the potential of effective treatment to patients with rare tumors.

Tumor-agnostic therapies are an example of the potential of molecularly driven oncology, whereby treatment choices are made based on unique genetic or molecular characteristics and not on the tissue of origin. Prominent examples are therapies that address NTRK fusion-positive tumors or microsatellite instability-high (MSI-H) tumors, which have shown clinical effect on a broad range of tumor types. The treatment of patients with rare or traditionally incurable cancers can provide new treatment opportunities through this technique because it is based on the molecular signature of the tumor and not its location. These approaches demonstrate the shift in oncology paradigm in which precision medicine can be used to provide increased applicability, individualized treatment, and potentially better patient outcomes because they were previously limited in treatment choices.

- ***Prevention and risk stratification***

Precision oncology is not used only in the treatment, but it is also pertinent in prevention and early cancer diagnosis. Germline genetic tests can be used to identify patients with inherited cancer predispositions, including BRCA1/2 mutation carriers or BRCA2 Lynch syndromes. Identifying these high-risk individuals means active intervention can be done such as increased surveillance, risk-reduction surgeries or chemoprevention, based on their unique genetic

profile. These measures have the potential to be much more effective than cancer treatment; they can decrease morbidity and mortality by preventing cancer progression, which proves the preventative strength of precision oncology.

In addition to personal testing, the population-based risk stratification is becoming more informed by polygenic risk scores and molecular models that would help to better inform the intensity of screening and tailor the prevention measures. As an illustration, BRCA mutation carriers can experience earlier and more frequent breast imaging, and Lynch syndrome mutation carriers are on harder colonoscopy regimens. Such methods enable clinicians to use resources effectively and target preventive measures where they are most applicable as well as reduce unnecessary interventions to low risk groups. By so doing, precision medicine can not only expand its influence on treatment, but also on prevention, creating a care continuum that ensures the prevention of cancer, but at the same time maximizes patient outcomes.

1.4. GLOBAL TRENDS AND RESEARCH PRIORITIES

The use of state-of-the-art technologies, like multi-omics profiling, single-cell and spatial analyses, liquid biopsies, and artificial intelligence (AI) has grown to be the driving force in global trends in precision oncology. Such strategies allow clinicians and scientists to get an in-depth insight into tumor biology and personalize the treatment, as well as track tumor dynamics in real-time. The data sharing via the cloud also enhances the speed at which the knowledge is disseminated, leading to research collaboration across the borders of institutes and countries. The combination of these innovations aid in the discovery of novel resistance mechanisms, adaptive therapeutic approaches, and patient specific outcomes as treatments are customized to the molecular and cellular properties of individual tumors.

Simultaneously, the research priorities are changing to accommodate scientific and systemic issues in precision oncology. Newer clinical trial designs such as adaptive, combination therapy and N-of-1 studies are utilized in order to speed up drug testing and the strategies to treat patients in ways that are optimal. At the health system level, the focus is made on offering fair access to complex diagnostics and therapies, adjusting regulation systems to new trial designs, cost-effectiveness, clinical utility evaluation, and ethical implementation of interventions. All these priorities are intended to help bring technological improvements positively to the care of patients and reduce inequalities and capitalize on the effect of precision oncology globally.

❖ Technological and Data Trends

The latest developments in multi-omics, spatial omics, liquid biopsies, AI, and cloud-based data sharing allow personalized and detailed tumor profiling, real-time monitoring, and predictive modeling, so innovations in the field will push towards more effective and personalized treatment of cancer.

- **Multi-omics and single-cell technologies:** Recent technological developments in genomics, transcriptomics, proteomics, metabolomics and epigenomics enable investigators to measure several layers of molecular information on tumors simultaneously. Single-cell sequencing offers a resolution to heterogeneity in tumors that has never been observed before, showing variability in gene expression, mutation patterns and cellular states even among tumor cells adjacent to one another. These differences are important to understand so that resistant subclones can be identified, disease progression can be predicted, and treatment can be individualized to each tumor ecosystem.
- **Spatial omics:** Spatial transcriptomics and proteomics provides a map of the physical positioning of cells in the tumor microenvironment. These methods will show cell cell interactions, immune infiltration patterns, and internal structure of tumors by retaining spatial context. Such understanding can be used to understand why certain areas of a tumor are sensitive to treatment and others are not, informing more efficient, targeted treatment.
- **Liquid biopsies:** Liquid biopsy technologies rely on circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs) to continuously monitor tumor dynamics with nonexploitative methods. They facilitate the early discovery of cancer, monitoring of minimal residual disease (MRD) post-surgery or therapy and discover novel resistance mutations. Liquid biopsies of serial sampling give a real time picture of the tumor evolution, and hence timely therapeutic corrections can be made.
- **AI and machine learning:** AI and machine learning (ML) are finding more and more applications to analyze varied extensive molecular data, predict phenotypes, model drug responses, and find patients who would respond better to specific clinical trials. These algorithms have the potential to combine genomic and clinical and imaging information to produce actionable insights more quickly than traditional approaches and thus accelerate precision oncology workflows.

- **Cloud and federated data sharing:** Collaborative systems and cloud-based systems enable the sharing of big oncology datasets across institutions in a secure manner and maintain patient privacy. The federated learning methods can be used to create predictive models based on decentralized data without necessarily comingling sensitive data. The method improves the identification of rare biomarkers, cross-population validation of molecular signatures, and facilitated research reproducibility.

❖ **Clinica and Trial Design Trends**

The combination of therapies, innovative trial designs, including adaptive, platform, basket, umbrella, and N-of-1, allow both personalized and efficient testing of targeted strategies and treatments to overcome resistance in cancer.

- **Adaptive trials, platform trials, basket trials, and umbrella trials:** New trial designs are more effective in addressing targeted therapies. With adaptive trials, one is able to make adjustments based on initial findings. Platform trials are trials in which more than one treatment is tested on a common control group. Basket trials compare a single therapy in a wide range of tumor types with a common molecular feature, whereas umbrella trials compare more than one therapy in a tumor type stratified by sub-groups based on their molecular characteristics. Such designs speed up the process of identifying effective treatments and limit patient exposure to non-effective treatments.
- **Combination strategies: Immunotherapies:** Combinations of targeted agents, immunotherapies and epigenetic drugs are a major strategy to overcome primary and acquired resistance. The combinations are rationally dictated by a knowledge of molecular pathways, tumor heterogeneity, and immune evasion. The strategies are geared towards greater efficacy, increased response time and elimination of tumor adaptation.
- **n-of-1 and precision trial designs:** N-of-1 trials are conducted when the patient has a unique or rare molecular profile, and in this case, the treatment regimen is wholly personalized. Every patient is his or her own control, and it is possible to evaluate extremely individualized treatment options. These types of designs are becoming more and more applicable because molecular profiling is discovering patient-specific actionable mutations that are not reflected in larger populations.

❖ Implementation and System-Level Priorities

The safe and sustainable adoption of precision oncology in the global arena requires equitable access, adjustment of regulations, cost-effectiveness, clinical utility, and ethical supervision to be ensured.

- **Equity and access:** Inequality in molecular testing and access to targeted therapies as well as engagement in clinical trials is still critical globally. There is a need to work towards equality in access to precision oncology particularly in low- and middle-income nations and underserved groups living in high-income areas.
- **Regulatory frameworks:** Regulators are adjusting to tumor-agnostic drug approvals, in which drugs are endorsed depending upon molecular markers, as opposed to tumor type. The standardization of companion diagnostics and agreement on testing criteria is a key to uniform patient selection and safe application of precision therapy.
- **Cost-effectiveness and reimbursement models:** Health systems and payers need evidence that precision-guided care is cost-effective to make a change and the outcomes of such care are better. Value-based reimbursement models, and cost-effectiveness studies are needed to support the broad application of molecular diagnostics and targeted therapies.
- **Clinical utility and outcomes:** Strong evidence supporting that molecularly directed interventions enhance survival, quality of life and use of healthcare resources is essential. Clinical outcomes combined with patient-reported outcomes and economic analysis as longitudinal studies provide information to inform clinical practice and policy decisions.
- **Ethical, legal and social concerns:** Precision oncology entails a number of ethical issues such as informed consent to genomic sequencing, data protection, handling of incidental germline findings, and resource priority. Resolving these concerns will guarantee the trust of the patients and fair use of new technologies.

REFERENCES

1. Fountzilas, E., & Tsimberidou, A. M. (2018). Overview of precision oncology trials: challenges and opportunities. *Expert review of clinical pharmacology*, *11*(8), 797-804.
2. Rulten, S. L., Grose, R. P., Gatz, S. A., Jones, J. L., & Cameron, A. J. (2023). The future of precision oncology. *International Journal of Molecular Sciences*, *24*(16), 12613.
3. Doroshow, D. B., & Doroshow, J. H. (2019). Genomics and the history of precision oncology. *Surgical oncology clinics of North America*, *29*(1), 35.
4. Yates, L. R., Seoane, J., Le Tourneau, C., Siu, L. L., Marais, R., Michiels, S., ... & Andre, F. (2018). The European society for medical oncology (ESMO) precision medicine glossary. *Annals of Oncology*, *29*(1), 30-35.
5. Le Tourneau, C., Kamal, M., & Bièche, I. (2018). Precision medicine in oncology: what is it exactly and where are we?. *Personalized Medicine*, *15*(5), 351-353.
6. Mateo, J., Steuten, L., Aftimos, P., André, F., Davies, M., Garralda, E., ... & Voest, E. (2022). Delivering precision oncology to patients with cancer. *Nature medicine*, *28*(4), 658-665.
7. Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiss, A., Lichter, P., & Kurzrock, R. (2023). The coming decade in precision oncology: six riddles. *Nature Reviews Cancer*, *23*(1), 43-54.
8. Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A. L., ... & Stenzinger, A. (2019). Variant classification in precision oncology. *International Journal of Cancer*, *145*(11), 2996-3010.
9. Ibarrola-Villava, M., Cervantes, A., & Bardelli, A. (2018). Preclinical models for precision oncology. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, *1870*(2), 239-246.
10. Karimanal, H., & Bandaru, D. (2024). A review on integration of Precision Medicine in Oncology Practice. *Journal of Pharma Insights and Research*, *2*(3), 016-022.
11. Song, I. W., Vo, H. H., Chen, Y. S., Baysal, M. A., Kahle, M., Johnson, A., & Tsimberidou, A. M. (2023). Precision oncology: evolving clinical trials across tumor types. *Cancers*, *15*(7), 1967.
12. Kamran, S. C., & Mouw, K. W. (2018). Applying precision oncology principles in radiation oncology. *JCO Precision Oncology*, *2*, 1-23.
13. Badve, S., & Kumar, G. L. (Eds.). (2018). *Predictive biomarkers in oncology: applications in precision medicine*. Springer.

14. Walter, W., Pfarr, N., Meggendorfer, M., Jost, P., Haferlach, T., & Weichert, W. (2022, September). Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. In *Seminars in cancer biology* (Vol. 84, pp. 3-15). Academic Press.
15. Rocca, A., & Kholodenko, B. N. (2021). Can systems biology advance clinical precision oncology?. *Cancers*, *13*(24), 6312.

Chapter 2…

GENOMIC AND MOLECULAR PROFILING IN CANCER

RASHMI CHANDA
Assistant Professor
Faculty of Pharmaceutical sciences,
ShriBalaji Institute of Pharmacy and Research Centre,
Raipur, Chhattisgarh, 492001
Email: Rashmichanda722505@gmail.com

SHIVANGI SHARMA
Assistant Professor
Shaheed Bhagat Singh College of Pharmacy, Palampur, HP, 176061
Email: ssharma09@gmail.com

AYUSHI SAXENA
Assistant professor
Varun Arjun College of pharmacy
Pin - 242001
Email: ayushisaxena401@gmail.com

MONIKA KASHYAP
Assistant Professor
Institute of Pharmaceutical Sciences, IET Bhaddal
Pin - 140108
Email: mk32ei@gmail.com

Mr. PRATIK TERSE
Designation- Assistant Professor
Shree Pushpasen Sawant College of Pharmacy, Kudal. Maharashtra.
Pin- 416521
Email: pratikterse@gmail.com

The core of the practice of precision oncology is genomic and molecular profiling, which gives a more precise idea on the specifics of each tumor. Through the DNA, RNA, protein expression, and epigenetic alterations in cancer cells, clinicians will be in a position to recognize actionable mutations, gene amplifications, or pathway dysregulations that promote tumor development. The resulting molecular understanding can be used to design individualized treatment regimens, and designed therapies can be tailored to the tumor profile as opposed to depending on the tissue of origin or the histological classification.



Figure 1: Genomic Profiling

Source: (https://link.springer.com/protocol/10.1007/978-1-4939-8639-2_14)

State-of-art technologies, including next-generation sequencing (NGS), whole-exome sequencing, RNA sequencing, and proteomic analyses, enable profiling of tumors on a scale that has never been reached before with unprecedented depth and resolution. Such tools not only identify somatic mutations, copy number variations, but also show fusions of genes, epigenetic alterations, and tumor mutational burden, which can also be used to affect treatment choices. The combination of multi-omics techniques can further be used to improve the knowledge of tumor heterogeneity, resistance mechanisms, and dynamic development of cancer cells and design more effective and adaptive regimes.

Genomic and molecular profiling has a clinical role in decision-making in different phases of cancer management, such as early disease detection and planning on how to handle advanced cancer. It allows identifying patients with a high probability of response to specific therapies, immunotherapies or a combination of the two and tracking response using biomarkers or circulating tumor DNA. Also, the profiling strategies can offer essential knowledge to clinical trial recruitment to guide patients to precision-mediated interventions and lead to the overall advancement of novel therapies. Genomic and molecular profiling is the future of individualized, outcome-oriented cancer treatment by blending technology and clinical application.

2.1. NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES

Next-Generation Sequencing (NGS) is an open-ended innovation in genomic technologies where the analysis of millions of DNA fragments in a single step has become possible. Contrary to conventional Sanger sequencing, where DNA is read sequentially, NGS can be massively paralleled, with significant data output and at a significantly lower price/base. The technology enables profiling of the genome, transcriptome, epigenome on a large scale, and it gives a multidimensional picture of tumor biology. NGS has formed the basis of precision oncology by identifying actionable mutations, gene fusions, copy number changes and other molecular abnormalities, enabling the discovery of molecular drivers that can be directly targeted with precision immune-based therapy.

NGS gives oncologists an opportunity to develop personalized treatment plans in clinical practice, identifying patient-specific genetic alterations and anticipating patient responses to therapy. It can also be used in longitudinal disease surveillance, identifying any resistance mutation emerging, or any form of clonal descent with time. In addition to informing the choice of targeted therapies, NGS is used to inform enrollment in the appropriate clinical trial, assists in risk stratification, and improves early diagnosis of complex or low-frequency cancer. NGS has transformed the practice of cancer management, which was in an interim between molecular understanding and the need to make tailored therapeutic decisions.

Types of NGS in Cancer

1. **Targeted Gene Panels**

Gene panels are specially created to examine a specific set of genes that are known to be of key importance in cancer formation and growth. These panels normally consist of 50 to 500

genes, which have been chosen on a robust basis of evidence showing their association with tumorigenesis, response of treatment or prognosis. They target identifying important genomic changes including single nucleotide changes (SNVs), small insertions and deletions (indels), copy number changes (CNVs), and particular rearrangements of structures that are clinically relevant. Technology The targeted panels, by focusing on a selected group of genes, obtain a high depth of sequencing and thereby is sensitive and can identify low-frequency mutations that would otherwise be missed with more genomic techniques. The combination of such a high coverage makes them especially useful in clinical decision-making, where even rare but therapeutically interesting mutations can be with high confidence detected.

The adoption of targeted gene panels has become a common practice in regular oncology practice because these methods have unique practical benefits as compared to larger genomic profiling methods. They are cheaper and their turnaround times are quicker and this is necessary in clinical setting because of quick treatment decisions. The data produced by these panels could be directly used to inform therapy choice, such as the use of targeted or immunotherapies or combination therapy based on the tumor profile of an individual. Since the panels concern well-characterized, actionable mutations, the outputs are very useful in the care of patients and aid oncologists prioritize interventions meeting a proven clinical benefit. Also, they are designed with a narrow focus so as to reduce the chances of identifying variants of uncertain value that may complicate interpretation and postpone treatment. Altogether, the targeted gene panels represent a trade-off of precision, speed, and clinical relevance, so they are a staple of individualized cancer treatment.

2. Whole-Exome Sequencing (WES)

Whole-exome sequencing (WES) is sequencing of the entire set of protein-coding sequences of the genome, the exome. Though these regions constitute only approximately 12 percent of the human genome, they are home to most mutations identified to cause disease, including most cancer-promoting mutations. WES can give a holistic picture of the possible coding variants, and allows the detection of both common and rare mutations, which can be overlooked with targeted gene panels. This renders it especially useful in the discovery of new or unusual mutations, broadening the knowledge base on tumor biology, and the possible genetic factors behind the development of cancer. WES enables researchers and clinicians to produce a more comprehensive mutational picture of a tumor by analyzing the entire exome, which can provide insight into complicated genomic changes, and their functional impacts.

WES is finding application in precision oncology to guide research and clinical-decision-making. It may be used to measure tumor mutational burden (TMB), a valuable biomarker of response to immunotherapies, and can identify neoantigens that could be used as the personalized cancer vaccine. Also, WES has the ability to reveal new treatment targets, which are out of the range of pre-defined panels, and offer prospects of new treatment approaches. Nevertheless, this increased scope has its costs: WES necessitates more complex bioinformatics treatment, more computing power, and interpretation to differentiate between clinically important and harmless mutations. Moreover, since WES mainly focuses on coding areas, it is not able to identify significant noncoding regulatory factors that affect the expression and behavior of tumors. WES may be considered as a potent resource to global genomic profiling of cancer and clinical car despite these constraints.

3. Whole-Genome Sequencing (WGS)

Whole-genome sequencing (WGS) constitutes an in-depth examination of the complete genomic environment, including more than just the protein-coding region of the genome, but the noncoding sequences, regulatory components, repetitive sections, and structure. This broad-based strategy allows identifying intricate genome changes, such as chromosomal rearrangements, large-scale insertions or deletions, copy number changes, and noncoding driver mutation that can contribute to the emergence and development of tumors. WGS enables researchers and clinicians to identify the full range of genetic changes that would otherwise go undetected by a specific set of gene panels or whole-exome sequencing and may inform understanding of the pathways that promote cancer progression, metastasis, and treatment resistance.

WGS has found extensive application in both research and clinical contexts in which common, aggressive, or treatment-resistant malignancies cannot be understood using the standard methods of investigation. Its comprehensive view helps to discover new therapeutic targets, noncoding mutations of regulatory relevance, and multifaceted structural changes, which could constitute a personalized approach to treatment. Nevertheless, WGS has high coverage coverage, but this has a trade-off: it is more expensive, it produces large volumes of intricate data and its correct interpretation requires more sophisticated bioinformatics infrastructure and computing resources. In spite of these hurdles, WGS is the most detailed technique of genomic profiling, which provides unmatched information about the coding and noncoding areas of the genome and becomes an indispensable instrument in precision oncology and cancer research.

4. RNA Sequencing (RNA-seq)

RNA sequencing (RNA-seq) offers a high-resolution picture of the tumor transcriptome, including both the dynamic expression patterns of genes and alternative splicing forms of transcripts, as well as fusion transcripts that can lead to cancer progression. In contrast to DNA-based technologies, which mainly provide an insight into the presence of mutations or structural changes, RNA-seq demonstrates the functional implications of such modifications in the genome, which genes and pathways are deregulated in the tumor. RNA-seq can reveal how tumors respond to their microenvironment at the molecular scale, aiding researchers and clinicians to gain vital insights into oncogenic signaling, pathway activation and cellular responses to the tumor microenvironment.

RNA-seq has become a workhorse in clinical oncology to identify actionable targets, especially the fusion genes most likely to respond to targeted therapies, including ALK and ROS1 rearrangements in lung cancer. In addition to identifying targets, RNA-seq allows tracking of tumor dynamics, such as gene expression following treatment, to identify processes that may mediate therapy resistance or sensitivity. This dynamic profiling may inform the changes in treatment strategies, inform the combination therapies, and can even lead to the discovery of new therapeutic approaches. Through the combination of the RNA-seq with the DNA-based analysis, the clinicians can have a better insight into the tumor biology as they can connect the genomic alterations with the functional consequences as well as enhance the accuracy of cancer treatment.

Key Advantages of NGS

1. High Sensitivity and Specificity

Next-Generation Sequencing has an impressive sensitivity and specificity capability, and can be used to identify low-frequency mutations found exclusively in a small fraction of heterogeneous tumor cells. This is particularly essential in cancers that exhibit high intratumoral heterogeneity, i.e. that different subclones might be in possession of different mutations. The NGS can be used to characterize oncogenic drivers and potential mechanisms of therapy resistance by obtaining a more detailed molecular profile of the tumor by revealing these rare variants. Narrow specificity will restrict the number of mutations, one of them is a true positive, and the chance of false-positive findings is low, which enhances the reliability of clinical decision-making.

2. Multiplexing Capability

The possibility of identifying many genetic changes at a single time per assay is one of the key benefits of NGS. Conventional techniques usually need individual tests on each mutation or gene, which is costly and time-consuming and may need more samples. Conversely, NGS is able to simultaneously analyze and identify single nucleotide variants (SNVs), induced and deleted (indels), copy number variations (CNVs), and structural rearrangements in hundreds to thousands of genes or genomic regions. Such high-throughput multiplexing method not only conserves time but also enables clinicians to acquire a detailed molecular portrait directing the choice of targeted therapy, immunotherapy eligibility and clinical trial enrollment.

3. Longitudinal Monitoring

NGS is now used in liquid biopsies, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) or exosomes, to allow time-dependent monitoring of cancer progression. Such a possibility enables clinicians to identify small residual disease (MRD) post-treatment, see emergent resistance mutations, and real-time therapeutic response without repeated invasive tissue biopsies. NGS enables adaptive treatment and early intervention in the event of relapse, as well as overall better patient management by offering a dynamic observation of tumor evolution.

Challenges

1. Data Interpretation Complexity

The large scale and quantity of NGS produced data demand advanced bioinformatics pipelines and expert skills to handle, process and interpret. Clinically relevant mutations can be accurately identified by differentiating between driver and passenger mutations; the former causes the progression of cancer and the latter are accidental. Combining sequencing data with clinical and pathological data is necessary, but difficult, and resoften demands multidisciplinary cooperation among molecular pathologists, oncologists, and bioinformaticians.

2. Variants of Unknown Significance (VUS)

NGS often reveals variants of unknown significance (VUS) - mutations the influence on which remains not yet defined. VUS existence may make it complex when it comes to making therapeutic choices, because it is not always clear whether a variant will cause development of the tumor or will influence responses to a drug. The clinicians should be careful in the interpretation of VUSs which may involve functional studies, databases and emerging literature to establish its pertinence.

3. Cost and Accessibility

Despite a reduction in the price of NGS in the last 10 years, it is still comparatively expensive in contrast to the traditional single-gene tests. Accessibility can be constrained by high costs, complicated infrastructure demands and slower turnaround times especially in resource-constrained environments. Moreover, the requirement of highly skilled staff and bioinformatics assistance may be further obstacles to the extensive clinical adoption, slowing down the integration of precision oncology in some areas.

2.2. SOMATIC VS GERMLINE MUTATIONS IN CANCER

Somatic mutations refer to genetic changes that are acquired throughout the lifetime of an individual and that can be found in non-germline cells and as such limited to the tumor tissue. Such mutations occur due to environmental exposures, mistakes of DNA replication, chronic inflammation, or spontaneous mutational occurrences, and they are central in the initiation, progression, metastasis, and resistance to therapy. Somatic mutations, such as EGFR mutations with non-small cell lung cancer or KRAS mutations with colorectal cancer, are clinically viable actionable targets of precision oncology, and therapies such as tyrosine kinase inhibitors or monoclonal antibodies can selectively target tumor cells and spare normal tissue. Clinicians can optimize treatment efficacy and reduce systemic toxicity by focusing on the changes attained.



Figure 2: Somatic Mutations and Germline Mutations

Source: (https://www.researchgate.net/figure/Fundamental-difference-between-germline-and-somatic-mutations-wwwlearncolontownorg_fig3_380066207)

Germline mutations, by contrast, are genetic alterations passed along to all cells including germ cells and that make individuals susceptible to inherited cancer syndromes. Examples of these are BRCA1/BRCA2 defects that predispose to breast and ovarian malignancies and TP53 defects that cause Li-Fraumeni syndrome. Germline profiling plays a pivotal role in risk assessment, early diagnosis, preventive intervention and family counseling. Contemporary oncology is becoming more and more unified in its combination of somatic and germline studies to offer a complete genetic focus. This two-fold approach will direct individualized treatment, determine prevention measures, and educate the relatives about a possible hereditary predisposition, so that cancer treatment will focus on the molecular nature of the tumor and on the inherited tendency of the patient.

1. *Somatic Mutations*

Somatic mutations are genetic changes in non-germline cells and hence, acquired within the lifetime of a person and not inherited. Such mutations do not affect the offspring and appear exclusively in tumor cells. The cause of somatic mutations is varied and can be characterized as follow: environmental exposures (ultraviolet radiation, tobacco smoke, or chemical carcinogens), malfunctions during the DNA replication, chronic inflammation, or spontaneous mutational processes. They are key in tumorigenesis, they play a part in tumor initiation, progression, metastasis, and therapy resistance. As an example, in non-small cell lung cancer (NSCLC) EGFR mutations cause constitutive activation of growth signaling pathways to promote tumor growth, whereas KRAS mutations in colorectal cancer confer a proliferative benefit and depend on response to selected targeted therapies. In treatment, cancer cells can be selectively killed through clinical therapies based on somatic mutations, including tyrosine kinase inhibitors (TKIs) or monoclonal antibodies, which can spare normal tissues, providing a basis of precision oncology.

2. *Germline Mutations*

Germline mutations are inherited inherited changes in genes that are found in all the cells of the body including the germ cells (sperm and egg) as well. The mutations may predispose the individuals to some of the cancers and hereditary cancer syndromes. Cases in point are BRCA1 and BRCA2 mutations that substantially raise the risk of breast and ovarian cancers and TP53 mutations that are linked to Li-Fraumeni syndrome where carriers are more prone to various cancers at an early age. The germline mutations are important in risk assessment, early diagnosis and prophylaxis, which include increased surveillance, prophylactic surgeries or

changes in lifestyles. In addition, the therapeutic implications of certain germline mutations are also therapeutically relevant; tumors bearing BRCA1/BRCA2 mutations are also sensitive to PARP inhibitors, which target the defective DNA repair pathways to selectively kill cancer cells. The fact that germline mutations have been identified also helps in family counseling since family may be at risk and may be helped by genetic testing and preventive measures.

3. *Clinical Integration*

Somatic and germline profiling are becoming more used together in modern oncology practice to offer a global genomic evaluation. This combined approach is useful in streamlining therapeutic interventions, establishing preventive interventions, and informing clinical decision-making. As an illustration, a patient can have a tumor with a somatic mutation that can be treated by a particular drug, and have a germline mutation that requires continued monitoring or alerts family members of their risk of cancer. Genetic counseling is vital in interpretation of germline results, risk education and in the process of advising family testing. The combination of the two types of mutations can be used to advance personalized medicine, whereby the treatment choices and preventive measures will be designed to match the molecular specificities of the tumor and the inherited risk factors of the patient.

2.3. TUMOR HETEROGENEITY AND CLONAL EVOLUTION

Tumor heterogeneity is the existence of genetically, epigenetically and phenotypically disparate cancer cell populations in one tumor or different metastases. Such diversity is due to continuous mutations, the influence of the microenvironment and therapeutic interventions, producing subclones that differ in molecular profiles and functional behavior. Multi-region sequencing and single-cell studies have demonstrated that a single tumor that seems homogenous histologically can contain an important amount of intratumoral heterogeneity that can influence the growth rate, metastatic capacity, and response to treatments. This heterogeneity is of great importance to precision oncology since it clarifies the reason why not all patients will respond to identical treatment and why other subclones will survive the treatment to become the cause of relapse.



Figure 3: Tumour Heterogeneity

Source: (https://en.wikipedia.org/wiki/Tumour_heterogeneity)

Clonal evolution also makes treatment more complicated as it explains how these subpopulations transform dynamically with time under selective forces including targeted therapies, immunotherapy, or chemotherapy. Liquid biopsies, which measure tumor DNA in circulation and other tumor-derived biomarkers, offer a minimally-invasive way to track clonal evolution, in real time. Clinicians can proactively change treatment plans by monitoring the appearance of resistant subclones or emerging driver mutations, including switching therapies, combining agents or entering patients into clinical trials that are based on emerging tumor profiles. Incorporation of understanding of tumor heterogeneity and clonal evolution into the clinical decision-making process is thus a key to maximizing personalized treatment, resistance overcoming, and better long-term outcomes in cancer care.

❖ Tumor heterogeneity

Heterogeneity in tumors is a vast diversity at genetic, epigenetic and phenotypic level within an individual tumor as well as among tumors of the same type in different individuals. Such diversity is a result of a set of mutations over time, variable expression of genes, epigenetic changes, and tumor microenvironment effects. There are two general classes of tumor heterogeneity:

- **Intratumoral heterogeneity:** This explains variability that occurs within an individual mass of the tumor. Diverse parts of the tumor can contain different subclones carrying different mutations or different profiles of expression. This heterogeneity leads to therapeutic complications because some subclones may have intrinsic or acquired resistance to certain drugs and total elimination of the tumor will become a challenge. The intratumoral heterogeneity is one of the driving forces behind the failure of therapy and relapse of the disease.
- **Intertumoral heterogeneity:** This is the dissimilarity seen between comparable tumors of the same histological type of different patients. The prognosis, therapeutic response, and susceptibility to metastasis may be affected by genetic and phenotypic differences between the patients. Intertumoral heterogeneity is important because it should be identified to formulate individualized treatment plans and to stratify patients during clinical trials.

❖ Clonal evolution

The dynamic evolution of tumors is associated with accumulating genetic and epigenetic changes in a certain sequence, which results in the differentiation of separate subclones with different biological characteristics. This is what is termed as clonal evolution and is driven by the process of natural selection in which subclones that develop survival benefits, such as chemotherapy resistance or the capacity to avoid immune detection, develop and proliferate, whereas vulnerable clones are killed off. Monitoring of these clonal dynamics with time is important in planning adaptive treatment regimens capable of anticipating resistance and enhance therapeutic results.

❖ Methods to study heterogeneity

A number of more sophisticated methods have been designed to probe tumor heterogeneity on various scales:

- **Multi-region tumor sequencing:** This is a technique that refers to sampling and sequencing of multiple regions of the same tumor to determine spatial differences in genetic and molecular phenotypes. It assists in showing that there are specific subclones and the distribution of the mutations throughout the tumor mass.
- **Single-cell sequencing:** Single-cell technologies can be used to characterize heterogeneity at the cellular level, un-masking differences between individual tumor cells that can be difficult to see in bulk sequencing. This method gives high-resolution information of mutation spectrums, gene expression and cellular states on tumors.
- **Liquid biopsy:** The subclonal mutations circulating in the blood can be detected by noninvasive techniques like circulating tumor DNA (ctDNA). Real-time monitoring of tumor progression and treatment response with liquid biopsy can be conducted without recurrent invasive tissue biopsy.

❖ **Clinical significance**

Knowledge of tumor heterogeneity and clonal evolution has profound implications to cancer management:

- It guides the rational development of combinations therapy in order to target multiple subclones at a time in order to avoid the occurrence of resistant populations.
- These applications can be used to optimize sequential treatment planning on the basis of the inferred evolutionary dynamics of tumor subclones.
- Heterogeneity information can be used to forecast disease relapse, metastatic possibilities, and the probability of responding to targeted treatment.
- Conclusively, applying knowledge of heterogeneity to clinical practice helps in the evolution of precision oncology approaches that can be specific to the tumor profile of an individual patient.

2.4. INTEGRATING GENOMIC DATA INTO CLINICAL PRACTICE

The process of integrating genomic data into clinical practice is a multi-step process that starts with few steps of collecting high-quality tumor tissue or liquid biopsy samples. Such samples are sequenced by next-generation sequencing (NGS) to reveal actionable mutations, copy number variations, and gene fusions that may inform therapy choices. This results in genomic

information which is then discussed by a multidisciplinary molecular tumor board, who take into account the clinical situation of the patient, comorbidities and past treatments to come up with individualized care plans. These plans can involve the use of specific therapies, combinatorial treatment plans, or participation of the patient in the associated clinical trials so that specific interventions can be developed based on the specific molecular outline of the cancer in the patient.

Genomic monitoring should also be done continuously, and usually with repeat tissue biopsies or less invasive liquid biopsies to monitor the tumor progression and the development of resistance mutations. Such a dynamic approach enables clinicians to adjust the regimen of treatment on-the-fly to achieve the most efficacy with the least toxicity. Nonetheless, the incorporation of genomic data into clinical practice is fraught with numerous issues, such as differentiating clinically actionable variants versus incidental findings, the high cost and inaccessibility of sequencing technologies, the ethics of genomic germline mutations and privacy of patient data, and a unified integration of genomic outcomes with other omics layers to gain a comprehensive understanding of tumor biology. They are essential to address to achieve the full potential of precision oncology and to provide cancer care at the most individualized level.

Clinical workflow

The application of genomic information in the clinical setting is a multi-step procedure which guarantees proper molecular characterization of tumors and informs individualized treatment plans. This workflow can be classified into sample collection, sequencing and analysis, interpretation, therapeutic decision-making and longitudinal monitoring.

Sample collection and quality control

The initial one is to acquire an appropriate tumor sample. This may be done by invasive (tumor biopsy or tumor resection) or noninvasive (liquid biopsy, the analysis of circulating tumor DNA (ctDNA) in blood or plasma) methods. Nucleic acids (DNA/RNA) purified off of these samples are the most important variables affecting the success of sequencing. Subpar samples may lead to incomplete or distorted genomic data, which may have implications on downstream analysis and clinical judgement. Thus, stringent quality assurances are applied to maintain the integrity of the samples before the act of sequencing.

Sequencing and bioinformatics analysis

The technologies of next-generation sequencing (NGS) are used to profile the tumor genome in detail. NGS has a broad range of genomic alterations, which include single nucleotide mutations, copy number variations, and gene fusions as well as mutational signatures related to specific cancer phenotype or therapeutic responses. The raw sequencing data are subjected to bioinformatics pipelines, where the matches are made to the reference genomes, variants detected, and prioritized by clinical relevance. Variants are generally classified as actionable (with accessible therapy), likely pathogenic and of undetermined importance to influence further clinical interpretation.

Molecular tumor boards

Genomic data is then reviewed by multidisciplinary molecular tumor boards, which typically include oncologists, pathologists, geneticists, bioinformaticians, and other relevant specialists. These teams collectively interpret the genomic findings, correlate them with clinical and pathological data, and develop personalized treatment recommendations. Decisions may include selecting FDA-approved targeted therapies, determining eligibility for immunotherapy, or considering enrollment in relevant clinical trials for investigational agents. The collaborative approach ensures that complex genomic information is translated into clinically meaningful insights.



Figure 4: Molecular Tumor Board

Source: (https://www.sciencedirect.com/science/article/pii/S2589004224016900)

Therapeutic decision-making

Clinicians can pair target therapies or investigational drugs to particular mutations or genomic profiles based on genomic interpretation. Multi-driver mutations or resistant subclones in tumors may only be targeted by a combination of strategies to adequately address all the oncogenic pathways. Individualized treatment regimens are thereby customized to the molecular environment of the tumor of each individual patient, maximizing efficacy and reducing non-therapeutic toxicity.

Monitoring and adaptation

Genomic profiling is not a single event, but serial monitoring with repeat biopsies or liquid biopsies makes it possible to identify resistance mutations or the advent of new subclones. Such dynamic strategy makes it possible to adjust therapy, interfere at an early stage in the case of tumor progress, to increase or decrease the treatment in time, thus enhancing the long-term clinical outcome.

- **Challenges and Considerations**

Although genomic data integration into clinical practice has a promising transformative potential, a number of important issues are associated with the integration, which need to be carefully addressed to integrate genomic data safely, effectively, and equitably. Such challenges include scientific, economic, ethical, and technical.

1. **Clinical validity vs. utility**

The difference between clinical validity and clinical utility is a fundamental issue to apply genomic data to precision oncology. Clinical validity describes the degree to which a genomic variant is linked to a disease or condition and clinical utility describes whether or not the knowledge of a variant can be meaningfully used to inform management or treatment decisions of patients. HTS technologies have vastly increased our capacity to observe genetic changes in tumors and have been able to detect not only familiar mutations but also unfamiliar variants the relevance of which is not yet evident. Not every identified variant is, however, therapeutically actionable. As an example, mutations are directly amenable to existing drugs, producing quantifiable clinical benefits, whereas others are incidental or nonpathogenic and have no current relevance to treatment. The utilization of raw genomic data without critical interpretation can result in wrong interventions, treatments that are unwarranted, or the opportunities to deliver effective treatment.

In order to overcome this difficulty, genomics has to be integrated in clinical practice with the help of multidisciplinary competencies and strong variant annotation tools. The teams of oncologists, geneticists, bioinformaticians, and molecular pathologists are necessary to distinguish between the clinically actionable mutations and those of uncertain value. The detailed and constantly revised data bases of genetic variants are useful in this process because they list the known therapeutic targets and new evidence of variations. Furthermore, it requires continued studies to build on our knowledge of variant function and its clinical outcome, thus enhancing the translation of genomic discovery to significant patient care. By making sure that the genomic interpretations are scientifically valid and relevant to clinical needs, medical professionals will be able to make informed treatment choices that will have the highest patient outcomes and lowest risks of a misinterpretation.

2. Cost and accessibility

The high prices and unavailability of sophisticated genomic technologies are the major impediments to the embracement of precision oncology. Other methods like next-generation sequencing (NGS) and multi-omics profiling do not only demand costly reagents and equipment but also very specific infrastructure and personnel. These tests are expensive so they can be prohibitive in resource-constrained environments and so many patients do not have the opportunity to access personalized cancer treatment. Even in health care systems that are well funded, the cost of such intensive profiling of the molecule might not allow its use on a routine basis, particularly when many tests are needed to inform the decision to make a treatment choice, and thus create unequal access to precision therapies. In addition to the price, geographic and systemic considerations also limit access to genomic-guided oncology. Full-scale genomic testing is often unevenly distributed across geographical regions, hospitals, and healthcare, with the result that inequities in access to personalized cancer care exist. Rural or underserved patients can also have an extra logistical burden, such as commute to specialized facilities and test results. These economic and structural obstacles are essential to overcome so that precision oncology is not only the privilege of a small group of citizens but it is widely available. Such initiatives as subsidized tests, local genomic centers, scalable and cost-effective technologies are necessary to enable widespread access to genomic-guided therapies and ensure equity between different populations of patients.

3. Ethical considerations

Precision oncology genomic testing frequently reveals incidental germline mutations- variants that are hereditary, can have implications beyond just the patient, and can affect other family

members. Such variants and their discovery present thorny ethical issues, such as the issue of informed consent, disclosure of findings, disclosure, and patient privacy. Before patients are subjected to incidental findings, they should be informed about the occurrence of such findings and its potential implication to the family planning, early health surveillance or prevention measures. These revelations can be emotionally disturbing, anxiety-inducing, or cause hard choices among patients and their family members without a keen handling. Besides this, handling of genomic information requires strict guard against abuse, prejudice and confidentiality invasion. There should be a clear ethical code and legal frameworks that will ensure the right of patients are not violated and also that the clinical utility of genomic data is optimized. This involves specifying access to the information, the possibility of its use in research or clinical practice and handling disclosure of information to family members. With the adoption of strong ethical frameworks, medical workers will be able to utilize genomic knowledge responsibly to support personalized care and prevention and to maintain trust and justice in treating patients.

4. Integration with other omics

Although genomic data offers essential information on tumor biology, this is just a dimension of the multifaceted molecular features of cancer. Combining genomics with other omics proteomics, transcriptomics, metabolomics and epigenomics allow a more detailed view of tumor behavior. Multi-omics strategies can display genetic changes in terms of functional change at protein, metabolite or regulatory tiers, which gives a comprehensive picture of tumor evolution, drug action and resistance. Such holism increases the precision of therapeutic decisions, promotes treatment personalization, and can discover new ways to intervene that would be overlooked by genomics itself. There are however complex technical and analytical issues raised by the integration of the multi-omics data. Computational power, advanced bioinformatics pipelines, and knowledge of data interpretation are needed to handle high-computational-power, large, and heterogeneous datasets due to multiple layers of molecular data. Furthermore, complex molecular signatures require interdisciplinary research between oncologists, molecular biologists, bioinformaticians and computational scientists to translate complex molecular signatures into clinically actionable information. It is necessary to develop standardized data integration, visualization and interpretation to optimize the potential of multi-omics approaches in precision oncology and to guarantee the robustness, reproducibility and clinical relevance of the findings.

REFERENCES

1. Malone, E. R., Oliva, M., Sabatini, P. J., Stockley, T. L., & Siu, L. L. (2020). Molecular profiling for precision cancer therapies. *Genome medicine*, *12*(1), 8.
2. Chakravarty, D., & Solit, D. B. (2021). Clinical cancer genomic profiling. *Nature Reviews Genetics*, *22*(8), 483-501.
3. Pishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., ... & Petricoin III, E. F. (2018). Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. *Clinical Cancer Research*, *24*(20), 5018-5027.
4. Alsina, M., Arrazubi, V., Diez, M., & Tabernero, J. (2023). Current developments in gastric cancer: from molecular profiling to treatment strategy. *Nature Reviews Gastroenterology & Hepatology*, *20*(3), 155-170.
5. Murali, R., Delair, D. F., Bean, S. M., Abu-Rustum, N. R., & Soslow, R. A. (2018). Evolving roles of histologic evaluation and molecular/genomic profiling in the management of women with endometrial cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, *16*(2), 201.
6. Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., ... & Kurzrock, R. (2019). Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nature medicine*, *25*(5), 744-750.
7. Cobain, E. F., Wu, Y. M., Vats, P., Chugh, R., Worden, F., Smith, D. C., ... & Chinnaiyan, A. M. (2021). Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors. *JAMA oncology*, *7*(4), 525-533.
8. Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G., ... & Kang, W. K. (2019). Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. *Cancer discovery*, *9*(10), 1388-1405.
9. Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., ... & Moore, R. A. (2018). The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. *Cell reports*, *23*(1), 313-326.
10. Yuan, Y., Ju, Y. S., Kim, Y., Li, J., Wang, Y., Yoon, C. J., ... & Liang, H. (2020). Comprehensive molecular characterization of mitochondrial genomes in human cancers. *Nature genetics*, *52*(3), 342-352.

11. Rabbie, R., Ferguson, P., Molina-Aguilar, C., Adams, D. J., & Robles-Espinoza, C. D. (2019). Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. *The Journal of pathology*, *247*(5), 539-551.
12. Pishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E., DeArbeloa, P., Hendifar, A., ... & Petricoin, E. F. (2020). Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. *The Lancet Oncology*, *21*(4), 508-518.
13. Fang, W., Ma, Y., Yin, J. C., Hong, S., Zhou, H., Wang, A., ... & Zhang, L. (2019). Comprehensive genomic profiling identifies novel genetic predictors of response to anti–PD-(L) 1 therapies in non–small cell lung cancer. *Clinical cancer research*, *25*(16), 5015-5026.
14. Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., ... & Abou-Alfa, G. K. (2018). Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. *Clinical Cancer Research*, *24*(17), 4154-4161.
15. Van Den Heerik, A. S. V., Horeweg, N., Nout, R. A., Lutgens, L. C., Van Der Steen-Banasik, E. M., Westerveld, G. H., ... & Creutzberg, C. L. (2020). PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. *International Journal of Gynecological Cancer*, *30*(12), 2002-2007.

Chapter 3…

BIOMARKER DISCOVERY AND CLINICAL UTILITY

Dr. T. DEBORAH PARIPURANAM
Assistant professor
Nadar Saraswathi College of Arts and science, Theni
Pin - 625531
Email: debovermi@gmail.com

Ms. JYOTI ASHOK SHIWANKAR
Assistant professor
Shri Sai college of Pharmacy, Mauda, Nagpur - 441104, Maharashtra
Email: jyoti93ok@gmail.com

Dr. SONIA KUKRETI
Assistant Professor
Graphic Era Deemed University
Pin - 248001
Email: soniakukretisana@gmail.com

Ms. SNNEHAA BHOSLE
Assistant Professor
TMV'S Lokmanya Tilak Institute of Pharmaceutical Sciences Pune
Pin - 411037
Email: shivank.sneha853@gmail.com

Dr. R.SATHIYASUNDAR
Professor
Cheran College of Pharmacy, CIHS, Coimbatore,
Tamil Nadu, India, 641039
Email: sundaranalysis@gmail.com

Although genomic data is critically important to tumor biology, it is not the entire surface of molecular information. Combining genomics with other omics which include proteomics, metabolomics, transcriptomics and epigenomics may provide a more detailed picture of cancer biology. The combination of multi-omics allows a comprehensive evaluation of tumor behavior, drug response, and mechanisms of drug resistance, and increases the accuracy of therapeutic therapy and its personalization. Nevertheless, the combination of complex molecular data in numerous layers brings about technical, computational and interpretive difficulties that demand advanced bioinformatics pipelines and inter-disciplinary skills.



Figure 1: Biomarker Discovery

Source: (https://www.svarlifescience.com/services/cro-services/biomarker-discovery-services)

Companion diagnostics (CDx) are an extension of biomarkers, with the direct aim of matching a treatment to the molecular profile of a patient to ensure that they are placed in therapies that are matched to their molecular profile. The CDx tests determine those patients who may respond effectively to targeted therapies, which can maximize effectiveness, minimize adverse event, and maximize health care resources. The approval process used by FDA tends to consider the therapeutic agent and its companion diagnostic together, and put a premium on clinical validation and predictive reliability. Examples are HER2 testing before trastuzumab therapy in breast cancer and MSI-H/dMMR testing before pembrolizumab therapy, and show how CDx provides safe and effective use of precision oncology interventions.

The development of emerging biomarkers, specifically circulating tumor DNA (ctDNA), exosomes, circulating tumor cells (CTCs), microRNAs (miRNAs), and tumor-derived proteins presents minimally invasive, dynamic cancer detection, monitoring, and therapeutic indicative methods. ctDNA can provide a real-time view of tumor genetics and thus can be used to detect cancer early, monitor minimal residual disease, and detect early resistance mutations. Exosomes transport nucleic acids and proteins indicative of tumor behavior and interactions with the microenvironment that can provide information on metastasis, immune evasion, and response to therapy. The same can be said of CTCs, miRNAs, and tumor-derived proteins as they provide complementary data and can be monitored longitudinally, risk-stratified, and adapted to treatment regimens, thereby improving the accuracy and individualization of oncology care.

Although biomarkers hold the potential of a transformation in clinical practices, clinical translation of biomarkers is beset by considerable challenges, such as technical variability, analytical and clinical validation, regulatory challenges, and cost considerations. The accuracy of measuring biomarkers can be influenced by variability in sample collection, processing and storage, which underscores the importance of standardized procedures. Analytical validation guarantees the sensitivity, accuracy, and reproducibility of assays especially in the low-abundance circulating biomarkers. It has been clinically validated that biomarkers are consistent predictors of endpoints like progression of disease or response to treatment. Moreover, high expenses, weak reimbursement, and multifaceted regulatory routes may reduce the adoption. To overcome these obstacles, precise validation, standardization and strategic planning is needed to ensure successful integration of biomarkers in precision oncology to enhance patient outcomes and to develop personalised cancer care.

3.1. PREDICTIVE VS PROGNOSTIC BIOMARKERS

Biomarkers are quantifiable biological markers that can give useful information about the processes, tumor behavior and response to treatment. They are an essential part of the clinical decision-making process, patient outcomes improvement, and precision medicine in the field of oncology. Biomarkers are useful in identifying cancer at the earliest stages, tracking the course of diseases, and evaluating the success of treatment processes by reflecting underlying molecular, genetic, or protein-level changes. Their sensitivity to dynamic features of tumor biology makes it possible to implement more informed treatment plans, individualized care,

and effective adaptation of therapy in a timely manner, which will increase its effectiveness and safety.



Figure 2: Prognostic Or Predictive Biomarkers

Source: (https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01162-7)

According to their clinical use, the biomarkers are typically divided into prognostic and predictive. Prognostic biomarkers give details regarding the general disease pathway regardless of treatment, which can be used to predict the outcome, including survival rate or risk of reoccurrence. Predictive biomarkers on the other hand are used to predict the possibility of response to a particular therapy and are used in selecting the most effective possible treatment that may be administered to an individual patient. Whereas prognostic biomarkers provide information on the natural history of the disease, predictive biomarkers provide the ability to individualize therapy, whereby the patients only get interventions with the best chances of benefiting them. Combined, these types of biomarkers complete one another, which is the basis of precision oncology and optimal cancer treatment.

- **Prognostic Biomarkers**

The prognostic biomarkers present data regarding the natural disease or its anticipated progression regardless of treatment. They are used mainly to categorize patients based on risk in order to assist clinicians in estimating the possibility of disease recurrence, progression or survival in general. This stratification allows making an informed clinical decision about the

level of monitoring, schedules of follow-ups, and considering the possibility of preventive or adjuvant intervention.

- **Function:** The prognostic biomarkers are known to detect patients who have more aggressive disease, increased risk of recurrence, or worse prognosis irrespective of the therapy used. This enables clinicians to focus on interventions, surveillance, or supportive care with patients that are at higher risk and spares low-risk patient's needless procedures or interventions
- **Example:** A common example of nuclear protein used in breast cancer is a marker of cellular proliferation, the nuclear protein, Ki-67. High Ki-67 expressing tumors are generally characterized by a high growth rate, high aggressiveness, and low survival regardless of whether the patient is in a chemotherapy, hormonal therapy, or targeted therapy.
- **Clinical Utility:** Prognostic biomarkers can be used to plan risk-adapted treatment. Patients at high risk might respond more to intensive treatment or close monitoring and low-risk patients might not need overtreatment, thus limiting side effects, lowering health care expenses, and enhancing quality of life. They are also critical in the design of clinical trials where researchers can be able to indicate the population of patients who are most likely to respond to new forms of treatment or interventions.

➢ **Predictive Biomarkers**

Predictive biomarkers indicate what to expect in a given therapeutic intervention so that clinicians may use therapeutic options that have the highest chance of succeeding and avoid those that are not most likely to succeed. These biomarkers have become the focus of the precision oncology practice, where the treatment approach is tailored on the molecular and genetic characteristics of a tumor in a patient.

- **Function:** The predictive biomarkers are used to direct the choice of treatment in those patients who are likely to respond to specific drugs or therapies. They also help to prevent exposure to therapies that are hardly likely to be beneficial, minimize the risk of being exposed to toxicity and unwarranted healthcare spending.
- **Examples:** mutations of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) can be used as predictive biomarkers. EGFR mutant patients tend to respond well to EGFR tyrosine kinase (TKIs) and show a shrinkage of the tumor and

a better progression-free survival. In contrast, EGFR-targeted therapy is rarely active in patients without these mutations and this shows the relevance of predictive biomarkers in therapy choices.

- **Clinical Utility:** Predictive biomarkers increase the precision of therapy, so that patients get the different treatment based on the molecular traits of their tumor. This lead to better clinical outcomes, less adverse effects as well as fewer costs. They play a critical role in drug development and clinical trials to help identify subgroups of patients most susceptible to experimental therapies.

➢ **Key Distinction**

The major difference between prognostic and predictive biomarkers is that they are used in different clinical contexts:

- Prognostic biomarkers give an understanding of the natural history of the disease, and it assists in estimating the risk and probable outcomes regardless of what treatment is to be administered.
- Predictive biomarkers demonstrate the success of a specific therapy, and they help the clinicians to select the best therapy option to use on a specific patient.

Ideally, some of the biomarkers might be prognostic and predictive with a purview to provide holistic details of the disease aggressiveness and response to treatment. The appropriate identification, validation and use of these biomarkers will be essential in the future development of personalized oncology therapy, maximization of treatment effectiveness, and ensuring the final enhancement of patient survival and quality of life.

3.2. COMPANION DIAGNOSTICS AND FDA APPROVALS

Companion diagnostics (CDx) refer to special laboratory tests that have been created to determine the best patients who would respond to a specific targeted therapy so that treatment can be effective and safe. Such diagnostics measures particular molecular, genetic, or protein-based changes in a tumor in a patient, which is directly associated with the mechanism of action of the therapeutic agent. CDx allows clinicians to select treatments that have a greater chance of benefit and to avoid exposing patients to ineffective treatments by identifying which cancer types have the biomarkers needed to be responsive. This is not only an effective way to deliver therapeutic results, but also the chance of having adverse effects is reduced, thus, representing the concept of personalized medicine.



Figure 3: Companion diagnostics (CDx)

Source: (https://blog.crownbio.com/importance-of-companion-diagnostics)

The use of companion diagnostics is frequently required by regulatory details, such as the U.S. Food and Drug Administration (FDA) as a requirement to approve targeted therapies. This will make sure that, the respective therapy is given to patients whose tumors satisfy the particular molecular parameters that have been determined by clinical trials. Drug and companion diagnostics co-development has now become a key approach of precision oncology, where diagnostic testing is used in the decision-making process of treatment. Connecting treatment eligibility to validated molecular markers, CDx enables the personalized choice of therapy, improves clinical responses, and reinforces patient safety, which cement its position as a staple in contemporary cancer treatment.

➢ **Role in Precision Oncology**

In contemporary oncology, companion diagnostics are essential because they optimize the effectiveness of the treatment, improve the level of safety and facilitate the personalized medicine. Their key functions include:

- **Patient Stratification:** CDx tests recognize patients who have particular molecular or genetic defects, including point mutations, gene amplifications, translocations, or abnormal protein expression, which is predictive of sensitivity to a specific

targeted therapy. CDx maximizes therapeutic benefit by selecting only those patients who have a high probability of responding and eliminates futile treatments in patients who are not likely to respond. This makes therapeutic interventions evidence based and biologically rational, as opposed to empirically prescribed.

- **Treatment Efficacy:** the selection of patients according to their biomarker status improves the probability of significant clinical response, which may be tumor regression, disease stabilization, and long-term progression-free survival and overall survival. CDx can reduce response variability in a heterogeneous population of patients, enabling clinicians to maximize response to therapy and enhance the chances of successful clinical endpoints.
- **Safety Enhancement:** What patients can avoid exposing themselves to are potentially toxic therapies, reducing the likelihood of adverse drug reactions, treatment-related morbidity and hospitalization. This helps in enhancing good patient quality of life, and minimize unproductive complications with unproductive treatments.
- **Efficient Healthcare Resources:** Companion diagnostics can lead to reduction of healthcare resources by avoiding expensive targeted treatment in patients who would not respond. This is especially important in oncology, where new therapeutics can be costly, and optimal patient selection can enhance cost-efficiency and use of resources.

Companion diagnostics transform cancer care practices in the direction of a one-size-fits-all treatment strategy to a multifaceted, biomarker-driven, personalized approach, in which the choice of treatment is determined by the molecular signature of the individual tumor in a patient.

➢ FDA Approvals

Regulatory authorities, specifically, the approval of companion diagnostics and their control is significantly influenced by regulatory agencies, especially, the U.S. Food and Drug Administration (FDA). FDA reviews the therapeutic agent and companion diagnostic together so that the drug and the test are both clinically valid, safe and effective to be used by the patient.

- **Simultaneous Evaluation:** The FDA tends to regard the therapeutic agent and companion diagnostic as a dependent system in which the clinical effectiveness and safety of the therapy is conditional upon proper patient selection using the CDx test.

This collaborative assessment makes the therapy and its diagnostic counterpart aligned, and suitable clinical practice is made possible.

- **Clinical Validation:** Companion diagnostics are subjected to thorough analytical and clinical validation which reveals the accuracy, reproducibility and predictive reliability. The validation procedures ensure that the test can always determine patients who are most likely to respond to the therapy in a wide range of clinical settings hence evidence-based treatment decisions.

➢ **Examples of FDA-Approved CDx-Drug Pairs:**

- **HER2-positive breast cancer:** In the treatment of HER2-positive breast cancer, before conducting trastuzumab treatment, it is essential to conduct the HER2 test to determine whether the cancer has overexpressed or amplified HER2 receptor. Treatment is only applicable to patients whose tumors are HER2-positive because non-HER2-amplified patients are not likely to respond. This underscores the importance of CDx in the targeted therapy.
- **Pembrolizumab of MSI-H or dMMR cancers:** Patients with a tumor of high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) should be diagnosed by first test before receiving pembrolizumab therapy. This will be able to selectively target patients whose tumors are likely to respond to immune checkpoint inhibition (maximizing clinical benefit and minimizing exposure to ineffective treatment).

➢ **Clinical Impact**

Introduction of companion diagnostics in clinical oncology practice has transformed the cancer care, and some of its major advantages include:

- **Precision Treatment:** CDx will make sure that therapies are precisely aligned with the molecular profile of the tumor of each patient. Companion diagnostics enhances treatment efficacy, resulting in improved response rates, increase in progression-free survival and overall survival rates as compared to non-stratified methods because they select the best patients who are likely to respond to a certain targeted therapy.
- **Decreased Toxicity:** In the unlikely cases that patients are not likely to respond to a certain therapy, they are not exposed to treatments which are ineffective. This

helps avoid treatment related side effects, adverse events and hospitalizations, enhances quality of life and safety, and saves healthcare resources.

- **Facilitated Clinical Decision-Making:** Companion diagnostics offer clinicians with valid biomarker information, which may be used to make evidence-based treatment decisions. When incorporated into the clinical workflow, CDx assists in making decisions more efficiently and confidently and, therefore, enables oncologists to choose the most adequate therapy timely.
- **Growth of personalized Medicine:** Companion diagnostics may bring about a shift in the empirical, one-size-fits-all treatment to the personalized, biomarker-based care. This combination of molecular diagnostics and targeted therapy is the defining philosophy of precision oncology and this allows the administration of treatments specific to the individual biological features of a tumor in a particular patient.

In sum, companion diagnostics is a decisive intersection of molecular diagnostics and therapeutic intervention, which is the key to the implementation of principles of precision medicine into clinical practice. CDx will lead to an improved clinical outcome, patient safety and the overall implementation of personalized oncology practice by making sure that the right patients get the right treatment and at the right time.

3.3. EMERGING BIOMARKERS (CIRCULATING TUMOR DNA, EXOSOMES, ETC.)

New biomarkers are re-defining precision oncology because they make it possible to monitor cancer non-invasively, dynamically and in real-time. In contrast to the more conventional tissue-based biomarkers, which necessitate invasive biopsies, these new biomarkers in many cases can be identified in blood, plasma, or other body fluids, and therefore, give an ongoing picture of tumor biology. This least invasive method can enable clinicians to evaluate the course of the disease, identify early recurrence, and evaluate the effectiveness of treatment without having to undergo a recurrent surgical procedure. These biomarkers can provide a more in-depth insight into the dynamics of cancers and make timely, data-driven therapeutic choices because they allow monitoring how tumors evolve over time.

Circulating tumor DNA (ctDNA), exosomes, and other circulating molecular markers are some of the most promising emerging biomarkers, as they can be used to detect minimal residual disease (MRD) and to identify new resistance mutations. Exosomes are small extracellular vesicles released by tumor cells and contain proteins, RNA, and DNA that can inform about

the tumor signaling, its metastatic potential, and microenvironment. The combination of these biomarkers with clinical practice has the possibility to enhance early diagnosis, direct individual approaches to treatment, and adopt adaptive therapy, a major step toward genuinely individualized cancer therapy.

- ***Circulating Tumor DNA (ctDNA)***

Circulating tumor DNA (ctDNA) are short strands of DNA released into the bloodstream by dying (apoptotic) or dying (necrotic) tumor cells. These genetic and epigenetic changes specific to tumors, including point mutation, copy number changes (amplifications or deletions of DNA strands), chromosomal rearrangements, and abnormal DNA methylation patterns, are contained in these DNA fragments. Since ctDNA is tumor cell based, it is a molecular snapshot of the tumor genome and includes not only intra-tumor heterogeneity but also reflects the tumor evolution processes over time. The percentage content of ctDNA in the overall circulating cell-free DNA (cfDNA) may differ among tumor type, stage, tumor burden, and other patient-specific factors.



Figure 4: Circulating tumor DNA (ctDNA)

Source: (https://en.wikipedia.org/wiki/Circulating_tumor_DNA)

- **Applications:**

1. **Early Cancer Detection:** ctDNA is capable of identifying tumor-specific genetic changes at very early stages, at a time when clinical symptoms are not yet apparent or when the tumors are too small to be detected by other standard imaging modalities. An early diagnosis of cancer through ctDNA is possible by studying a certain pattern of mutations or methylation peculiar to cancer cells, which can significantly change the clinical scenario. This premature diagnosis is especially useful among individuals at high risk, and other cancers which are otherwise asymptomatic at early phases.

2. **Surveillance of Minimal Residual Disease (MRD):** Minimal residual disease (MRD) can be a sensitive biomarker, which ctDNA can detect following definitive therapies including surgical resection, chemotherapy, radiotherapy, or targeted therapies. Although imaging reveals full remission, the presence of small amounts surviving malignant cells may release DNA in circulation. The presence of ctDNA after treatment may give a clue of risk of relapse, and the clinician may be able to intervene with therapeutic measures promptly or change the post-treatment schedule.

3. **Emerging Resistance Mutations:** Tumors may develop new genetic changes during therapy that allow them to be resistant to targeted therapy. ctDNA analysis is now capable of real-time detection of emerging resistance mutations, without requiring repeated invasive tissue biopsies to do so. Early detection of resistance mechanisms allows the clinician to adjust or change a therapy that may lead to better patient outcomes and extend treatment effectiveness.

- **Advantages:**

- **Minimally Invasive:** ctDNA blood testing does not need a large amount of tissue biopsy like traditional tissue biopsy; this makes it far less invasive. This saves the patients the pain and the risks posed by the procedure and the logistical problem of the repetition of tumor sampling.

- **Dynamic Longitudinal Monitoring:** ctDNA offers a solution to track molecular profile of tumors in the longitudinal. Sequential blood sample technology enables clinicians to monitor the tumor burden, efficacy of the treatment, and watch genetic evolution in near real-time. The monitoring is particularly helpful when it comes to evaluating the effectiveness of the treatment and identifying the signs of recurrence at an early stage.

- **Individualized Treatment Adjustment:** An ongoing study of ctDNA facilitates adjustment of therapy as an adaptive approach. The assessment of the changes in the molecular profile of a tumor in a patient during the treatment enables the clinician to adjust the intervention to focus on the novel mutations or resistant clones and, therefore, maximize the use of personalized treatment plans and increase the chances of a successful therapeutic outcome.

Exosomes

Exosomes are membrane-enclosed extracellular vesicles, generally of 30 to 150 nanometers diameter, actively released by both tumor cells and other normal and pathological cells into different bodily fluids, such as blood, urine, saliva and cerebrospinal fluid. These vesicles host a wide range of cargo made of biomolecules, such as DNA, multiple forms of RNA, such as messenger RNAs (mRNAs) and microRNAs (miRNAs), proteins and lipids. Exosomes contain the contents of the cells of origin and as such are an indicator of the physiological and pathological condition of those cells and as such a molecular snapshot of the tumor and the microenvironment. Exosomes are actively involved in intercellular communication, which affects such processes as tumor growth, angiogenesis, immune regulation, and metastasis because they transfer their molecular cargo to the recipient cells.

- **Applications:**

1. **Non-Invasive Biomarker Discovery:** Exosomes represent a rich and accessible source of tumor-derived nucleic acids and proteins, which can be analyzed without the need for invasive tissue biopsies. By profiling exosomal cargo, researchers can identify novel biomarkers for early cancer detection, disease progression, and therapeutic monitoring. This non-invasive approach is especially valuable for patients who are unable or unwilling to undergo repeated tissue sampling, allowing for broader and safer implementation in clinical settings.

2. **Insights into Tumor Microenvironment and Metastasis:** The molecular contents of exosomes provide critical information about the tumor microenvironment. Analysis of exosomal RNA and protein profiles can reveal mechanisms of intercellular communication between tumor cells and stromal or immune cells, uncover strategies of immune evasion, and indicate the metastatic potential of tumor cells. These insights enhance understanding of tumor biology, including how tumors interact with their

microenvironment, modulate immune responses, and establish pre-metastatic niches in distant organs.

3. **Predictive Information for Therapy Response:** Molecular profiling of exosomes allows clinicians and researchers to obtain predictive information regarding how tumors may respond to specific therapies. Changes in exosomal cargo can provide early indications of therapeutic efficacy or resistance, enabling timely adjustments in treatment plans. This real-time monitoring of tumor dynamics facilitates personalized medicine approaches and improves the likelihood of treatment success by allowing adaptive therapeutic strategies based on the evolving molecular profile of the tumor.

➢ **Advantages:**

- **Minimally Invasive Sampling:** Exosomes can be derived out of several easy-available body fluids which include blood, urine, saliva and cerebrospinal fluid. This enables a large number of repeated and non-invasive sampling which is especially useful in longitudinal studies of disease progression, therapeutic response, and in early recognition of relapse.

- **Stable Molecular Cargo:** The lipid bi-layer in exosomes cushions their nucleic acids and proteins against degradation by enzymes in circulation, which not only increases the stability and dependability of biomarker detection. This stability enhances reproducibility of the molecular analysis and that the exosomal cargo reflects the molecular phenotypes of the parent tumor cells.

Other Circulating Biomarkers

In addition to circulating tumor DNA (ctDNA) and exosomes, a number of other circulating biomarkers have become potential cancer diagnostic, prognostic, and therapeutic follow-up tools. These biomarkers can give complementary data and complement the capability of non-invasively assessing tumor dynamics, heterogeneity, and treatment response.

1. **Circulating Tumor Cells (CTCs):** Circulating tumor cells are intact cancer cells, discharged into the bloodstream by tumor primary or metastatic lesions. CTCs may be highly infrequent in circulation, and their recognition and characterisation give useful information about tumor biology. CTCs analysis enables the evaluation of tumor heterogeneity because these cells can have different genetic and phenotypic characteristics than primary tumor. CTCs are also indicative of tumor metastatic

potential and can be used as a dynamic biomarker to monitor response to therapy. High-technology approaches like immunoaffinity capture, microfluidic enrichment and molecular profiling are providing the opportunity to examine CTCs in large details such as analyzing mutations, examining gene expression patterns, and analyzing protein markers, and provide a glimpse into tumor dynamics in real time.

2. **MicroRNAs (miRNAs):** MicroRNAs are small, non-coding RNA molecules and are important in regulation of gene expression through post-transcription. Circulating miRNAs are very stable in the bloodstream and they are not broken down due to being linked to protein complexes or being incorporated into extracellular vesicles. It has been shown that dysregulation of distinct miRNAs is linked to tumor initiation, tumor progression, tumor metastasis, and therapy response. Since they are circulating freely, they are very attractive as non-invasive biomarkers to detect cancer, prognogenic, and therapeutic monitoring. Sensitive and specific data on disease state, molecular subtype, and possible mechanisms of resistance is sensitive and specific and can be obtained by profiling miRNA signatures in patient plasma or serum.

3. **Tumor-Derived Proteins:** Tumor cells and their microenvironment secrete a plethora of proteins into circulation such as growth factors, enzymes, cytokines, and cell-surface antigens. These proteins produced by the tumors may be used as early disease detection biomarkers, risk stratifications or even as a measure of treatment response. The circulating protein levels and patterns have the potential to indicate the tumor burden, biological aggressiveness and therapy induced changes. Sensitive and quantitative detection of these proteins is done by use of techniques like enzyme-linked immunosorbent assays (ELISA), mass spectrometry, and protein microarrays and can be integrated into liquid biopsy methods along with nucleic acids-based biomarkers.

Clinical Relevance

Together, these new circulating biomarker categories, such as circulating tumor DNA, exosomes, circulating tumor cells (CTC), microRNAs (miRNAs) and tumor-derived proteins, provide a potent, minimally invasive means of real-time tumor biology. Circulating biomarkers in contrast to the traditional tissue-based assays can capture a dynamic view of the molecular landscape of cancer and its changes during therapy because traditional assays can only provide a fixed snapshot of the tumor at one point in time. The integration of these biomarkers in the clinical processes enables a number of vital developments in the field of oncology:

1. **Early Cancer Detection:** Recently discovered circulating biomarkers can detect specific changes in tumors related to molecular alterations ahead of the appearance of clinical symptoms and/or any lesion that can be detected using imaging methods. The timely intervention through cancer detection is easy since cancer may be detected at an early stage thus yielding better prognosis and higher chances of being treated. In high-risk populations or cancers with no symptoms at early stages, ctDNA, exosomal cargo and circulating miRNAs offer a sensitive and non-invasive screening and surveillance method.
2. **Increased Risk Stratification:** Clusters of molecular profiles observed in the biomarkers of such biomarkers will provide clinicians with a more accurate strategy of stratification of patients based on their risk of relapse, progression, or metastasis. As an example, minimal residual disease can be detected through ctDNA or changes in CTC numbers, and could be used to designate patients who are more at risk of relapse, which would result in closer monitoring and more proactive therapeutic interventions. This stratification enhances clinical decision making and informs individualized treatment of patients.
3. **Adaptive and Personalized Treatment Strategies:** Dynamic monitoring of circulating biomarkers makes adaptive therapy in which the treatment is changed in response to real-time molecular changes occurring in the tumor. As an illustration, the identification of acquired resistance mutations in ctDNA or changes in exosomal occupancy may result in a revision of individual therapy or the adoption of combination-based therapy. Such personalized treatment has the highest therapeutic effect, minimizes the needless exposure to ineffective treatments, and is consistent with the principles of precision medicine.
4. **Observing Therapeutic Response and Emerging Resistance:** Serial changes in circulating biomarkers will give a glimpse of how a patient is responding to the therapy and also the mechanisms developing resistance. Declines in ctDNA or a decrease in CTC are frequently associated with favorable treatment response, and an increase or the development of novel molecular changes could point to both treatment resistance and disease advancement. The consistent observing enables clinicians to take timely actions, to alternate or escalate therapy according to the patient requirements in order to maximize patient results.The application of these new circulating biomarkers in standard clinical practice is a paradigm shift in the field of oncology and a move beyond

the traditional tissue biopsies to real-time, precision-guided treatment of cancer. These biomarkers can be used to enhance survival rates, increase the quality of life, and revolutionize the overall quality of care of a cancer patient by making it more accurate, easier to detect, induce necessary adjustments of therapy, and follow the changes all the time.

3.4. CHALLENGES IN STANDARDIZATION AND VALIDATION

Although biomarkers have the potential to revolutionize precision oncology, their use in daily clinical environment is complicated and difficult. Laboratory to laboratory variability can be caused by technical and analytical problems including inconsistency in the collection of samples and the methods of sample processing and assay. Furthermore, molecular data is high dimensional, and bioinformatics pipelines and interpretation criteria are different, which complicates reproducibility. These technical challenges have to be addressed so that biomarker measures are accurate, reliable, and comparable when used in various clinical environments, which will be necessary in making therapeutic choices and assessing patient outcomes.

In addition to technical issues, there are clinical, regulatory, economic, and biological issues that make biomarker implementation more difficult. In clinical terms, biomarkers need to show obvious use in either diagnosis, prognosis or treatment choice, and this necessitates widespread confirmation in varying groups of patients. Regulatory frameworks will require strict evidence of an analytical and clinical validation, and the economic aspects involve the cost-efficiency of biomarker testing at large scale. Biomarker performance can be influenced by heterogeneity of the tumor and dynamic changes in molecular content over time biologically, which require repeated measurements and dynamic interpretation. It is important that these complex issues be addressed to transform the research of biomarkers into effective and consistent tools that can help to improve precision oncology.

1. Technical Variability

Technical variability is one of the key problems in the biomarker research and its clinical implementation. This is indicated by the variances and discrepancies that occur during the sample collection, handling, process and storage of the samples and which may significantly affect the accuracy, reliability and reproducibility of the measurements of the biomarkers. Technical variability may blur the real biological messages and therefore cause discrepancies between laboratories or even within a study and hence restrict the clinical applicability of the biomarker.

Examples of Technical Variability:

- **Circulating Biomarkers:** The concentration of circulating tumor DNA (ctDNA), exosomal nucleic acids or circulating microRNAs can be greatly sensitive to pre-analytical factors. The stability and quantification of these biomarkers can all depend on factors like the kind of blood collection tube, selection of anticoagulant, the interval that elapses between the collection and processing of the samples, the storage temperatures and the number of freeze-thaw cycles. Even a slight variation in these variables may lead to a great difference in measurements and thus in interpretation and clinical decision-making.

- **Tissue-Based Biomarkers:** Tissue also varies. Protein integrity, nucleic acid quality, or antigenicity may change depending on time, fixative type, tissue section thickness, and storage, and this may interfere with downstream assays, including immunohistochemistry, sequencing, or PCR-based analyses. This low consistency may cause false negative or poor quantification of biomarkers.

Need for Standardization:

To mitigate technical variability, the development and implementation of standardized protocols for all pre-analytical and analytical procedures is critical. Standardization encompasses guidelines for sample collection, handling, processing, storage, and quality control, ensuring that biomarker measurements are reproducible and accurately reflect underlying biological phenomena rather than technical artifacts. Consistent protocols facilitate inter-laboratory comparability, enable meaningful integration of data across clinical trials, and support reliable biomarker-based clinical decision-making. Without such standardization, variability can compromise the interpretation of results, reduce confidence in biomarker utility, and limit the translation of promising biomarkers into routine clinical practice.

2. Analytical Validation

Analytical validation is an essential part of biomarker research and clinical use to ensure that a biomarker assay works reliably, accurately and reproducibly. This is especially important when the biomarker is of low abundance, e.g., circulating tumor DNA (ctDNA), rare circulating tumor cells (CTCs), or circulating microRNAs (miRNAs), where small analytical artifacts can heavily affect the sensitivity, sensitivity of detection, and sensitivity of interpretation. Analytical validation creates a sense of assurance that what is being measured by the assay is what it is supposed to measure and that the results can be relied on to make clinical decisions.

- **Key Considerations:**
  - **Accuracy:** Accuracy is the capacity of an assay to determine the biomarker of interest properly and to measure it accurately. In the case of circulating biomarkers, this involves the separation of genuine positive signals, and background noise, nonspecific signals or artifacts. Precise measurement is critical in that it requires the presence, absence or concentration of the biomarker to be representative of the actual biological status of the patient, and is necessary in identifying early disease, assessment of minimal residual disease or response to treatment.
  - **Sensitive:** The ability of an assay to identify very low quantities of biomarker molecules, which is essential to early diagnosis of cancer or to monitor minimal residual disease after treatment, is known as sensitivity. Sensitive assays may be used to detect small tumor-derived fragments, rare CTCs or low-abundance miRNAs in circulation thereby allowing clinicians to detect cancer or recurrence at the point at which intervention may be most effective. To minimize background interference, increase signal detection, and accurately measure low-copy-number biomarkers the analytical methods commonly require optimization.
  - **Reproducibility:** Reproducibility is the ability to give an assay consistent result when performed under repeated measurements across different operators, instruments and different laboratory conditions. Repeated reproducibility is essential to longitudinal sample comparisons in the same patient, cross-trial integration of results, and standardization of clinical procedures. The reliability of biomarker-directed decisions, including adjusting treatment according to developing resistance mutations or treatment response, is also based on reproducibility.

Strong analytical validation is thus required to build confidence in biomarker measurements. Assay results can be misleading without comprehensive validation and hence cause improper choice of treatment, delays and failure to identify recurrence of diseases. Analytical validation, through precision in accuracy, sensitivity and reproducibility, is the basis of safe and effective circulating biomarker use in precision oncology.

3. Clinical Validation

In addition to technical and analytical reliability, biomarkers have to pass a strong clinical validation to determine their relevance and applicability in actual patient care. Clinical validation indicates that the biomarker reliably has significant clinical outcomes, including disease progression, response to therapy, recurrence, or survival in general. This is necessary

so that not only are biomarker measurements scientifically correct, but also clinically actionable.

- **Requirements for Clinical Validation:**
  - **Testing in Big and Heterogeneous Populations of Patients:** The biomarkers are to be assessed using large cohorts that are representative of the heterogeneity of real-world populations. This involves variability by age, sex, ethnicity, tumor type, stage of disease and comorbidities. This diversity makes the biomarker robust in its performance and generalizability without the risks of biases that could be introduced by the study of a biomarker applied to limited sets of patients. Clinical validation in different populations is useful in ensuring that the readings of biomarkers is accurate in all patients and that it is applicable in different clinical backgrounds.
  - **Predictive and Prognostic Value:** validation studies should be able to demonstrate that the levels of biomarkers (or their change with time) are predictive of clinically meaningful outcomes. This involves the capacity to predict therapeutic response, minimal residual disease, risk of recurrence and survival probabilities. A biomarker which has a high correlation with these results can give clinicians actionable information that can be used to influence the choice of treatment, therapy timing and patient guidance.
- **Importance:**

Biomarkers cannot be depended upon in everyday clinical practice to risk-stratify, inform treatment choices, or make predictions unless they have strong clinical validation. Although a biomarker may be analytically accurate and can be reproducible technically, its clinical value needs to be demonstrated to be worth including in care pathways. Clinical oncology The use of biomarkers in clinical settings depends on the sound evidence that measurement has resulted in improved patient treatment, new personalized therapy, and finally improved clinical outcome. The last, most necessary step before biomarkers can safely and effectively be utilized in precision medicine is clinical validation, which fills the gap between laboratory results and patient benefit in the real world.

4. Regulatory and Cost Considerations

Regulatory and economic factors are critical in translating biomarkers research in the clinical practice. Regulatory approval is an important gateway to demonstrate that biomarker-based diagnostics such as companion diagnostics are safe, effective and have meaningful clinical

utility. Such agencies like the U.S. Food and Drug Administration (FDA) insist on full preclinical and clinical data that will prove the biomarker to be a reliable source of clinical decision-making, enhancing patient outcomes, and not unduly risky. Adoption of biomarkers in clinical workflows requires the satisfaction of these regulatory requirements.

- **Challenges:**
  - **High Costs:** Due to the complex clinical validation and regulatory compliance procedures that are required to approve biomarkers, they require a lot of money. Research frequently involves very many and heterogeneous patient populations, longitudinal follow-up and advanced analytical methods, which are costly. These financial requirements in the cases of new or emerging biomarkers can be prohibitive and restrict the development and commercialization of potentially useful diagnostic tools.
  - **Limited Reimbursement:** Although regulatory acceptance is received, the clinical use of biomarkers can be limited by the lack of insurance coverage or prohibitive reimbursement. In the absence of proper reimbursement, hospitals and laboratories may not be willing to adopt new tests and patients may encounter access barriers. This may help delay the adoption of innovative technologies in the biomarker technologies into routine practice and minimise their net effect on patient management.
  - **Regulatory Complexity:** Biomarkers based on sophisticated technologies, including liquid biopsies, next-generation sequencing (NGS), or multi-omic assays have especially complicated regulatory pathways. The novelty and sophistication of these assays frequently need supplementary validation procedures, comprehensive performance criteria and stringent quality control criteria. The regulatory requirements may extend the gap between discovery and clinical application, putting the potentially life-saving diagnostics at the end of clinical use among patients.

Such difficulties demonstrate the significance of strategic planning in the development of biomarkers. A cost-effective study design, early interaction with regulatory bodies, and partnerships among researchers, clinicians, industry stakeholders, and payers are required to help in translating biomarkers into clinical practice. The consideration of regulatory and cost issues is a proactive approach to delivering the prospective biomarkers an opportunity to reach a wide clinical acceptance and provide real-world value in precision oncology.

REFERENCES

1. Kraus, V. B. (2018). Biomarkers as drug development tools: discovery, validation, qualification and use. *Nature Reviews Rheumatology*, *14*(6), 354-362.
2. Parker, L. A., Chilet-Rosell, E., Hernández-Aguado, I., Pastor-Valero, M., Gea, S., & Lumbreras, B. (2018). Diagnostic biomarkers: are we moving from discovery to clinical application?. *Clinical Chemistry*, *64*(11), 1657-1667.
3. Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., ... & Pelleymounter, M. A. (2020). Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. *Nature Reviews Neurology*, *16*(7), 381-400.
4. Califf, R. M. (2018). Biomarker definitions and their applications. *Experimental biology and medicine*, *243*(3), 213-221.
5. Arbitrio, M., Scionti, F., Di Martino, M. T., Caracciolo, D., Pensabene, L., Tassone, P., & Tagliaferri, P. (2021). Pharmacogenomics biomarker discovery and validation for translation in clinical practice. *Clinical and Translational Science*, *14*(1), 113-119.
6. Srivastava, A., & Creek, D. J. (2019). Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics. *Proteomics*, *19*(10), 1700448.
7. Boerrigter, E., Groen, L. N., Van Erp, N. P., Verhaegh, G. W., & Schalken, J. A. (2020). Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. *Expert review of molecular diagnostics*, *20*(2), 219-230.
8. Ng, S., Masarone, S., Watson, D., & Barnes, M. R. (2023). The benefits and pitfalls of machine learning for biomarker discovery. *Cell and tissue research*, *394*(1), 17-31.
9. Pantel, K., Hille, C., & Scher, H. I. (2019). Circulating tumor cells in prostate cancer: from discovery to clinical utility. *Clinical chemistry*, *65*(1), 87-99.
10. Hristova, V. A., & Chan, D. W. (2019). Cancer biomarker discovery and translation: proteomics and beyond. *Expert review of proteomics*, *16*(2), 93-103.
11. Ceccherini, E., Michelucci, E., Signore, G., Coco, B., Zari, M., Bellini, M., ... & Rocchiccioli, S. (2024). The clinical utility of the saliva proteome in rare diseases: a pilot study for biomarker discovery in primary sclerosing cholangitis. *Journal of Clinical Medicine*, *13*(2), 544.
12. Zou, J., & Wang, E. (2019). Cancer biomarker discovery for precision medicine: new progress. *Current medicinal chemistry*, *26*(42), 7655-7671.

13. Chen-Plotkin, A. S., Albin, R., Alcalay, R., Babcock, D., Bajaj, V., Bowman, D., ... & Zhang, J. (2018). Finding useful biomarkers for Parkinson's disease. *Science translational medicine*, *10*(454), eaam6003.
14. Ou, F. S., Michiels, S., Shyr, Y., Adjei, A. A., & Oberg, A. L. (2021). Biomarker discovery and validation: statistical considerations. *Journal of Thoracic Oncology*, *16*(4), 537-545.
15. Vacante, M., Borzì, A. M., Basile, F., & Biondi, A. (2018). Biomarkers in colorectal cancer: Current clinical utility and future perspectives. *World journal of clinical cases*, *6*(15), 869.

Chapter 4…

IMAGING AND RADIOGENOMICS IN PRECISION DIAGNOSIS

ASHIMA DEVI
Associate professor
Vinayaka College of Pharmacy, Kullu HP
Email: pm_vcp@rediffmail.com

ASHRITA DUBEY
Assistant Professor
Glocal University
Pin - 247121
Email: ashritadubey@gmail.com

Dr. SHRADDHA WALEKAR GHAISAS
Lecturer
MGM Dental College and Hospital
Kamothe, Navi Mumbai, 421202
Email: Shraddhawalekar7@gmail.com

Dr. MUKESH KUMAR MEENA
Assistant Professor
Department of Pharmaceutical Sciences, Mohanlal Sukhadia University,
Udaipur, Rajasthan, 313001, India
Email: mukesh_meena27@mlsu.ac.in

Dr. SABEEN FATMA
Faculty
Department of Biotechnology, Chaudhary Charan Singh University,
Meerut, 250002
Email: sabeenfatima16@gmail.com

The use of molecular imaging that encompasses Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) offers a robust tool of visualizing and quantifying cellular and molecular biological processes in a non-invasive manner. These modalities also provide functional, metabolic and physiological data, in contrast to traditional imaging, which mainly represents the anatomic structures so that they can be detected early, staged, and the tumor monitored dynamically. PET involves the use of radiolabeled tracers such as 18F-FDG to identify localized regions of increased metabolic activity, and can be of particular use in oncology to identify primary and metastatic lesions, treatment response, and therapy adjustments.



Figure 1: Molecular Imaging Techniques

Source: (https://www.mdpi.com/2073-4360/13/17/2989)

MRI provides high-resolution soft tissue contrast and advanced functional imaging techniques, including diffusion-weighted imaging (DWI), functional MRI (fMRI) and magnetic resonance spectroscopy (MRS), which together allow insights into tissue cellularity, tissue perfusion, and tissue biochemical composition. CT frequently paired with PET provides fast, high-resolution anatomy that is essential in structural assessment, procedure guidance, and overall staging. Combined, these imaging modalities are the foundation of precision oncology because they incorporate anatomical, functional, and molecular viewpoints.

Radiomics also complements the value of the molecular imaging further by deriving high-dimensional quantitative characteristics of the medical images that reflect the shape, texture, intensity, and spatial heterogeneity of the tumor. Those characteristics demonstrate latent biological attributes like cellular density, necrosis, fibrosis and vascularization that could be invisible under conventional imaging. Radiomic can contribute to phenotyping of tumors, prognostic modeling, risk stratification, and therapy design plans, as it offers non-invasive, reproducible, and complete-tumor analysis. With the combination of radiomic data and clinical, genetic and molecular data, clinicians have the capacity to create prediction models that forecast response to treatment, determine regions resistant to therapy and monitor disease progression over time. The method enables clinical decisions that are better informed and data-driven and the development of customized approaches to treatment.

Radiogenomics provides an additional step of integration by comparing imaging phenotypes with genomic and molecular phenotypes and can predict tumor behavior, therapeutic sensitivity, and patient prognosis non-invasively. Real-time imaging is additive to these techniques in that they enable continuous functional and molecular observation of therapeutic response with frequent detection of early signs of metabolic or structural alterations before clinical manifestation. PET, advanced MRI, and liquid biomarkers such as circulating tumor DNA (ctDNA) are technologies in which clinicians are able to plan adaptive therapy based on dynamic tumor dynamics so as to alter treatment regimens. Together, molecular imaging, radiomics, radiogenomics, and real-time monitoring can offer a multidimensional, non-invasive framework that can increase the precision of oncology, improve patient outcomes and enable truly personalized cancer care.

4.1. MOLECULAR IMAGING TECHNIQUES (PET, MRI, CT)

Molecular imaging can be defined as a set of progressive, non-invasive methods developed to visualize and measure biological processes at both the molecular and cellular scales in living organisms. In comparison to the traditional approaches of imaging, where the main emphasis is often put on anatomy or structure, the functional, metabolic, and physiological aspects of tissues and organs are observed in case of the molecular imaging. Such an opportunity allows clinicians to monitor disease processes in real time and identify early pathological changes as well as dynamic reactions to treatment. In cancer, as an example, molecular imaging can show the metabolic activity of tumors, receptors and cell proliferation patterns, which can hardly be provided by anatomical scans.

The most important molecular imaging modalities are Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), as well as Computed Tomography (CT), each of which has its own advantages. PET involves the use of radiolabeled tracers, which have been used in detecting metabolic or molecular activity, and is therefore invaluable in identifying active tumor site, or monitoring treatment response. MRI can give high-quality images of the anatomy and also functional data using methods such as diffusion-weighted imaging and spectroscopy and thus determine the composition and microenvironment of the tissues. CT is primarily structural, but may be supplemented with molecular contrast agents in order to show vascular patterns, or tissue-specific uptake. Combined, these modalities represent a potent, integrative strategy in early diagnosing, individualized treatment planning, and real-time tracking the disease progression and treatment response.

❖ **Positron Emission Tomography (PET)**

PET, which is highly sensitive with molecular imaging, is used to show biochemical and metabolic processes in tissues on a non-invasive basis and in a quantitative way. In contrast to the traditional anatomical imaging, PET images the functional activity on a molecular scale, which gives information on the cellular metabolism, receptor expression and other physiological processes. This ability enables clinicians to identify the activity of a disease before the structural changes are apparent, and PET is a priceless resource in oncology, neurology, and cardiology.



Figure 2: Positron Emission Tomography (PET)

Source: (https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan)

Mechanism:

PET is based on radiolabeled tracers, radiolabeled molecules or molecules that have been labeled with a positron emitter like fluorine-18 (^18F). Fluorodeoxyglucose is an analog of glucose known as a tracer commonly used in oncology (18F-FDG). Following intravenous delivery, the uptake of the proliferating tumor cell is preferentially metabolically active cells (such as metabolically active tumor cells), with rapidly proliferating cells (typically high glucose uptake) tending to be preferentially labeled by 18F-FDG. The radioactive isotope produces the positrons during the process of decay. Once these positrons come in contact with electrons in the adjacent tissues, they come to an end, and they emit pairs of gamma photons that move in opposite directions. The PET scanner captures such gamma rays and re-forms three-dimensional images of regions of metabolic activity. The accumulation of tracers can be evaluated by quantitative measurements using standardized uptake values (SUVs) which can be compared across time points or in different patients.

Applications in Oncology:

1. **Cancer Detection:** PET with an 18F-FDG is popularly applied to detect primary tumors and cancerous lesions as the areas where glucose metabolism is high, a typical characteristic of malignant cells. PET has the potential to identify occult tumors as seen on other imaging modalities and allow earlier diagnosis and treatment.

2. **Staging:** PET is important in the staging of cancer to ascertain the disease. The presence of metastatic lesions in the lymph nodes, bones, liver, lung, or other organs, which may be not observed with CT or MRI, can be revealed with the help of whole-body PET imaging. Proper staging leads to the treatment planning, estimation of prognosis and eligibility to curative or palliative treatment.

3. **Therapy Monitoring:** PET can be useful in assessing therapeutic response, whereby we monitor metabolic alterations in tumors which is usually visualized before anatomical alterations, e.g. reduction in size in CT or MRI. Reductions in tracer uptake are signs of effective treatment, but continued uptake or increased uptake of the tracer can reflect resistance or progression of the disease. PET is thus able to direct early changes in treatment options and enhance patient outcomes.

Advantages:

- **High Sensitivity:** PET imaging has an extremely high sensitivity in terms of identifying localized regional hyperactivity of metabolism, and in many instances, it is able to reveal malignant or abnormal cellular processes in the body before visible change is observed using more conventional imaging techniques of CT or MRI. This is possible because this early disease detection capability enables clinicians to apply early interventions, optimize treatment plans and possibly enhance patient outcomes. Early diagnosis is also of vital importance when it comes to tracking the progression of a disease and predicting complications, thus, aiding in managing a patient more accurately and specifically.
- **Whole-Body Imaging:** The ability of PET to image the entire body allows one to see both primary tumors and other possible areas of metastasis simultaneously, a characteristic that is considered one of the greatest strengths of the technique. The comprehensive examination will enable proper latex staging of the disease, guide the choice of the most viable treatment courses of action and improve the monitoring of cancer dissemination. Whole-body imaging can be especially useful in the detection of occult metastases or multifocal disease that otherwise may not be detected by a localized imaging modality, and improve clinical decision-making and targeted, more effective interventions.
- **Quantitative Analysis:** PET imaging offers quantitative measurements of radiotracer uptake that are highly objective and reproducible and most are described as standardized uptake values (SUVs). Such measurements capture metabolic activity of tumors, and they can be used to monitor changes through time. Quantitative analysis enables clinicians to assess the response to therapeutic interventions accurately, measure baseline and follow-up research, and make evidence-based judgments about whether to modify or continue the treatment or not. PET allows planning of treatment individually, and increases the possibility of forecasting the prognosis and therapeutic outcome, providing the numerical and pictorial display of tumor metabolism.

❖ **Magnetic Resonance Imaging (MRI)**

Magnetic Resonance Imaging (MRI) is a non-invasive imaging system that uses high magnetic fields and radiofrequency (RF) pulses to create high-resolution anatomy images of organs and tissues. As opposed to imaging procedures, which use ionizing radiation, MRI exploits the

magnetic characteristics of hydrogen nucleuses in water and fat molecules to create a contrast to various forms of tissue. In addition to traditional anatomy imaging, new MRI technologies offer functional, physiological, and molecular imaging of tissue biology, thus MRI is a highly powerful instrument in oncology, neurology, and cardiology.

Advanced MRI Techniques:

1. **Diffusion-Weighted Imaging (DWI):** DWI measures the random Brownian movement of water molecules in the tissues. Cellularity of tissues and integrity of tissues can be indicated by the degree of water diffusion. In tumors, elevated cellular areas normally limit the movement of water, so the signal intensity is high on DWI with low apparent diffusion coefficient (ADC) measures. DWI is usually employed in the characterization of tumors, the early signs of malignancy, and treatment response evaluation. It is specifically useful in making a distinction between benign and malignant lesions, as well as in detecting residual or recurrent disease.
2. **Functional MRI (fMMRI):** Functional MRI is a technique that measures the variation in blood oxygenation, which is connected to the perfusion and functional activity of the brain. fMRI is very popular in brain mapping to determine regions of the brain that are involved in motor, sensory and cognitive processes. Oncologists use fMRI to learn about tumor vascularization, heterogeneity of perfusion and the influence of tumors on the surrounding functioning tissue. This information helps during the planning of surgery, radiation therapy targeting and assessment of treatment induced changes in tumor physiology.
3. **Magnetic Resonance Spectroscopy (MRS):** MRS is a method that assesses the biochemical make up of tissues by identifying select metabolites. Metabolic changes are a feature of cancer, and MRS can detect increased concentrations of choline and lactate and other metabolites related to tumor growth, hypoxia, or necrosis. The method allows the non-invasive metabolic profiling of tumors as a complement to structural imaging, as well as the provision of extra diagnostic and prognostic data.



Figure 3: Magnetic Resonance Imaging (MRI)

Source: (https://www.researchgate.net/figure/Basic-Compartments-of-the-Magnetic-Resonance-Imaging-MRI-System-Moore-and_fig2_269465794)

Advantages:

- **Excellent Soft-Tissue Contrast:** MRI provides superior differentiation of soft tissues, allowing precise delineation of tumor boundaries, local invasion, and involvement of adjacent structures.
- **No Ionizing Radiation:** MRI is safe for repeated follow-up studies, making it suitable for longitudinal monitoring of disease progression and therapeutic response.
- **Functional and Molecular Insights:** Advanced MRI techniques such as DWI, fMRI, and MRS enable non-invasive assessment of tumor biology, including cellularity, perfusion, and metabolism, facilitating comprehensive evaluation beyond anatomical imaging.

❖ **Computed Tomography (CT)**

Computed Tomography (CT) is an imaging modality that has become common and is used to produce detailed images of the body in cross-sectional images through the use of X-rays. CT

creates high-resolution tomography images by rotating an X-ray source and a detector around the patient, which offers a precise anatomical detail of tissues, organs and skeletal frames. CT allows structural and functional information integration with molecular imaging modalities (including Positron Emission Tomography, PEPS/CT) to contribute greatly to the accuracy of the diagnosis, staging, and treatment planning in cancer therapy.

Applications in Oncology:

1. **Structural Assessment:** CT scanning is one of the tools that are used most to identify tumors, assess the involvement of the organs, and find the abnormalities in the anatomy that accompanies malignancy. It offers precise visualization of tumor size, shape and local spread, and involvement of adjacent tissues, lymph nodes and the adjacent organs. CT would also be useful in the identification of calcifications, necrotic, or vascular invasion in tumors, which would be part of the assessment of the overall structure.
2. **Instruction on Biopsies and Interventions:** CT is often used to direct less invasive interventions, including core needle biopsies, fine-needle aspirations, and percutaneous ablations. CT offers real time localization of anatomy that is important in ensuring that lesion is targeted correctly without causing too much damage to the body. Also, CT images are used to aid in surgical planning and treatment targeting to ensure effective delivery of treatment.
3. **Combined PET/ CT Imaging:** PET can be tested with CT to detect metabolic activity and localization of anatomy at the same time. PET determines areas of high metabolism or increase in molecular activity whereas CT can give detailed structural context which enhances diagnostic confidence and accuracy. The hybrid imaging method is more especially helpful in staging cancers, identification of metastases, evaluation of response to treatment and in planning targeted therapies.

Figure 4: Computed Tomography (CT)

Source: (https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/computed-tomography-ct-scan)

Advantages:

- **Rapid Imaging:** CT offers fast acquisition times, enabling quick assessment of large body regions and making it suitable for critically ill patients or emergency settings.
- **High Spatial Resolution:** CT provides excellent visualization of structural abnormalities, bone involvement, and calcifications, facilitating detailed anatomical evaluation.
- **Wide Availability:** CT scanners are widely accessible in most clinical centers and are relatively straightforward to operate, making them a standard imaging tool in oncology.

❖ **Clinical Utility**

Techniques such as Molecular imaging such as, Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) enable a detailed picture of tumor biology beyond conventional anatomical imaging. Temporal, functional, metabolic, and structural modalities provide clinicians with a way to make better decisions based on diagnosis, staging, therapy, and follow-up by providing them with functional, metabolic, and structural information simultaneously. Their use within the clinical workflows has become a necessity in precision oncology.

- **Early Tumor Detection:** Molecular imaging enables the detection of the malignancy before structural alteration manifest on conventional imaging. PET, e.g., can detect areas of heightened metabolic activity that is evidence of tumor growth, whereas the most recently developed MRI methods, e.g., diffusion-weighted imaging (DWI) can identify alterations in the cellularity of the tissues. Tumors can be spotted early, which leads to a timely intervention that may better prognosis and chances of curative treatment.
- **Precise Staging:** It is important to determine the extent of the disease precision in order to plan treatment. PET/CT, and multiparametric MRI can provide a whole-body evaluation of primary lesions and metastases. These imaging methods can give specific details on the size of the tumor, invasion of the surrounding area, the presence of lymph nodes, and distant metastases. During accurate staging, the choice of surgical methods, radiation therapy, and systemic treatment are provided, and thus the patient outcomes are maximized.
- **Monitoring Therapeutic Response:** Molecular imaging can be used to monitor the efficacy of treatment in real-time by assessing the metabolic or perfusion or cellular integrity of a tumor. The changes in tracer uptake can be shown by PET, and the response is positive after therapy, sometimes before tumor changes are noticeable. Correspondingly, MRI can be used to examine cellular level tissue response, e.g., DWI or perfusion. This has enabled clinicians to use adaptive treatment planning, adjusting therapies on-the-fly to optimize effect and reduce exposure to treatment regimens that do not work.
- **Individualized Treatment Planning:** The combination of PET, MRI and CT results enables individual choices of therapeutic plans according to tumor biology, anatomic position, and functional states. PET determines the active regions of a tumor in relation to metabolism, MRI examines the characteristics and the vascularization of tissues, and CT allows a specific localization of the structures. With such complementary data, clinicians are able to customize the surgery, radiation, and systemic therapies to the distinct profile of each patient disease, improving accuracy and minimizing treatment-associated toxicity.

Molecular imaging is one of the pillars of precision oncology, as it can offer a multidimensional perspective on tumor volumes. The technologies facilitate informed clinical judgment, provide

adaptive and individualized care, and help to achieve better patient outcomes, which ultimately will promote the quality of care in cancer management.

4.2. RADIOMICS AND IMAGE-BASED PHENOTYPING

Radiomics is a new field of medical imaging that converts typical scans (CT, MRI, and PET) into high-dimensional and quantitative data. In contrast to traditional imaging where evaluation of the tumor size and shape or location is based on visual assessment, radiomics can retrieve hundreds and thousands of subtle features reflecting tumor heterogeneity, texture, intensity and spatial organization. These characteristics can be usually characteristic of the underlying biology such as density of cells, their vascularization, hypoxia and stromal makeup, which cannot be seen with the human eye. Radiomics can help to better understand the behavior and aggressiveness of tumors and how they may react to treatment by quantifying these properties systematically, allowing more informed and accurate clinical decision-making.

Radiomics can be combined with other modalities of data, including genomic, proteomic and clinical data, to enable multidimensional tumor phenotyping. This is because this image-based phenotyping assists in risk stratification, predicting the outcome of prognosis and personalizing the treatment plan by showing the patterns that may associate with the treatment response or disease progression. Also, radiomics can inform the selection of patients in clinical trials, treatment efficacy, and early resistance indications, without subjecting patients to invasive procedures. Radiomics enhances precision in oncology and provides a noninvasive source of information about tumor biology that is not readily available with molecular assays or histopathology as it converts conventional imaging into a rich resource that can be analyzed.

- **Types of Radiomic Features**

Radiomics involves the extraction and quantitative analysis of numerous imaging features from medical images, each designed to capture specific biological, structural, or functional properties of tumors. These features are broadly classified into the following categories:

1. Shape and Size Features

The geometric and spatial features are represented by shape and size characteristics of tumors. They offer objective data on the morphology of tumors that extend beyond visual examination to assist the inference of biological behavior. Typical shape and size measures are:

- **Volume:** It is a measurement of three-dimensional space of the tumor. It is believed that the bigger the volume of the tumor, the later the disease and the worse the prognosis.
- **Surface Area:** Measures the external border of the tumor, giving information on the complexity of tumor.
- **Sphericity:** This test compares the tumor to a perfect sphere. Lower sphericity of tumors is more irregular and can tell of aggressive growth.
- **Compactness:** The ratio of the tumor size in terms of its surface area, and volume can indicate growth patterns.
- **Elongation:** This is a description of the ratio between the major and minor axes of the tumor: either the tumor grows stretched or in a rounded manner.
- **Irregularity:** Records irregularities in smooth, regular forms, to emphasise complex tumor edges, which could indicate invasive possibility.

Clinical relevance:

Highly irregular, long, or non-spherical tumours tend to have more aggressive biological behaviour, be more invasive, and have worse prognosis. The analysis of shape may also help in treatment response assessment and surgery planning.

2. Texture Features

The texture features examine pixel or voxel intensities within the tumor in terms of spatial distribution and variation. These characteristics are able to capture tumor heterogeneity and structural intricacy, which are based on internal biological mechanisms:

- **Entropy:** The degree of randomness in terms of intensity patterns, and as entropy increases, the heterogeneity of the tumor also increases.
- **Uniformity:** Will indicate the regularity of the intensity values, and the greater the uniformity, the more homogenous the tumor region.
- **Coarseness:** Refers to the texture pattern granularity or roughness, which can be related to tissue organization or fibrosis.
- **Contrast:** Compares the intensity of the adjacent pixels or voxels to show the areas with in different cellular density.

- **Correlation:** Measures the linear dependence of intensity values across neighboring voxels and indicates structural regularity or structure.

Clinical relevance:

Texture analysis can identify necrotic regions, fibrosis, stromal content, and cellular density variations within tumors. These heterogeneities are critical in predicting tumor aggressiveness, metastatic potential, and treatment response.

3. Intensity-Based Features

Intensity-based features is concerned with distribution and intensity of imaging signal intensities in the tumor. They tend to offer functional information on tumor microenvironment:

- **Signal Mean and Median:** The mean of the tumor voxels has been used as a measure of overall activity or tissue composition.
- **Variable:** Standard Deviation and variance: Measure the distribution of the intensity values, which mean that it is heterogeneous or composed of mixed tissue.
- **Maximum and Minimum Intensity:** Mark extreme values, which can be highly metabolically active or necrotic areas.

Clinical relevance:

Variations in intensity may indicate vascularization, perfusion, hypoxia, or metabolic activity. For example, high uptake in PET imaging signifies metabolically active tumor regions, while low-intensity areas in MRI may correspond to necrotic or fibrotic tissue.

4. Spatial Distribution Features

Spatial distribution characteristics determine the distribution of imaging signals in the tumor or with respect to normal tissues. These functions can map the patterns of tumor infiltration, the heterogeneity gradients, and the interactions with the surrounding structures:

- **Gradient Features:** Assess the change in intensity value between the edges of the tumor, and it will show sharp edges or gradual changes.
- **Cluster or Neighborhood Analysis:** Identify areas of similar or dissimilar intensity to measure both local heterogeneity and tumor subregions.

- **Tumor-to-Background Ratios:** Compare the intensity of tumor to the surrounding tissues to assess invasion, edema, or stromal interactions.

Clinical relevance:

Spatial distribution analysis is essential for understanding tumor progression, infiltration into adjacent tissues, metastatic potential, and resistance to therapy. It can also guide radiation therapy planning and predict regions at higher risk of recurrence.

➢ **Applications of Radiomics**

Radiomics has wide clinical use in cancer diagnostics; the applications can be quantitative to a significant extent of improvement of the traditional method of diagnosing and histopathological examination of the given cancer. Radiomics provides the ability to provide richer insights into tumor biology and make informed clinical decisions based on the conversion of imaging data into high-dimensional, mineable information:

1. Tumor Phenotyping

Radiomics can be used to accurately define tumor subtypes based on imaging-based quantitative characteristics and not necessarily on invasive tissue biopsies or histopathological analysis.

- **Complete Analysis:** Radiomics unlike single-region biopsies analyses the entire volume of the tumor, which is non-spatially heterogeneous, producing subclonal and microenvironmental variations and differences within the tumor.
- **Discrimination of Subtle Differences:** Differences in texture, intensity and shape of the imaging data content can give insights into subtle phenotypic variation between the tumor subtypes that would not be apparent by conventional histology.
- **Clinical Relevance:** Radiomics-based tumor phenotyping can allow patients to be stratified better, aggressive vs. indolent tumors to be identified, and the most appropriate therapeutic interventions to be chosen.

Radiomics offers clinically important heterogeneity in diagnosis by revealing a non-invasive, global perspective of tumor biology that could be overlooked by other common biopsy techniques and enhances diagnostic accuracy.

2. Predicting Clinical Outcomes

Quantitative features derived by radio metrics such as tumor texture, heterogeneity, and shape have been very much linked to patient prognosis, metastasis, and recurrence.

- **Prognostic Modeling:** Radiomic signatures are applicable to predictive models to forecast such outcomes as overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS).
- **Risk Stratification:** Radiomics can be used to tailor monitoring procedures to high-risk patients by detecting them through the use of imaging features, making it possible to monitor them more closely and intervene in time.
- **Recurrence Prediction:** Although there is no consensus on which features indicate intratumoral heterogeneity and irregular morphology, such features are commonly associated with aggressive behavior and risk of local or distant recurrence.

Radiomics offers a powerful, non-invasive, methodology of predicting disease pathway and informing clinical decision-making, through quantitative evaluation, to ultimately enhance patient management.

3. Guiding Therapy

Radiomic features are very important in forecasting response to treatment and tailoring therapy choice in oncology patients.

- **Therapy Selection:** Radiomics has the potential to select the patients who will likely respond to chemotherapy, immunotherapy, targeted therapy, or radiotherapy, based on the correlations between imaging characteristics and patient response.
- **Predicting Resistance:** Heterogeneity and certain texture patterns in the tumor can be used to predict subregions that can be resistant to therapy, enabling clinicians to modify treatment plans ahead of time.
- **Connection to the world of AI and Machine Learning:** Sophisticated computational systems will be able to integrate radiomic data with patient demographics, genomic profiles, and clinical parameters to create very accurate prediction algorithms.
- **Adaptive Therapy Planning:** Radiomics-informed models allow real time modifications to the treatment regimen, experimental therapeutic choices on eligible patients, and dose planning in radiation therapy.

Radiomics can be used in the context of precision medicine, supplying the quantitative, predictive framework and enhancing the effectiveness of treatment and reducing the toxicity associated with an unsolicited treatment.

- **Advantages of Radiomics**

Radiomics offers numerous benefits over conventional imaging techniques and invasive biopsy-based approaches, providing a more comprehensive, non-invasive, and data-driven framework for precision oncology:

1. Non-Invasive

Radiomic analysis applies existing medical images, including CT, MRI, or PET scans, in order to extract quantitative features without undergoing extra tissue sampling.

- **Patient Comfort and Safety:** Radiomics will considerably decrease patient discomfort and anxiety by removing invasive procedures, such as biopsies with a needle or surgical surgery, which cause side effects and post-procedural complications. This also prevents risks of bleeding, infection and post procedure pain. Non-invasive imaging-based assessment may be of special benefit to patients with tumors in anatomically challenging sites.

- **Ease of access:** Due to the fact that radiomic features are obtained out of routinely obtained imaging studies, these features can be universally used in patient populations that do not need extra procedures. This renders radiomics as viable and scalable in a clinical as well as research setup.

- **Rapid Assessment:** Radiomics can be used to conduct near-real-time analysis of the tumor traits based on images, which are already observed in the course of a regular clinical practice. This can speed up the process of diagnosis and enable timely clinical decision-making and promptly initiate treatment.

2. Reproducible and Longitudinal

Radiomic results can be reproducible over time on serial radiograph images of the same scans to enable a dynamic analysis of tumor behavior and treatment response.

- **Treatment Monitoring:** Dynamic radiomic measurements should be able to measure alterations in tumor size, shape, texture, and intensity during therapy, and these measurements give objective tumor response measurements. It is especially useful in

analyzing reactions to chemotherapy, targeted therapy, or radiotherapy, in which the conventional imaging measures might not be sensitive enough.

- **Early Recurrence Detection:** Longitudinal radiomic analysis has the capability to identify subtler morphological or textural alterations in the tumor tissue that is not clinically evident and indicative of recurrence. With this early identification, intervention is timely and better **management of patients is possible.**
- **Consistency and Reproducibility:** Standard imaging acquisition procedures and quantitative feature extraction make radiomic measurements reproducible across7 time points and imaging centers. This reproducibility enables multicentrism studies and enables clinicians to reliably trace the progression of the disease over time.

3. Captures Whole-Tumor Heterogeneity

Radiomics assesses the whole tumor volume (in contrast to tissue biopsies, which only sample a small part of the tumor), and it can detect spatial, phenotypic, and molecular heterogeneity.

- **Whole-Tumor Profiling:** Radiomics measures changes in texture, intensity and shape across the entire tumor, necrotic, fibrotic, calcified or highly vascularized. This is complete profiling that gives a more precise description of tumor biology than focal biopsy samples.
- **Subclonal Detection:** Radiomic features have the capability to display the spatial heterogeneity of the tumor in terms of specific subclonal populations. The identification of such heterogeneity is essential in the understanding of tumor aggressiveness, metastatic capability and possibilities of treatment resistance.
- **Better Clinical Understanding:** Radiomics offers improved clinical insight because its method to assess the entire tumor of a patient instead of an individual sampled area can minimize the occurrence of sampling bias and offer a comprehensive view of tumor biology. This allows the use of more informed clinical decisions about therapy planning, prognosis, and risk stratification.

4. Supports Data-Driven Precision Oncology

The combination of radiomic features, artificial intelligence (AI), and machine learning algorithms can be used to build predictive and prognostic models that are specific to a particular patient.

- **Personalized Diagnostics and Prognostics:** Radiomics-based models have the potential to categorize tumor subtypes, forecast aggressiveness, and predict patient-specific outcomes. This individualized method enables clinicians to personalize monitoring and therapy to the specifics of tumor.
- **Therapeutic Decision-Making:** Radiomic analysis could be used to find the patients who are most likely to achieve response to certain treatments, predict the occurrence of resistance, and shape adaptive therapy plans. This makes sure that patients are getting the best interventions and the toxicity is avoided at unnecessary levels.
- **Clinical Practice Application:** Radiomics provides evidence-based precision oncology by integrating features based on imaging with clinical, genomic, and molecular data. These hybrid models will improve patient outcome, resource productivity, and help to implement data-based and personalized treatment in standard clinical practice.

4.3. INTEGRATION OF IMAGING WITH GENOMICS (RADIOGENOMICS)

Radiogenomics is a novel form of precision oncology that uses integrated molecular profiling with state-of-the-art imaging methodologies to learn more about the biology of tumors. Radiogenomics can be used to reveal relationships between observable tumor features (shape, texture, vascularity, and metabolic activity) and molecular-scale changes by quantitatively analyzing imaging features and correlating them with genomic, transcriptomic, and proteomic data. This combination will enable clinicians to understand the heterogeneity of tumors, clonal evolution, and disease aggressiveness in a deeper way without depending exclusively on invasive tissue samples. Radiogenomics therefore provides a whole view of the tumor landscape, both spatially and molecularly, at once and in a non-invasive manner.

Clinical applications of radiogenomics have a tremendous potential, including diagnosis, prognosis, and the choice of personal therapy. Biomarkers of imaging that are related to certain genetic mutations or profiles of expression can be used to predict the behavior of tumors, response to treatment, and recurrence. As an example, some radiomic sequences could be a sign of the existence of mutations that provide resistance to targeted therapies, to intervene early or change therapy. Also, radiogenomics can aid in patient stratification during clinical trials by determining subpopulations that have high likelihood of responding to certain treatment. This discipline will improve the accuracy of workflows in oncology, thereby

enhancing the ability to monitor tumors dynamically and eventually lead to personalized, evidence-based cancer treatment by reducing the gap between the traditional radiology and molecular diagnostics.

Concept

The basic principle of radiogenomics is that tumors with particular genetic or molecular mutations tend to have characteristic radiographic appearance and could be captured quantitatively by state-of-the-art imaging systems. The CT, MRI, and PET are all techniques that help attain high-resolution structural, functional, and metabolic data, which is an indicator of underlying molecular and genomic characteristics. These imaging phenotypes are non-invasive surrogates of molecular events and may enable clinicians to forecast behavior, treatment response and clinical outcomes of tumors without repeated invasive biopsies.

- **Tumor Heterogeneity:** Radiogenomics is especially useful in the capture of tumor heterogeneity, such as differences in subclonal mutations and differences in the tumor microenvironment. The heterogeneity can frequently be radiomic (such as texture (cellular density and organization), shape (growth patterns and invasiveness), intensity (activity of metabolism or vasculature), and spatial distribution (gradients of heterogeneity across the tumor).
- **Bridge Imaging and Genomics:** Radiogenomics finds statistically significant associations between quantitative features of imaging and molecular and genomic data. These associations are able to reveal patterns like profile of the expression of genes, the state of mutation and epigenetic alterations that are reflected in imaging features. Such integrative approach allows to gain a deeper insight into tumor biology and informs clinical choice-making, such as individual treatment plans.

Benefits

Radiogenomics has a number of major benefits that can be improved to clinical oncology:

- **Non-Invasive Molecular Prediction:** Radiogenomics uses high-quality imaging methods like MRI, CT, and PET, in combination with complex computational tools, to compare imaging phenotypes to underlying genomic changes. Through this, it is able to non-invasively forecast important molecular characteristics of tumors such as particular somatic mutations, alterations in copy numbers or gene-expression patterns. The method minimally necessitates repeated tissue biopsies that are invasive, have

procedural risks, and do not necessarily resolve the spatial heterogeneity of tumors. Radiogenomics minimizes patient discomfort, reduces the risks of complications, and eliminates the biases related to the heterogeneous distribution of tumor cells in various areas of a lesion by preventing repeated sampling.

- **Personalized Treatment Selection:** Radiogenomics helps clinicians to be more specific with individual therapy. Phenotypes obtained by imaging can be correlated with molecular changes, thus yielding predictions about how a tumor will respond to certain drugs. Indicatively, a tumor with radiomic characteristics that depict the presence of mutations in gene receptors such as EGFR or KRAS may be targeted to a specific therapy that enables exploitation of such genetic weakness. On the other hand, the patients who have tumors that are not likely to respond to particular treatments are able to be spared undue exposure to ineffective treatment and the costs of healthcare and toxicity are minimized. The combination of imaging and molecular information aids clinicians to make more informed decisions to maximize the effectiveness of treatment and to minimize adverse effects.
- **Biomarker Discovery:** Radiogenomics is a method that enables the discovery of new biomarkers by linking quantitative imaging phenotypes to genomic profiles. These biomarkers may be very essential in early diagnosis, predicting the patient prognosis or even to direct therapeutic interventions. The radio genomic experiments may reveal the relationships of the genotype and phenotype not known before, and this will offer a better insight into the tumor biology. As an example, the small differences in tumor texture or vascularization that have been identified by imaging can present a clue to the presence of some mutations or epigenetic alterations can be used as new drug targets or diagnostic tests. The potential is an addition to the accuracy oncology map with a broader range of measurable and clinically relevant biomarkers.
- **Tumor Evolution:** Radiogenomics can be used to longitudinally assess tumor progression and respond to treatment. Clinicians can track the dynamics of tumors on-the-fly by repeated time analyses of imaging data and mapping the changes to genomic evolution. The method also makes it possible to identify developing resistance to treatment, clonal evolution, or recurrence of the disease itself before it manifests in clinical terms. Radiogenomics is therefore in support of adaptive treatment, whereby therapeutic approaches are adjusted in advance in response to changing tumor biology.

Such constant monitoring offers a potent instrument to learn how tumors behave in time and enhance patient outcomes by interfering in a timely manner.

Applications

Radiogenomics has been utilized successfully in various types of cancers, and has proven to have robust correlations between radiomic signature and genomic changes:

- **Gliomas:** In gliomas, higher-order MRI features can give quantitative imaging consequences, including tumor heterogeneity, edema patterns, necrosis, and contrast enhancement capabilities. These radiomic signatures have been demonstrated to be highly associated with major molecular changes, such as as IDH mutation status, 1p/19q co-deletion, and MGMT promoter methylation. The clinical importance of such correlations is that they inform the prognosis and the treatment plan. As an example, patients with IDH-mutant gliomas tend to have a more favorable survival rate and potentially react to chemoradiation differently than to IDH-wildtype tumors. Through radiogenomic mapping, clinicians are able to make predictions of these molecular profiles without the need to use invasive procedures such as recurrent surgical biopsies and can plan treatment with greater accuracy and individuality.
- **Lung Cancer:** CT-based radiomic features such as the shape, texture, density, and vascularity of tumors in lung cancer, especially non-small cell lung cancer (NSCLC), has been related to genomic changes such as EGFR mutations, KRAS mutations and ALK rearrangements. These associations are capable of providing non-invasive molecular stratification that can be used to direct the choice of selected therapies, including tyrosine kinase inhibitors against EGFR-mutant tumors or ALK inhibitors against ALK-positive tumors. Radiogenomics thereby adds to the potential of customizing treatment prior to invasive tissue biopsies, which can be problematic in patients with tumors or comorbidities that are difficult to reach.
- **Breast Cancer:** Imaging modalities including MRI and PET in breast cancer have resulted in radiomic patterns linked to important molecular phenotypes, including HER2, hormone receptor (ER/PR), and more comprehensive expression profiles. This group of correlations helps in the precision of treatment planning, to determine those patients who are likely to respond to specific therapies, hormone-based therapies, or chemotherapy programs. Also, longitudinal radio genomic studies are able to track therapy response, early signs of resistance or recurrence and thereby make necessary changes to treatment plans in time, which results in patient outcome improvement.

- **Prostate Cancer:** mp MRI in prostate cancer involves imaging based on tumor cellularity, perfusion and tissue composition. These radiomic profiles have been associated with genomic risk scores, changes in androgen receptor signaling pathways and aggressive tumor subtypes. Combining imaging and genomic data, clinicians are able to enhance risk assessment, differentiate between indolent and aggressive tumors, and make a decision on personalized treatment including active surveillance, surgery or targeted therapy. Radiogenomics thereby provides greater accuracy to diagnosis and stratification of patients according to molecular and phenotypic risk.

In each of these cases, radiogenomics has shown potential to address the gap between imaging and molecular biology to improve the accuracy of non-invasive diagnostics, prognostic stratification and therapeutic decisions. Radiogenomics, by offering a complete picture of tumor biology without subjecting patients to repeated invasive surgeries, is an important advancement in the precision oncology field, making clinicians use data to make data-driven and personalized treatment choices that ultimately enhance patient outcomes.

4.4. REAL-TIME IMAGING FOR MONITORING TREATMENT RESPONSE

The real-time imaging has become a critical element of the precision oncology as it enables the clinician to check tumor response during the therapy process. In contrast to traditional imaging methods that are frequently based on delayed evaluation of structural or anatomic changes, real-time imaging titles changes in tumor biology, metabolism, and microenvironment in real time. Functional MRI, scans with molecular tracers using PET, and optical imaging techniques can be used to demonstrate the early effects of treatment, including blood flow changes, cell activity, or receptor expression. This real-time feedback gives a better view of the current tumor response and proactive decision-making can be taken instead of relying on the traditional endpoints such as tumor shrinkage.

The capacity to receive real time monitoring of treatment response is a significant contribution to clinical flexibility and patient outcomes. Clinicians are able to make quick adjustments on the form of therapy-escalating, switching, or combining therapies- according to early signs of success or resistance. This minimises unwanted exposure to non-relief-giving treatments, minimizes the side effects and the overall therapeutic index is enhanced. In addition, real-time imaging can be used to inform the assessment of new therapeutics and adaptive trial design, with rapid and quantitative data on drug activity. When applied to routine oncology care by

incorporating functional and molecular imaging, precision medicine can leave behind the fixed evaluation of a patient, allowing the truly personalized and responsive treatment plans.

- **Functional and Molecular Monitoring:** Functional imaging method can be used to measure cellular and metabolic activity within tumors which may be apparent before tumors appear on standard structural imaging. An example is the use of Positron Emission Tomography (PET), which is able to measure changes in glucose metabolism or other metabolic indicators within days of treatment. Early changes in metabolism can act as an indicator of responses when a tumor is responding to treatment and such responses are seen long before the actual tumor begins to shrink. Diffusion-Weighted Imaging (DWI) and Dynamic Contrast-Enhanced MRI (DCE-MRI) are advanced magnetic resonance imaging (MRI) techniques capable of detecting alterations in the cellular density, tissue perfusion and microstructural organization. These micro changes frequently lead to macroscopic tumor regression and give a sensitive and early indication of treatment effect. Clinicians can make informed decisions about whether or whether to continue or modify therapy by real-time monitoring of these functional and molecular parameters.
- **Liquid monitoring of the response:** The real-time imaging combined with the circulating biomarkers increases accuracy in monitoring treatment further. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes demonstrate the molecular aspects of tumor burden, genetic changes, and dynamics of responses. These biomarkers provide a multidimensional view of the tumor behavior when combined with imaging data, which enables clinicians to simultaneously measure both structural and molecular responses. This combination helps to enhance the detection of residual disease with small residual diseases, early recurrence, or developing therapy resistance, which would not be evident immediately either by using imaging or biomarkers alone. Using these complementary modalities, real time monitoring will be more elaborate and resourceful.
- **Adaptive Therapy Planning:** Adaptive real-time imaging has one of the most important benefits in adaptive treatment strategies. Non-responder or tumor with less than optimal therapeutic response can be identified early to enable clinicians to promptly change treatment regimens. This may include altering doses of drugs, replacement therapy, the use of combination treatment, or new therapeutic agents. Continuous monitoring of tumor response allows clinicians to reduce the exposures of

patients to ineffective therapy, decrease treatment toxicity and fully benefit of the treatment. Real-time imaging-guided adaptive therapy helps to make the interventions personalized, targeted, and responsive to the dynamics of tumor biology.

- **Key Takeaway:** In sum, real-time imaging is a groundbreaking development in the field of oncology and the combination of anatomical, functional and molecular data into a dynamic framework. It enables clinicians to track the effectiveness of therapeutic interventions as they emerge, to identify signs of resistance early, and provide responsive and precision interventions. Through the ability to make personalized treatment changes in time, real-time imaging does not only improve clinical outcomes, but also improves patient safety, lowers unnecessary toxicity, and truly individualizes the approach to cancer management.

REFERENCES

1. Pinker, K., Chin, J., Melsaether, A. N., Morris, E. A., & Moy, L. (2018). Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. *Radiology*, *287*(3), 732-747.
2. Shui, L., Ren, H., Yang, X., Li, J., Chen, Z., Yi, C., ... & Shui, P. (2021). The era of radiogenomics in precision medicine: an emerging approach to support diagnosis, treatment decisions, and prognostication in oncology. *Frontiers in Oncology*, *10*, 570465.
3. Liu, Z., Duan, T., Zhang, Y., Weng, S., Xu, H., Ren, Y., ... & Han, X. (2023). Radiogenomics: a key component of precision cancer medicine. *British Journal of Cancer*, *129*(5), 741-753.
4. Saxena, S., Jena, B., Gupta, N., Das, S., Sarmah, D., Bhattacharya, P., ... & Suri, J. S. (2022). Role of artificial intelligence in radiogenomics for cancers in the era of precision medicine. *Cancers*, *14*(12), 2860.
5. Panayides, A. S., Pattichis, M. S., Leandrou, S., Pitris, C., Constantinidou, A., & Pattichis, C. S. (2018). Radiogenomics for precision medicine with a big data analytics perspective. *IEEE journal of biomedical and health informatics*, *23*(5), 2063-2079.
6. Mahajan, A., Sahu, A., Ashtekar, R., Kulkarni, T., Shukla, S., Agarwal, U., & Bhattacharya, K. (2023). Glioma radiogenomics and artificial intelligence: road to precision cancer medicine. *Clinical radiology*, *78*(2), 137-149.
7. Guo, Y., Li, T., Gong, B., Hu, Y., Wang, S., Yang, L., & Zheng, C. (2025). From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients. *Advanced Science*, *12*(2), 2408069.
8. Fathi Kazerooni, A., Bagley, S. J., Akbari, H., Saxena, S., Bagheri, S., Guo, J., ... & Nasrallah, M. P. (2021). Applications of radiomics and radiogenomics in high-grade gliomas in the era of precision medicine. *Cancers*, *13*(23), 5921.
9. He, W., Huang, W., Zhang, L., Wu, X., Zhang, S., & Zhang, B. (2024). Radiogenomics: bridging the gap between imaging and genomics for precision oncology. *MedComm*, *5*(9), e722.
10. Trivizakis, E., Papadakis, G. Z., Souglakos, I., Papanikolaou, N., Koumakis, L., Spandidos, D. A., ... & Marias, K. (2020). Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care. *International journal of oncology*, *57*(1), 43-53.

11. Vaidya, T., Agrawal, A., Mahajan, S., Thakur, M. H., & Mahajan, A. (2019). The continuing evolution of molecular functional imaging in clinical oncology: the road to precision medicine and radiogenomics (Part I). *Molecular diagnosis & therapy*, *23*(1), 1-26.
12. Liu, Z., Wu, K., Wu, B., Tang, X., Yuan, H., Pang, H., ... & Qi, Y. (2021). Imaging genomics for accurate diagnosis and treatment of tumors: A cutting edge overview. *Biomedicine & Pharmacotherapy*, *135*, 111173.
13. Sanchez, I., & Rahman, R. (2024). Radiogenomics as an integrated approach to glioblastoma precision medicine. *Current Oncology Reports*, *26*(10), 1213-1222.
14. Lo Gullo, R., Daimiel, I., Morris, E. A., & Pinker, K. (2020). Combining molecular and imaging metrics in cancer: radiogenomics. *Insights into imaging*, *11*(1), 1.
15. Pinker, K., Shitano, F., Sala, E., Do, R. K., Young, R. J., Wibmer, A. G., ... & Morris, E. A. (2018). Background, current role, and potential applications of radiogenomics. *Journal of Magnetic Resonance Imaging*, *47*(3), 604-620.

Chapter 5…

PRECISION DRUG DELIVERY SYSTEMS

ROHINI GUPTA
Assistant Professor
Department of Pharmacology
Government Medical College Jammu, Pin - 180002
Email: rohinigupta299@ymail.com

Site-specific drug delivery technologies are the modern therapeutic approaches aimed at delivering drugs to the diseased tissues or cells in a direct manner to increase treatment efficacy with the minimum harm to the healthy tissues. Contrary to the traditional systemic therapies where the drug is given to the entire body, and may result in severe toxicity in the patient, these precision delivery mechanisms can deliver more drug to the target site, enhancing the therapeutic index and patient outcome. The major methods are passive targeting where the enhanced permeability and retention (EPR) effect in tumors are exploited, active targeting, in which ligands or antibodies are selectively bound to diseased cells, and the stimuli-responsive system, which involves an exit of drugs in response to a particular internal or external stimulus such as pH, enzymes, heat, or light. In particular, these strategies are crucial in oncology, when the exact targeting minimizes collateral damage and increases anticancer effects.



Figure 1: Precision Drug Delivery Systems

Source: (https://journals.physiology.org/doi/full/10.1152/physrev.00015.2016)

Modern delivery systems are liposomes, nanoparticles, and polymers. Liposomes are globular vesicles with the capacity to entrap both hydrophilic and hydrophobic medications, which provide biocompatibility, degradation resistance and specific local delivery by modifying its surface such as PEGylated preparations such as Doxil. Nanoparticles (lipid-based, polymeric, and metallic) offer targeted drug delivery, enhanced biodistribution, and the capacity to traverse biological barriers, and surface functionalization has allowed passive and active targeting. Polymer-based systems such as PLGA nanoparticles and dendrimers enable sustained or stimuli-responsive drug delivery, improved pharmacokinetics and targeted delivery to be

customized, so they offer versatile vectors to carry chemotherapeutics, nucleic acids and imaging agents.

Precision delivery is further enhanced by ligand-targeted therapies and controlled release platforms in that molecular recognition is coupled with temporal control of drug release. Ligand-targeted systems e.g. antibody-drug conjugate or folate receptor targeted nanoparticles are selective, which selectively binds receptors overexpressed on diseased cells, promoting intracellular drug delivery and reducing systemic toxicity. Diffusion-based and degradation-based carriers, and stimuli-responsive platforms, known as controlled release systems, are systems that retain therapeutic levels of drug over time or in response to biological or external stimuli, leading to less frequent dosing, and enhanced patient compliance.

In general, site-specific drug delivery has a beneficial effect on therapy outcomes, minimizing toxicity, maximizing therapy efficacy, and increasing patient adherence. Targeted systems restrict exposure of the drug to normal tissues and amplify cytotoxic responses on cancerous cells and overcome evasion of the drug through drug efflux pumps. The sustained and stimuli-responsive release guarantees the optimal drug concentrations in the disease microenvironment with increased anticancer activity and reduced adverse effects. These technologies are one of the largest developments in precision medicine, which has created safer and more efficient treatments in a variety of diseases, specifically in cancer therapy.

5.1. OVERVIEW OF SITE-SPECIFIC DRUG DELIVERY TECHNOLOGIES

Site-specific drug delivery technologies are designed to deliver therapeutic agents to diseased cells or tissues, a significant improvement over the traditional systemic therapies. Conventional treatments, including chemotherapy, tend to spread drugs all over the body including normal and cancerous cells. Such unspecific exposure may lead to serious toxicity, restrict the maximum tolerable dose and decrease the total efficacy of treatment. Contrary to this, site-specific delivery systems focus the therapeutic agents on the target site, improving drug efficacy and sparing normal tissues, which increases the therapeutic index and minimizes adverse effects.

These accuracy delivery plans are specifically revolutionary in oncology, where the selective targeting of the tumor cells plays a key role. Site-specific systems allow the accumulation of drugs in tumor tissues and reduced systemic exposure by favoring ligand binding, stimuli-responsive release or molecular recognition of the site. Such specific mode of action leads not

only to increased potency of treatment, but also to higher dosing and combination therapies that would otherwise be too toxic. Altogether, site-specific drug delivery improves patient outcomes, minimizes the complications associated with treatment, and is one of the foundations of contemporary precision medicine in cancer therapy.

- **Key Approaches Include:**
  - **Passive Targeting:** Passive targeting takes advantage of the natural physiology of diseased tissues. Enhanced permeability and retention (EPR) effect is one of the most extensively studied phenomena utilized in the cancer therapy. Tumor vasculature is characterized by irregularity and hyper porosity with big fenestrations enabling nanoparticles and macromolecular drugs to selectively localize into tumor tissues. Besides, tumors are characterised by the poor lymphatic drainage which further enhances retention of therapeutic agents in tumor microenvironment. Passive targeting does not need a particular molecular recognition, and in most cases, size, shape and physicochemical properties of the drug carriers can determine selective accumulation in the diseased site.
  - **Active Targeting:** Active targeting refers to the active use of molecular recognition factors, e.g., ligands, antibodies, aptamers or peptides, designed to specifically bind receptors or antigens that are overexpressed by diseased cells. This will allow delivery of a drug selectively, avoiding normal cells and minimising systemic toxicity. An example is that monoclonal antibodies that have been conjugated to chemotherapeutic agents have the capability of specifically binding tumor-associated antigens to enable internalization and release of the drug specifically in cancer cells. Nanoparticle-based carriers can be used in conjunction with active targeting to increase further stability, circulation time, and accumulation of the drug at its disease location.
  - **Stimuli-Responsive Systems:** The stimuli-responsive drug delivery systems are intended to release their therapeutic cargo based on a certain internal or external stimuli. Internal stimuli are the changes in pH, enzymatic activity or redox potential that are tumor microenvironmental. As an example, pH-sensitive nanoparticles can be engineered to release the drug selectively in the pH-acidic tumor tissues and be stable at normal body physiological pH. Localized drug release may also be induced by external stimuli, which may include heat, light, ultrasound, or magnetic fields, which offers both temporal and spatial control of therapy. These systems increase the

therapeutic effect, reduce off-target effects, and provide solutions to overcome the drug resistance mechanisms.

- **Clinical Relevance:** There are great clinical implications of site-specific drug delivery systems. These technologies enhance therapeutic index by delivering therapeutic agents to the disease site so that higher effective dose levels can be achieved at the minimal adverse effects. They are also able to deal with issues like deficiencies in multidrug resistance by enhancing intracellular levels of accumulation and avoiding efflux pathways. In general, site-specific drug delivery is an urgent breakthrough in precision medicine with more effective and safer treatment approaches in a variety of conditions, especially in cancer.

5.2. LIPOSOMES, NANOPARTICLES, AND POLYMER-BASED SYSTEMS

Advanced drug delivery platforms are liposomes, nanoparticles and polymer-based systems developed to improve the level of therapeutic efficacy and precision. Liposomes are vesicles consisting of phospholipid bi-layers that surround hydrophilic or hydrophobic drugs to provide biocompatibility, degradation protection, and functionalization, such as PEGylated Doxil. Lipid, polymeric, and metallic nanoparticles can be used to provide controlled drug release, enhanced biodistribution, and traversing of biological barriers; surface modifications can be used to passively or actively target nanoparticles as observed in the case of mRNA vaccine delivery. Polymer-based systems, e.g., PLGA nanoparticles and dendrimers, offer sustained or stimuli-responsive release, improved pharmacokinetic properties, and targeted customization, and are therefore flexible carriers of chemotherapeutics, nucleic acids and imaging agents.

Liposomes

Liposomes are vesicles that are spherical in shape, made of one or more bilayers of the phospholipid which surround an aqueous core, to create a structure that resembles natural cell membranes. This distinctive architecture enables multi-purpose encapsulation of therapeutic agents: hydrophilic drugs may be solubilized in the aqueous interior, whereas hydrophobic drugs may become a part of the lipid bi-layer. The dual ability allows the delivery of a broad spectrum of drugs, both small molecule and large biomolecule, such as nucleic acids and proteins.

Liposomes have a number of pharmacological benefits: they are highly biocompatible so drugs are not lost due to enzymatic degradation or premature clearance to increase bioavailability and

circulation time. Furthermore, they can be loaded with other molecules, including ligands, antibodies or polyethylene glycol (PEG) to enable targeted delivery to a given tissue or tumor cell and to minimize reticuloendothelial system (RES) recognition.



Figure 2: Liposomes

Sources: (https://en.wikipedia.org/wiki/Liposome)

One example of this is the PEGylated liposomal doxorubicin, Doxil, which is a clinically relevant example. This development shows lower cardiotoxicity with conventional doxorubicin, which retains and or improves therapeutic value. Doxil emphasizes the opportunities of liposomes to offer a controlled pharmacokinetics, reduce off-target effects, and prevent patient outcomes in the field of oncology. Moreover, liposomes have been discussed in delivering anti-inflammatory drugs, antibiotics, and gene therapies, demonstrating how wide they can be used.

- ***Nanoparticles (NPs)***

Nanoparticles are solid colloidal particles that are 1-100 nanometers old, and which are intended to wrap, adsorb or conjugate drugs to achieve control over drug release, biodistribution, as well as, pharmacokinetics. NPs can be divided into polymeric, metallic, and lipid-based nanoparticles and are specific in their characteristics according to their therapeutic purposes.

As an example, lipid nanoparticles (LNPs) have become a leading option in the delivery of mRNA vaccines, such as COVID-19 vaccines. The lipid matrix shields the delicate mRNA against enzymatic destruction, enables cellular intake and allows evasion of the endosome, all of which underscores the clinical viability of nanoparticle-mediated delivery. Another advantage of nanoparticles is that the drug loading is high, an increase or slow release, and that nanoparticles bypass biological barriers, including the blood brain barrier that is vital in treating neurological diseases.



Figure 3: Lipid Nanoparticles

Source: (https://insidetx.com/review/complete-guide-to-understanding-lipid-nanoparticles/)

One of the strategies of nanoparticles targeting is surface modification. Passive targeting takes advantage of the increased permeability and retention (EPR) phenomenon in tumors where leaky vasculature permits accumulation to favorably occur. Active targeting entails the conjugation of nanoparticles to antibodies, peptides, or small molecules to target a cellular surface receptor to enhance specificity of delivery and reduce off-target toxicity.

- ***Polymer-Based Systems***

Medical drug delivery systems are polymer-based systems that employ biocompatible and biodegradable polymers (PLGA; poly lactic-co-glycolic acid) and PEGylated polymers and dendrimers to entrap or conjugate therapeutics. The systems allow sustained or controlled

release, enhance the pharmacokinetics through increased circulation time and decrease immunogenicity and rapid clearance in the body.



Figure 4: Polymer-Based Drug Delivery Systems

Source: (https://www.researchgate.net/figure/Basic-polymer-based-drug-delivery-systems_fig1_381966432)

Both passive and active targeting Polymer-based carriers can be adapted. As an example, antibodies or peptides that specifically target tumor-specific receptors can be surface-functionalized onto PLGA nanoparticles to enhance therapeutic efficacy, and reduce systemic side effects. Dendrimers are highly branched polymers whose architecture can be well-controlled, can be loaded with drugs, release can be tuned, and can be multivalent to enable targeted functionalization, and thus dendrimers are ideal in the delivery of chemotherapeutic agents, nucleic acids, and imaging contrast agents.

External or internal stimuli can also be utilized to release drugs in a polymers-based system, where the release is triggered by a stimulus e.g. pH, temperature, or enzymatic activity at the disease site, increasing further therapeutic precision.

5.3. LIGAND-TARGETED THERAPIES AND CONTROLLED RELEASE PLATFORMS

Ligand-targeted therapies Ligand-targeted therapies are an advanced method of targeted drug delivery and involve the use of antibodies, peptides, aptamers or small ligands to identify and target overexpressed receptors on diseased cells. This specific binding has been used to deliver

drugs straight to tumor or pathological cells producing greater cytotoxic effects on malignant cells and avoiding healthy cells, decreasing the systemic toxicity. This is also achieved by such strategies to overcome resistance mechanisms by making sure that there are increased intracellular concentrations of the drug at the disease site. Examples are antibody-drug conjugates such as T-DM1 and folate receptor-targeted nanoparticles, which are examples of how ligand-directed delivery can be used to enhance efficacy and safety in cancer treatment.

Controlled release platforms complement targeted approaches by regulating the timing, location, and rate of drug release, often in response to specific physiological or external stimuli such as pH, enzymes, or temperature. These systems, which include diffusion-controlled, degradation-controlled, and stimuli-responsive carriers, maintain optimal therapeutic drug concentrations over extended periods, minimize off-target effects, and reduce the need for frequent dosing, thereby improving patient adherence. By combining ligand targeting with controlled release strategies, these advanced delivery platforms maximize treatment precision, enhance therapeutic outcomes, and provide a more patient-friendlier and effective approach to modern oncology care.



Figure 5: Ligand-Targeted Therapies in Anticancer Therapy

Source: (https://www.nature.com/articles/nrc903)

❖ ***Ligand-Targeted Therapies***

Ligand-targeted therapies an example is a family of precision drug delivery systems whereby therapeutic agents are attached to ligands that can selectively identify and react with receptors or antigens that are overexpressed on diseased and especially tumor cells. The common ligands are monoclonal antibodies, peptides, aptamers and small molecules, all of which are directed to do selective targeting. As the drug-ligand complex is bound, it is internalised by the tumor cell, facilitating the intracellular delivery of the therapeutic payload and increased cytotoxicity and sparing of healthy tissues.

A number of clinically practical examples demonstrate the usefulness of this method. Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate to which trastuzumab, a monoclonal antibody against the HER2 receptor, has been conjugated to the cytotoxic drug emtansine. This conjugation enables targeted transfer of the drug to an overexpressing cancer, which by virtue of HER2 is present in the breast cancer, greatly lowering the toxic effects of the systemic toxicity of the drug as compared to normal chemotherapy. The other example is folate receptor-targeted nanoparticles, which take advantage of folate receptors overexpression on ovarian and breast cancer cells to improve the uptake and accumulation of drugs in the tumor tissues selectively. Ligand-targeted therapies have the following advantages: they are more specific, have fewer side effects in the body, have superior uptake by target cells and can potentially circumvent resistance mechanisms of standard therapies.

❖ ***Controlled Release Platforms***

The controllable release platform is the drug delivery system designed to deliver therapeutic agents at a specified rate within a specified time frame or in response to particular physiological or external stimuli. These systems aid in avoiding excessive drug concentration at target site, decrease dosing regimen and enhance compliance in patients. The controlled release can be attained in a number of ways:

- **Diffusion-controlled systems:** Drug molecules slowly leave the carrier matrix with time.
- **Degradation-controlled systems:** The release of drugs can be achieved by means of the degradation of the carrier material (biodegradable polymers) by hydrolysis or enzymatic activity.

- **Stimulus-responsive systems:** The release of drugs is activated by internal (e.g., pH, enzymes, redox conditions) or external (e.g., temperature, light, magnetic fields) stimuli.

Controlled release sites include hydrogel-based depots, capable of maintaining localized drug delivery over a long duration; pH-sensitive nanoparticles, capable of releasing drugs selectively to acidic tumor microenvironment; and thermo-responsive micelles, capable of releasing their cargo in temperature gradients. Those platforms have relevant therapeutic benefits as they ensure stable drug concentrations at the disease site, thereby limiting variability that may limit efficacy or raise the risk of toxicity, and low drug administration frequency.

5.4. ROLE IN REDUCING TOXICITY AND IMPROVING EFFICACY

Accurate drug delivery systems are necessary in order to promote the therapeutic index of anticancer agents by ensuring they achieve their maximum efficacy at the site of delivery and reduce toxicity to normal tissues. This twofold benefit assists in enhancing patient outcomes, lowering adverse effects and enhancing patient treatment tolerability.

1. **Less Toxicity:** Systemic toxicity is one of the key issues of traditional chemotherapy and this is the case because the drug diffuses across the whole body and targeting healthy tissues as well as cancer cells. Accurate delivery methods, including liposomes, nanoparticles, and ligand targeted therapies, can severely reduce how much drugs get to normal tissues. As an example, liposomal doxorubicin wraps the chemotherapeutic agent in a lipid bilayer and minimizes free drug circulation in the blood. The specificity ensures that the cardiac toxicity that is usually accompanied by the use of conventional doxorubicin is not experienced, thus sparing the heart but preserving anti-cancer capacity. Likewise, nanoparticles and polymer-based carriers can be designed to release drugs selectively in the tumor microenvironment, avoiding such undesirable side effects of drugs on organs as the liver, kidneys and gastrointestinal tract.
2. **Better Efficacy:** Precision drug delivery adds to therapeutic efficacy by raising the concentration of drugs at the target site. Increased local concentrations of drugs enhance the cytotoxic action of malignant cells and may overcome the frequent resistance mechanisms. Indicatively, several cancer cells carry efflux pumps which are active in eliminating chemotherapeutic agents, lowering intra cellular drug concentrations. Nanoparticle-based systems and ligand-targeted systems can circumvent these pumps by enabling direct intracellular delivery so that sufficient accumulation of drug is

produced to cause cell death. Moreover, sustained-release and stimuli-responsive carriers keep therapeutic drugs in the tumor microenvironment at long-term levels, which increase anticancer activity and reduce the risk of subtherapeutic exposure.

3. **Better Adherence to drug therapy:** Controlled-release and targeted drug delivery systems enhance patient compliance, as well, as the frequency and severity of dosing-side effects are minimized. The sustained-release system is based on the use of hydrogel depots, biodegradable polymeric systems to enable the sustained drug delivery over days or weeks, thus avoiding repeated high-dose deliveries. By reducing off-target toxicity, targeted therapies increase tolerability and allow patients to more comfortably accomplish prescribed treatment regimens.

REFERENCES

1. Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. *Heliyon*, *9*(6).
2. Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., ... & Wang, J. (2022). Smart drug delivery systems for precise cancer therapy. *Acta Pharmaceutica Sinica B*, *12*(11), 4098-4121.
3. Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021). Targeted drug delivery strategies for precision medicines. *Nature Reviews Materials*, *6*(4), 351-370.
4. GBARABA, S. V., MUSTAPHA, A. Y., OLAMIDE, B., TOMOH, A. O., & FORKUO, A. Y. (2025). Smart Drug Delivery Systems: The Future of Precision Medicine. *IRE Journals*, *8*(9), 821-829.
5. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. *Nature reviews drug discovery*, *20*(2), 101-124.
6. Gao, J., Karp, J. M., Langer, R., & Joshi, N. (2023). The future of drug delivery. *Chemistry of Materials*, *35*(2), 359-363.
7. Sivakumar, M., Muthu, Y., & Elumalai, K. (2025). Advancements in drug delivery systems: a focus on microsphere-based targeted delivery. *Biomedical Materials & Devices*, *3*(2), 1030-1057.
8. Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022). Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. *Journal of Nanobiotechnology*, *20*(1), 395.
9. Qu, J., Liang, Y., Shi, M., Guo, B., Gao, Y., & Yin, Z. (2019). Biocompatible conductive hydrogels based on dextran and aniline trimer as electro-responsive drug delivery system for localized drug release. *International Journal of Biological Macromolecules*, *140*, 255-264.
10. Wang, P., Jin, Z., Song, G., & Zhang, X. B. (2021). Recent progress and strategies for precise framework structure-enabled drug delivery systems. *Materials Today Sustainability*, *13*, 100065.

11. Liu, J., Liu, W., Zhang, K., Shi, J., & Zhang, Z. (2020). A magnetic drug delivery system with “OFF–ON” state via specific molecular recognition and conformational changes for precise tumor therapy. *Advanced Healthcare Materials*, *9*(3), 1901316.
12. Safarkhani, M., Ahmadi, S., Ipakchi, H., Saeb, M. R., Makvandi, P., Ebrahimi Warkiani, M., ... & Huh, Y. (2024). Advancements in aptamer-driven DNA nanostructures for precision drug delivery. *Advanced Science*, *11*(26), 2401617.
13. Glassman, P. M., & Muzykantov, V. R. (2019). Pharmacokinetic and pharmacodynamic properties of drug delivery systems. The Journal of pharmacology and experimental therapeutics, 370(3), 570-580.
14. Hu, M., Ge, X., Chen, X., Mao, W., Qian, X., & Yuan, W. E. (2020). Micro/nanorobot: a promising targeted drug delivery system. *Pharmaceutics*, *12*(7), 665.
15. Durán-Lobato, M., Niu, Z., & Alonso, M. J. (2020). Oral delivery of biologics for precision medicine. *Advanced Materials*, *32*(13), 1901935.

Chapter 6…

TARGETED THERAPIES IN PERSONALIZED TREATMENT

ANJU DAHARIA
Kamla Institute of Pharmaceutical Sciences, Bhilai
Email: anjudaharia055@gmail.com

LOKKANYA DEWANGAN
Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Bhilai
Email; lokkanyadewangan@gmail.com

TUSAR VERMA
Shri Shankaracharya Institute of Pharmaceutical
Sciences, and Research, Bhilai
Email: tv121719951996@gmail.con

ALKA VERMA
Shri Shankaracharya Institute of Pharmaceutical Sciences, and Research, Bhilai
Email: alkaakverma@gmail.com

SWAPNIL DESHMUKH
Kamla Institute of Pharmaceutical Science, Bhilai
Email: swapnilpharma020@gmail.com

Targeted therapies are a type of cancer therapy aimed at disrupting certain life cycle processes vital to the growth, survival and cellular division of the tumor. As compared to traditional chemotherapy, which indiscriminately attacks high-dividing cells, targeted therapies can target genetic or protein abnormalities specific to cancer cells and decrease the systemic toxicity of treatment and enhances treatment efficacy. One of the largest categories of targeted therapies is kinase inhibitors that suppress uncontrolled proliferation and survival of cancer by targeting enzyme dysregulation such as EGFR, BRAF, and ALK. On the one hand, these inhibitors, which are available in various generations, are chosen according to the molecular profiling in accordance with the specifics of tumors in the patient, which guarantees precision medicine strategies that will enhance the results.

Targeted therapies have revolutionized the treatment of cancers including non-small-cell lung cancer (NSCLC), melanoma, breast cancer and colorectal cancer. EGFR and ALK inhibitors prevent important signaling pathways and increase apoptosis and decrease tumor growth in NSCLC. BRAF/MEK inhibitors used in melanoma use the MAPK pathway and control the proliferation, whereas antibodies against HER2 and antibody-drug conjugates are used against HER2-positive breast cancer to improve the survival. EGFR-targeted therapy is effective in patients with colorectal cancer and RAS wild-type tumors where molecular testing and individualized choice of treatment options should be preferred in order to reach the best clinical outcomes.

A significant problem is resistance to targeted therapies, though. Secondary mutations, switching of pathways, or phenotypic modifications, including epithelial-to-mesenchymal transition, enable cancer cells to evade treatment. Next-generation inhibitors such as osimertinib of EGFR T790M mutations and lorlatinib of resistant ALK mutations have been developed to counter the resistance and provide more-durable responses. There is a tendency to use these agents in series or combined with other therapies, in order to sustain its effectiveness and tumor avoidance.

Combination therapies with targeted therapy and chemotherapy/immunotherapy are better therapies that improve effectiveness in treating cancer by destroying cancer in multiple ways. Tumors can be sensitized to targeted agents by chemotherapy and the immune system of the patient can be utilized through immune therapy with targeted drugs enhancing the immune recognition and infiltration. These multi-pronged modalities stem out the chances of resistance, enhance clinical responses, and extend survival. Yet they need special attention to toxicity,

optimization of sequencing, and patient selection along molecular profiling in order to utilize the benefits to the fullest extent and reduce the negative effects.

6.1. KINASE INHIBITORS AND PATHWAY BLOCKERS (EGFR, BRAF, ALK, ETC.)

Targeted therapies are an advanced form of anticancer therapy that targets a specific molecule, gene, or signaling pathway that is indispensable to the survival, growth and dissemination of cancerous cells. As opposed to traditional chemotherapy, which indiscriminately targets the high dividing cells, such as healthy ones, targeted therapies are specific to cancer cells by attacking molecular defects. This accuracy lowers systemic toxicity, increases the therapeutic index and the ability to personalize treatment plans according to the tumor profile of a patient. The invention of such therapies depends on the use of molecular diagnostics, including genomic profiling and biomarker analysis, that would help to screen the patient as the most likely getter of certain targeted agents. As targeted therapies act upon the underlying molecular pathogenesis of cancer and not its symptoms, they are more effective, associated with reduced adverse events and can also be used in combination regimens with chemotherapy or immunotherapy to achieve better results.

- ***Kinase Inhibitors***

Kinases are enzymes responsible in cell signaling through the catalysis of phosphorylation or the addition of phosphate to proteins. This change is essential to regulate cellular functions like growth, differentiation, survival, metabolism and apoptosis. Dysregulation of kinase activity in cancers is caused by mutation, overexpression, or gene rearrangements in most cases resulting in unregulated proliferation and resistance to cell death. Since kinases are hubs of critical signaling pathways, they make very attractive targets of cancer treatment. These aberrant signals are specifically blocked by kinase inhibitors, both small molecule and monoclonal antibody, with the effect of preventing tumor progression without damaging normal cells.



Figure 1: Kinase Inhibitors

Source: (https://www.caymanchem.com/news/kinase-inhibitors?srsltid=AfmBOoqERph2V2yJioFtly61z5mYEFIIfs-ebaKvzmAHT0xVKBgSM7-m)

1. EGFR (Epidermal Growth Factor Receptor) Inhibitors

EGFR is also a receptor tyrosine kinase which controls the cell proliferation, cell survival and cell differentiation. EGFR may be overexpressed or mutated in cancers like non-small-cell lung cancer (NSCLC), colorectal cancer, and head-and-neck cancers and leads to unregulated signaling and tumor growth.

- **Drugs and Generations:**
  - ***First-generation:*** Erlotinib, Gefitinib – These drugs competitively inhibit the ATP-binding site of EGFR, preventing phosphorylation and downstream signaling.
  - ***Second-generation:*** Afatinib – Irreversibly inhibits EGFR, including some resistance mutations.

- ***Third-generation:*** Osimertinib – Specifically targets T790M EGFR mutations, a common mechanism of acquired resistance to earlier drugs.

- **Mechanism of Action:** EGFR inhibitors bind to the tyrosine kinase domain of the receptor, blocking activation of downstream pathways such as:
  - **RAS/RAF/MEK/ERK pathway:** Controls cell proliferation.
  - **PI3K/AKT pathway:** Regulates survival and apoptosis.

Blockage of these pathways causes slowed tumor cells growth, accelerated programmed cell death and in most cases tumor regression. Response to clinical therapy is contingent on the presence of certain EGFR mutations, and therefore genomic profiling is important in selecting therapy.

2. BRAF Inhibitors

BRAF is a serine/threonine kinase that is a part of the MAPK (Mitogen-Activated Protein Kinase) pathway, which is in charge of cell growth and differentiation as well as survival. BRAF V600E mutation leads to constitutive BRAF pathway activation, which leads to uncontrolled proliferation. BRAF mutations are common in thyroid cancer, melanoma and colorectal cancer.

- **Drugs:**
  - Vemurafenib, Dabrafenib – These selectively inhibit the mutated BRAF kinase.
- **Mechanism of Action:** BRAF inhibitors prevent the inappropriate signaling of the MAPK pathway, arresting the cells in the cell cycle and causing apoptosis. To ensure avoidance of resistance due to pathway reactivation, BRAF inhibitors are typically used together with MEK inhibitors, the same pathway downstream drug, and increase efficacy and patient response time.

3. ALK (Anaplastic Lymphoma Kinase) Inhibitors

ALK is a receptor tyrosine kinase that takes part in cell survival and proliferation. Gene rearrangements or fusions of ALK occur in subsets of NSCLC, and in a few lymphomas, leading to sustained oncogenic signaling.

- **Drugs and Generations:**
  - ***First-generation:*** Crizotinib – Effective in ALK-positive tumors but prone to resistance.

- ***Second-generation:*** Alectinib – Overcomes certain resistance mutations and has better CNS penetration.
- ***Third-generation:*** Lorlatinib – Targets resistant ALK mutations, including those unresponsive to earlier inhibitors.

- **Mechanism of Action:**

ALK inhibitors suppress signaling through pathways including:

- **PI3K/AKT:** Promotes survival.
- **RAS/RAF/MEK/ERK:** Promotes proliferation.
- **JAK/STAT:** Promotes growth and immune evasion.

This blockade reduces tumor proliferation and induces apoptosis. Sequential therapy with newer generation inhibitors is often necessary to overcome acquired resistance.

6.2. FDA-APPROVED TARGETED THERAPIES BY TUMOR TYPE

Targeted therapies have radically transformed the oncology paradigm, with the emphasis on traditional, widely cytotoxic chemotherapy giving way to the necessity of precision medicine directed by the molecular nature of a specific patient tumor. In contrast to the traditional chemotherapy, which destroys all the rapidly dividing cells, tumors, or normal ones, targeted therapies are selective; they target a specific molecule, receptor, or signaling pathway that is vital to tumor growth, survival, metastasis, and angiogenesis. Such specificity enables a better control of the tumor and at the same time reduces collateral damage of normal tissues, thereby, lowering the side effects and enhancing the overall quality of life of the patients. Targeted therapies represent the ideals of personalized medicine since they employ treatment regimens that are explicitly based on the biology of the specific disease in a person, as opposed to an overview strategy.

Cancer biology is complex and heterogeneous and has led to the evolution and the acceptance of targeted therapies across a wide range of tumor types. Molecular profiling and biomarker testing and genetic profiling are essential in determining whether the patient who carries tumors with actionable mutations or certain protein expression is suitable to receive such therapies. An example is that medications that EGFR mutations in non small cell lung cancer, or HER2 amplifications in breast cancer are used only once these particular molecular changes are

present. This strategy is effective in making sure that patients are provided with interventions that have the maximum probability of being effective without undergoing unwarranted treatments that would not benefit them much. Because of this, molecular diagnostics and biomarker-based approaches have taken a central stage in precision oncology, informing clinical decision-making and streamlining therapeutic performance.

FDA-approved targeted therapies combined with accurate diagnostics have created a new paradigm in cancer therapy, in which therapy is tailored to optimally achieve effectiveness and minimally toxicity. This is a combined strategy that helps to not only better patient outcomes through provision of the most appropriate interventions, but also to improve resource use in healthcare through targeting treatment to those with the highest potential to respond. Moreover, the recent emergence of new targeted agents and combination therapies continues to widen the therapeutic repertoire that can be utilized to achieve precision oncology and overcome resistance mechanisms and maximize long-term patient survival. Integrating treatment plans with the molecular and genetic phenotype of every tumor, this model is the highest level of personalized medicine in oncology where treatment is scientifically customized, clinically efficient, and tailored to maximize treatment utility and patient quality of life.

Lung Cancer

- **Non-Small Cell Lung Cancer (NSCLC):** NSCLC is a cancer with one of the most widely investigated targeted therapies because of its high incidence and characterized drivers of the disease. Important molecular targets are:



Figure 2: Lung Cancer

Source: (https://www.parkwaycancercentre.com/lk/news-events/news-articles/news-articles-details/advanced-lung-cancer-diagnosis-treatment)

- **EGFR (Epidermal Growth Factor Receptor) Mutations:** EGFR is a receptor tyrosine kinase involved in regulating cell proliferation, survival, and apoptosis. Mutations in EGFR, particularly exon 19 deletions or L858R point mutations, result in constitutive activation of downstream signaling pathways, including RAS/RAF/MEK/ERK and PI3K/AKT, driving tumor growth.
    - **FDA-approved drugs:** Erlotinib, Gefitinib, Afatinib, Osimertinib.
    - **Mechanism:** These drugs inhibit EGFR tyrosine kinase activity, reducing uncontrolled proliferation and promoting apoptosis in EGFR-mutant tumor cells.
- **ALK (Anaplastic Lymphoma Kinase) Rearrangements:** ALK fusions, such as EML4-ALK, lead to constitutive kinase activity, activating pathways like PI3K/AKT, RAS/RAF/MEK/ERK, and JAK/STAT, which drive oncogenesis.
    - **FDA-approved drugs:** Crizotinib (first-generation), Alectinib (second-generation), Lorlatinib (third-generation).
    - **Clinical relevance:** Molecular testing using FISH, IHC, or NGS is essential to detect ALK rearrangements, ensuring only patients with ALK-positive tumors receive these inhibitors.

Targeted therapy in NSCLC has significantly improved response rates and progression-free survival compared with traditional chemotherapy, particularly when molecular selection is used.

Melanoma

- **BRAF-Mutant Melanoma:** BRAF genes are mutated and most are V600E which constitutively activates the MAPK pathway to result in uncontrolled growth.



Figure 3: Melanoma

Source: (https://en.wikipedia.org/wiki/Melanoma)

- **BRAF inhibitors:** Vemurafenib, Dabrafenib - are specific inhibitors of mutant BRAF kinase, which prevents MAPK signaling and promotes apoptosis.
- **MEK inhibitors:** Cobimetinib, Trametinib - the MEK1/2 downstream inhibitors are effective at augmenting the impact of BRAF inhibitors and slowing down resistance.

- **Combination therapy:** BRAF and MEK inhibitors are often co-administered to reduce compensatory pathway activation and improve durability of response.
- **Molecular testing:** Only patients with confirmed BRAF V600 mutations benefit from these therapies, highlighting the importance of precision diagnostics in melanoma management.

Breast Cancer

- **HER2-Positive Breast Cancer:** HER2 (Human Epidermal Growth Factor Receptor 2) amplification or overexpression is witnessed in 15-20 per cent of breast cancer and is linked with aggressive cancer. Oncogenic signaling is inhibited with the help of HER2-targeted therapies to enhance survival.



Figure 4: Breast Cancer

Source: (https://en.wikipedia.org/wiki/Breast_cancer)

- **Monoclonal antibodies:** Trastuzumab, Pertuzumab - extracellular binding to HER2 and inhibition of receptor dimerization and downstream PI3K/AKT and RAS/RAF/MEK/ERK signaling.
- **Antibody-drug conjugates (ADCs):** Ado-trastuzumab emtansine - provides cytotoxic reagents directly to the cells with the HER2-positive phenotype.

➢ **Clinical significance:** The application is only applicable in patients with confirmed cases of HER2 overexpression or gene amplifications, and, in this respect, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) tests are paramount. Targeted HER2 therapy has significantly increased life expectancy and changed prognosis in the HER2-positive breast cancer.

Colorectal Cancer

➢ **EGFR-Targeted Therapy in RAS Wild-Type Tumors:** EGFR is one of the primary motivational factors of colorectal cancer development, yet only in patients with RAS wild-type tumors, its inhibition is effective. KRAS or NRAS gene mutations bypass EGFR-induced downstream signaling and make EGFR inhibitors inefficient.



Figure 5: Colorectal Cancer

Source: (https://link.springer.com/rwe/10.1007/978-3-319-90761-1_80-1)

- **FDA-approved drugs:** Cetuximab, Panitumumab monoclonal antibody that inhibits proliferation and induces apoptosis, extracellularly blocks EGFR.
- **Molecular profiling:** RAS status assessment is required prior to receiving therapy to determine those patients who may respond.

These therapies by focusing on EGFR in the right patient slow the tumor disease progression and enhance clinical responses, representing the principle of precision oncology of matching the therapy to the genetic profile of the tumor."

➢ **Key Considerations in Precision Oncology**

- **Molecular Testing:** Molecular profiling in a comprehensive way is the main driver of precision oncology because it allows the detection of actionable mutations, gene amplifications, and structural rearrangements that promote tumor development. Next-generation sequencing (NGS) techniques allow a comprehensive genomic view of a large number of alterations present at once whereas polymerase chain reaction (PCR) is essential in detection of specific mutations with high sensitivity. The expression of proteins can be evaluated by immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) is commonly used to detect chromosomal defects. All of these approaches create the foundation of patient stratification and therapeutic decision-making.
- **Individualized Therapy:** Treatments are chosen based upon the molecular and genetic features of the specific tumor, and care is made not to generalize but rather to match

therapy with the specific disease profile of the patient. The method is most likely to result in clinical benefit with minimal unwarranted toxicity and side effects. As an example, EGFR-mutated patients can receive EGFR-inhibitors, and HER2-amplified patients are provided with HER2-targeted therapies. Individualized therapy paves the way to real personalization by addressing the unique vulnerabilities of tumours.

- **Combination Strategies:** Resistance to single-agent targeted treatment is a big issue in oncology. To mitigate this, combination regimens in which targeted agents are used together with chemotherapy, immunotherapy or with other targeted drugs are becoming more widely used in precision oncology. The combinations of this act to target tumors in several ways, minimize the chances of resistance, and generate long-term responses. An example of such a combination is the use of immune checkpoint inhibitors together with targeted therapy, which has demonstrated potential in increasing long-term disease control in a variety of cancers.
- **Varied clinical consequences:** The adoption and adaptation of targeted therapies in clinical practice by regulatory authorities such as the U.S. FDA has changed the face of cancer treatment. Biomarker-driven therapies have shown that patients undergoing such treatment have a much better outcome with a better response rate, prolonged progression-free survival and overall survival rates than a traditional treatment method. These achievements demonstrate the potential to change the landscape of precision oncology and convert previously incurable cancers into controlled or even curable diseases.

6.3. MECHANISMS OF RESISTANCE AND NEXT-GENERATION INHIBITORS

Targeted therapies are revolutionizing the treatment of cancer by selectively targeting molecules and signaling pathways necessary to growth and survival of tumors. Nonetheless, the efficacy of the therapies is often affected by the resistance of the cancer cells. The cancer cells are highly genetically unstable and adaptive in nature as compared to normal cells, and thus respond to the selection pressure induced by specific therapy. Resistance may occur in a variety of ways, such as secondary mutations in the target protein, the activation of other signaling pathways, epigenetic changes, or phenotypic plasticity, whereby tumor cells can survive therapy. Such adaptations are associated with decreased drug efficacy, disease progression, and disease relapse that becomes a major challenge to sustained clinical benefit.

To design next-generation therapeutic inhibitors capable of surmounting such challenges, an understanding of the molecular and cellular foundation of therapeutic resistance is absolutely necessary. Researchers are developing new agents that can inhibit resistance pathways, inhibit the compensatory signaling, or integrate several therapeutic interventions to deny break-even mechanisms. Moreover, biomarker-based strategies enable clinicians to track the development of resistance in real time and change treatment regimens. Next-generation inhibitors would recreate long-term activity, extend patient survival, and continue to improve the promise of precision oncology by merging knowledge of resistance mechanisms into drug design and clinical practice.

Common resistance mechanisms:

- **Secondary Mutations:** One of the most prevalent types of resistance can be the secondary or acquired mutations in the target protein itself. Such mutations usually take place at the drug-binding site or close to it, and this inhibitor is unable to bind to its target effectively. Here, to illustrate, in non-small cell lung cancer (NSCLC) patients with EGFR mutations, the T790M mutation develops in a significant proportion of patients that receive first-generation EGFR inhibitors including erlotinib or gefitinib. This mutation changes the binding site of ATP of EGFR, decreasing the ability of the drug to bind and making therapy ineffective. Likewise, mutations in the ALK-positive NSCLC, including L1196M or G1202R, can be resistant to first-generation ALK inhibitors, including crizotinib. These late mutations prove the dynamic essence of tumor evolution and the necessity of therapies that will be able to overcome these adaptive alterations.
- **Note:** Activation of Alternative Pathways Cancer cells do not rely on just one signaling pathway to survive; they are frequently redundant or parallel pathways that can take over in the event that the original pathway is inhibited. It is through this phenomenon that the tumors can overcome the therapeutic blockade and proceed to proliferate. As an example, even in the presence of EGFR inhibition, MET amplification in EGFR-mutant NSCLC can stimulate cell growth. Equally, PI3K/AKT/mTOR or MAPK pathways activation in different cancers can be used as escape mechanisms as they help tumors to survive even after targeted therapy. This pathway redundancy reiterates that cancer signaling networks are complicated and requires mechanisms that either act in concert or proactively prevent compensatory responses.

- **Phenotypic Changes:** Adaptive phenotypic changes are also a method of cancer cells becoming resistant. Among them is epithelial-to-mesenchymal transition (EMT) in which cancer cells change their proliferative epithelial identity into an invasive mesenchymal identity. This change is linked to an elevated metastatic capability and decreased responsiveness to drugs. Phenotypic changes that do not involve changes in apoptotic signaling can also reduce the efficacy of targeted therapies e.g. metabolic reprogramming or epigenetic modifications. These alterations indicate the impressive plasticity of tumor cells and present a substantial challenge of the long-term efficacy of treatment.
- **Next-Generation Inhibitors:** In response to resistance mechanisms, new generations of targeted therapies are being developed that help either overcome a particular resistance mutation or block by pass signaling pathways. The intent of these medications is to afford long-term effectiveness even in cancer cells that have developed resistance against previous-generation treatment.
    - **Osimertinib:** Osimertinib is the third-generation EGFR inhibitor that is specifically active in NSCLC tumors that contain the resistance mutation T790M. Significantly, it only attacks mutant EGFR and not wild-type EGFR, minimizing off-target toxicity and enhancing tolerability.
    - **Lorlatinib:** The next-generation ALK inhibitor that is useful against tumors with resistant ALK mutations resistant to the initial or second generation ALK inhibitors, providing a critically important treatment option with patients who have developed refractory ALK-positive NSCLC.

Clinicians can enhance the longevity of response by predicting resistance and designing inhibitors with the critical strategies to address these mechanisms. The next-generation inhibitors are commonly administered sequentially, or following chemotherapy, immunotherapy, or other targeted therapies, to slow or reverse the development of resistance.

6.4. COMBINATION STRATEGIES WITH CHEMOTHERAPY OR IMMUNOTHERAPY

Targeted therapies have revolutionized the field of oncology because they specifically inhibit molecular pathways that are needed to promote tumor growth and survival. These agents in spite of their specificity may have problems using them as monotherapy. A large proportion of

the patients respond partially, and there is adaptive resistance to tumors by alternative signaling pathways or genetic mutations that ultimately results in progression or relapse of the disease. These constraints underscore the importance of adjunct ARY treatment modalities capable of dealing with tumor heterogeneity, and the dynamism of cancer biology.

To address these obstacles, the combination of targeted therapies and chemotherapy or immunotherapy has garnered a lot of interest. Chemotherapy may simply kill fast dividing cancerous cells, and immunotherapy may evoke the immune system of the patient to identify and kill tumor cells. These combination strategies, when combined with specific agents, have the potential to address cancer in a multifactorial manner and possibly increase overall effectiveness of treatment. Clinical trials indicated that the strategies could extend survival, enhance response rate, and decrease the chances of resistance and provide a stronger and longer lasting therapeutic effect on the patient regardless of the cancer type.

- **Combination with Chemotherapy**

Chemotherapy has played a historic role in the field of oncology, but its main effect is non-selective cytotoxicity, which is directed against actively dividing cells. Although successful, chemotherapy may, in some cases, be ineffective because cancer cells may switch to other survival mechanisms. Cytokine therapy can be improved by incorporation of target therapies with chemotherapy to influence the treatment outcomes by sensitizing the tumor cells to cytotoxic effects.

As a case example, the use of HER2-targeted inhibitors like trastuzumab or pertuzumab together with conventional chemotherapy regimens has become the norm in the HER2-positive breast cancer. The agents are directed against HER2-mediated signaling pathways that induce cell survival and proliferation. This suppression renders cancer cells more susceptible to the effects of chemotherapy (or mitotic block) on their DNA damage or mitosis, which in turn enhances the response rates, progression-free survival, and the overall survival. Basically, chemotherapy is a mass production cytotoxic attack, whereas targeted therapies have selective down regulation of important oncogenic pathways and lead to synergistic anti-tumor activity.

Further, it can be used in combination with chemotherapy to overcome intrinsic resistance to some tumors. Partially responsive tumors could become fully responsive when supportive survival pathways are simultaneously inhibited, and hence, lower the chances of disease progression.

Combination with Immunotherapy

Immunotherapy is a new paradigm shift in the treatment of cancer, the goal of which is to unite the own immune system of the patient against the tumor cells. The immune checkpoint inhibitors can be used like anti-PD-1 or anti-PD-L1 antibodies that can reverse the immune suppression in the tumor microenvironment to enable T-cells to identify and kill cancer cells successfully.

Immunotherapy can be enhanced with targeted therapies to modify tumor microenvironment in a manner that boosts immune recognition. As an example, BRAF and MEK inhibitors in melanoma do not only suppress oncogenic signaling, but also enhance antigen presentation and immune cell infiltration in the tumors. These agents, with immune checkpoint inhibitors, can generate stronger and sustained anti-tumor effects than each treatment alone. Such synergy is able to enhance treatment efficacy but can also delay or overcome developed resistance which can be a frequent problem with monotherapy.

Moreover, tailored therapy may diminish immunosuppressive signaling in the tumor, establishing the environment that is more conducive to immune-mediated tumor destruction. The prospect of such combination strategies is especially high in the cancers in which immune evasion plays a significant role in the progression.

Rationale for Combination Therapy

The rationale behind such a combination of targeted therapies and chemotherapy or immunotherapy is that this provides a multi-pronged attack on cancer, which improves therapeutic efficacy and tumor adaptability:

1. **Parallel inhibition of multiple signaling pathways:** It is not uncommon to find several keys signaling pathways on which tumors depend to grow, survive and proliferate. Combination therapies by hitting more than one of these pathways prevents tumor compensatory attempts by alternative survival pathways. Multi-targeted treatment enhances the possibility of disrupting tumor growth and attaining a more holistic treatment effect.

2. **Decrease in resistance formation:** Cancer cells are very flexible and may acquire resistance to single-agent therapy through activating alternative pathways or machinery. The combination therapies prevent more than one possible escape route at a time, making it highly unlikely that the cancerous cells will develop adaptive

resistance. This assists in the longer-term effectiveness of treatment and may delay or prevent relapse.

3. **Greater clinical response:** Therapeutic modalities, including targeted agents with chemotherapy or immunotherapy, can be synergized together and result in more profound and sustained clinical response. This has a tendency to bring better results such as an increase in response rate, prolonged progression-free survival and, in a few instances, an increase in overall survival, which in the end results in patients having a more lasting and effective treatment protocol.

Key Considerations and Challenges

Although combination therapies clearly have a potential, their application is fraught with a number of challenges:

- **Toxicity:** When a drug is combined with others, the side effects can be increased; these effects can be mild (such as fatigue, nausea), moderate, or severe (such as myelosuppression, organ toxicity). These effects are critical to put under close surveillance and supportive care.
- **Ideal sequencing and dosing:** The timing, sequence and dosage of each therapy may have a considerable impact. As an example, synergies could occur when they are given concurrently, yet there is a possibility that sequential therapy can reduce overlapping toxicities. Pharmacokinetic modeling and careful data of clinical trials are usually necessary to establish the most preferred regimen.
- **Patient selection:** Combination therapy will not be equally effective in all patients. The molecular profiling and biomarker testing are required to determine the patients most likely to be responsive to the treatment and subsequently the treatment can be tailored to the individual.

Although combination strategies are an effective way to overcome monotherapy limitations, it still needs thorough planning, a custom approach toward the patient and continuous monitoring in order to achieve maximum benefits and minimum risks.

REFERENCES

1. Saeed, R. F., Awan, U. A., Saeed, S., Mumtaz, S., Akhtar, N., & Aslam, S. (2023). Targeted therapy and personalized medicine. In *Therapeutic Approaches in Cancer Treatment* (pp. 177-205). Cham: Springer International Publishing.
2. Molla, G., & Bitew, M. (2025). The Future of Cancer Diagnosis and Treatment: Unlocking the Power of Biomarkers and Personalized Molecular-Targeted Therapies. *Journal of Molecular Pathology*, *6*(3), 20.
3. Couri, T., & Pillai, A. (2019). Goals and targets for personalized therapy for HCC. *Hepatology international*, *13*(2), 125-137.
4. Wang, M., Herbst, R. S., & Boshoff, C. (2021). Toward personalized treatment approaches for non-small-cell lung cancer. *Nature medicine*, *27*(8), 1345-1356.
5. Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., ... & Cervantes, A. (2020). Personalized medicine: recent progress in cancer therapy. *Cancers*, *12*(4), 1009.
6. Hoeben, A., Joosten, E. A., & van den Beuken-van Everdingen, M. H. (2021). Personalized medicine: recent progress in cancer therapy. *Cancers*, *13*(2), 242.
7. Pakkala, S., & Ramalingam, S. S. (2018). Personalized therapy for lung cancer: striking a moving target. *JCI insight*, *3*(15), e120858.
8. Wang, R. C., & Wang, Z. (2023). Precision medicine: disease subtyping and tailored treatment. *Cancers*, *15*(15), 3837.
9. Schuppan, D., Ashfaq-Khan, M., Yang, A. T., & Kim, Y. O. (2018). Liver fibrosis: Direct antifibrotic agents and targeted therapies. *Matrix Biology*, *68*, 435-451.
10. Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C. K., Rimawi, M. F., & Schiff, R. (2020). Towards personalized treatment for early stage HER2-positive breast cancer. *Nature Reviews Clinical Oncology*, *17*(4), 233-250.
11. Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., ... & Calabrese, L. (2020). Moving towards personalized treatments of immune-related adverse events. *Nature reviews Clinical oncology*, *17*(8), 504-515.
12. Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., ... & Cheng, Q. (2022). Glioma targeted therapy: insight into future of molecular approaches. *Molecular cancer*, *21*(1), 39.

13. Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., ... & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. *Cell*, *187*(7), 1617-1635.
14. Conrad, C., & Gilliet, M. (2018). Psoriasis: from pathogenesis to targeted therapies. *Clinical reviews in allergy & immunology*, *54*(1), 102-113.
15. Yen, T. T., Wang, T. L., Fader, A. N., Shih, I. M., & Gaillard, S. (2020). Molecular classification and emerging targeted therapy in endometrial cancer. *International Journal of Gynecological Pathology*, *39*(1), 26-35.

Chapter 7…

IMMUNOTHERAPY IN THE PRECISION ERA

Dr. SHRADDHA WALEKAR GHAISAS
Designation:lecturer
Mgm Dental College and Hospital
Kamothe, Navi Mumbai, Pincode 421202
Email: Shraddhawalekar7@gmail.com

ISHANI
HoD, Pharmacy
Institute of Pharmaceutical Sciences,
IET BHADDAL TECHNICAL CAMPUS ROPAR, 140108
Email: ishani.ph17@gmail.com

ASHRITA DUBEY
Assistant Professor
Glocal University
Pin - 247121
Email: ashritadubey@gmail.com

Dr. RITESH KUMAR
Associate Professor
Sharda School of Pharmacy, Sharda University Agra,
Uttar Pradesh, India, 282007
Email: ritesh.kumar@agra.sharda.ac.in

Dr. KAMINEE SAHU
Professor
Gyan Ganga Institute of Technology and Sciences Pharmacy
Pin - 483003
Email: kaminisahu26@gmail.com

Immunotherapy has revolutionized cancer treatment where the immune system of the body is used to combat tumors and the immune checkpoint inhibitors (ICIs) have been at the center stage. To avoid immune surveillance, tumors use the PD-1/PD-L1 and CTLA-4 checkpoint pathways that inhibit T-cells. The drugs that help to restore the activity of T-cells include pembrolizumab, nivolumab, atezolizumab (PD-1/PD-L1 inhibitors), and ipilimumab (CTLA-4 inhibitor), which help to prolong the life of some cancers like melanoma, lung cancer, and urothelial carcinoma. Nevertheless, this is not applicable to all patients and predictive biomarkers are essential in-patient selection. Underlying biomarkers are PD-L1 level, tumor mutational load (TMB), and microsatellite instability-high (MSI-H) that can detect more responsive tumors with respect to ICIs.



Figure 1: Immunotherapy

Source: (https://www.news-medical.net/health/What-is-Immunotherapy.aspx)

Other than ICIs, tumor-specific neoantigen-targeted personalized cancer vaccines are emerging. These therapeutic vaccines, unlike preventive vaccines, are meant to cause the development of specific immune response against cancer cells. Examples of platforms are peptide-based vaccines, mRNA vaccines, and dendritic cell (DC) vaccines each of which is aimed at presenting neoantigens to the body to stimulate cytotoxic T-cells. Clinical results have been positive, particularly in melanoma and glioblastoma, and vaccines are commonly used hand in hand with ICIs to improve effect.

Adaptive cell therapies (ACT) including CAR-T and TCR-T cell therapies take the field of personalized immunotherapy a step further by engineering or clustering patient-derived T-cells to target tumor antigens. CAR-T treatment has been exceptionally effective in hematologic malignancies, especially with CD19-targeted therapies, with TCR-T treatment potentially extending to solid tumors as the range of targets can include intracellular antigens. Although breakthroughs were made, issues such as cytokine release syndrome, neurotoxicity, antigen heterogeneity and solid tumor barriers have limited the broader use.

One of the biggest challenges of all immunotherapies is its ability to forecast the patients who are going to respond. Lack of precision is caused by tumor heterogeneity, dynamic tumor micro environments, and incomplete biomarkers. Although PD-L1 and TMB inform therapy, they have limitations that highlight the necessity of superior predictive instruments. Future prospects would be the integration of multi-omics, predictive modeling with AI and rational combination therapies to reprogram the tumor microenvironment, circumvent resistance, and expand patient response. Combined, these advances are leading the new wave of personalized cancer immunotherapy.

7.1. IMMUNE CHECKPOINT INHIBITORS AND PREDICTIVE BIOMARKERS

The use of immunotherapy in cancer therapy has brought a new twist in the treatment process in the sense that it uses the immune system of the patient to identify and eliminate the malignant cells. Although the immune system is inherently competent to respond to abnormal cells through detection and destruction, tumors usually develop ways of avoiding immune surveillance. One of the most important approaches is to take advantage of the immune checkpoints to control the immune system of self-tolerance and suppress excessive activation of the immune system. With the help of them, the T-cells can be successfully silenced by the tumors, and the cancer cells may develop uncontrolled growth and spread. Immune checkpoint inhibitors (ICIs) are medicines that prevent these inhibitory processes and instead rejuvenate T cells to allow the immune system to spearhead an organized assault on cancerous cells.

Based on the evidence that ICIs are not effective in all patients and tumor types, predictive biomarkers that facilitate treatment should not be ignored. PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) can be used as a biomarker to select patients with the highest likelihood of respondence to checkpoint blockade therapy. Improving immunotherapy by including biomarker testing in clinical practice can enable the oncologist to

optimally personalize the treatment to maximize efficacy and minimize exposure to unnecessary side effects. This treatment strategy is a combination of immune checkpoint inhibition and accurate patient selection based on specific biomarkers, which can get as much therapeutic benefit as possible and is one of the foundations of contemporary precision oncology.

❖ ***Immune Checkpoint Inhibitors (ICIs)***

1. **PD-1/PD-L1 Inhibitors:** Programmed cell death protein 1 (PD-1) is a T-cell receptor and the ligand is PD-L1 expressed on many tumor cells. In case of PD-1 PD-L1 binding, T-cell activity is inhibited, and tumor cells escape immunodetection. Pembrolizumab, nivolumab and atezolizumab block PD-1, PD-L1, and therefore restore T-cell functions to treat tumor cells. Those treatments are effective against various cancers, such as melanoma, lung cancer, and urothelial carcinoma.

2. **CTLA-4 Inhibitors:** Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is another checkpoint molecule on T-cells that modulates immune-activation mainly in lymph nodes in the priming step of T-cell responses. A CTLA-4 inhibitor, ipilimumab, hampers this checkpoint, resulting in an augmentation of T-cell activation and proliferation, which raises the capacity of the immune system to assail tumor cells. CTLA-4 inhibitors have demonstrated significant efficacy in cancerous diseases that are highly immunogenized, including melanoma.

❖ ***Predictive Biomarkers***

Identifying patients likely to benefit from ICIs is crucial, as not all tumors respond equally to immunotherapy. Predictive biomarkers help guide patient selection and optimize treatment outcomes:

1. **PD-L1 Expression:** Tumors expressing high levels of PD-L1 are often more responsive to PD-1/PD-L1 inhibitors. Immunohistochemistry tests quantify PD-L1 on tumor or immune cells, helping clinicians determine the likelihood of therapeutic success.

2. **Tumor Mutational Burden (TMB):** TMB measures the total number of mutations within a tumor's genome. Tumors with high TMB generate more neoantigens, which are recognized as foreign by the immune system, enhancing the efficacy of ICIs. High TMB has been associated with better responses in lung cancer, melanoma, and other solid tumors.

3. **Microsatellite Instability-High (MSI-H):** Tumors with defective DNA mismatch repair exhibit MSI-H, resulting in a high rate of mutations and increased neoantigen formation. MSI-H tumors are particularly sensitive to ICIs because their abnormal proteins make them more visible to the immune system. This biomarker is commonly used to guide immunotherapy in colorectal and other gastrointestinal cancers.

7.2. PERSONALIZED CANCER VACCINES AND NEOANTIGEN TARGETING

Individualized cancer vaccines constitute the latest methodology in immunotherapy where the goal is to use the body of a patient with regard to its immune system to specifically target and eliminate cancer cells. Contrary to conventional preventive vaccines, which guard against infection, therapeutic cancer vaccines are developed to treat pre-existing cancer tumors by prompting powerful and specific anti-tumor immunity. These vaccines stimulate T cells to attack cancer cells but not normal tissue by introducing the immune system to tumor-associated antigens, and this attack is less destructive than that of other usual therapies because it destroys the cancer and not normal tissue. The method makes the immune system a patient-specific tool against cancer that is highly accurate.



Figure 2: Personalized Cancer Vaccines

Source: (https://www.mdpi.com/1422-0067/24/23/16591)

Recent developments in genomic sequencing, bioinformatics and immunogenomics have enabled the development of vaccines that can be targeted to the individual genes of tumor. The foundational component of this strategy is that of neoantigens, new protein sequences that are products of tumor-specific mutation, which are non-existent in normal tissues. Neoantigens are extremely specific to the tumor of a specific patient, so by targeting them, it is possible to activate the immune in the most specific manner possible, reducing the chances of autoimmune reactions and increasing the effects of the therapy. Not only do personalized cancer vaccines mark an important advance towards personalized immunotherapy, but also have potential to be combined with other precision therapies, including checkpoint inhibitors, to enhance response rates and long-term outcomes in cancer therapy.

Neoantigen-Based Vaccines

Neoantigen-based vaccines are one of the most recent approaches to cancer immunotherapy based on the ability to capitalize on individual tumor mutational landscapes. Neoantigens are new peptide sequences that are produced due to tumor specific mutation, including single nucleotide variants, insertions, deletions, or fusions of genes. Since these antigens are not present in normal tissues, they are not immunologically regulated by central tolerance and are very immunogenic with high chances of not causing autoimmunity. This attribute provides them with a clear cut above conventional tumor-associated antigens that are commonly expressed on normal tissues and will result in less vigorous or less specific immune action.

Having added tumor-specific neoantigens to vaccine preparations, scientists hope to induce and expand populations of T-cells with stunning specificity against cancer cells. After vaccination, dendritic cells load the neoantigen peptides onto the MHC system, which activates the cytotoxic Cy8+ T-cells and helper CD4+ T-cells, which are both essential in coordinating anti-tumor immunity. Such a specific method increases the awareness of tumor cells and their destruction, with a lower level of collateral damage to the normal tissues.

Various vaccine systems are under use as neoantigen delivery systems and they include, synthetic peptide-based vaccines, RNA based vaccines, viral vectors and dendritic cell based vaccines. The platforms have different strengths in the aspects of immunogenicity, scalability and production speed. Recent discoveries in next-generation sequencing (NGS) and bioinformatics-based neoantigen prediction algorithms have made the discovery of patient-specific neoantigens faster, and it is now possible to design highly personalized vaccines within clinically relevant timelines.

There is promising evidence of efficacy given by clinical trials. Indicatively, neoantigen melanoma vaccines have been able to trigger strong T-cell responses that are associated with progression-free survival. There, too, initial work in glioblastoma and non-small cell lung cancer has revealed promising evidence of immune response and tumor regression. In addition, neoantigen vaccines regimens have been used in combination with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies) with an enhanced ability to generate antitumor effect by reversing T-cell exhaustion and immune suppression in the tumor microenvironment.

In spite of their promise, there are a number of challenges. The design of neoantigen-based vaccines is resource- and time-consuming since it involves custom sequencing, computational forecasting, and vaccine production. Besides, the heterogeneity of tumors and the possibility of evolution of tumor cells and loss of targeted neoantigens are obstacles to long-term efficacy. However, the accuracy, specificity, and safety profile of neoantigen-based immunotherapy makes them one of the most promising frontiers to the personalized treatment of cancer, and the possibilities of this technology to change treatment regimens in different malignancies.

- **Types of Personalized Cancer Vaccines:**
  1. **Peptide-Based Vaccines:** It consists of tumor neoantigens produced as short synthetic peptides. They are then introduced into the patient by the major histocompatibility complex (MHC) molecules, which activate an immune response against the tumor, upon their introduction. They can be comparatively manufactured and they might need adjuvants to enhance immune responses.

  2. **mRNA Vaccines:** mRNA vaccines are the latest and a potent platform, in which neoantigens are encoded, giving the patient their own cells to manufacture and present them to the immune system. The method allows scaling and quick customization. After the mRNA vaccines demonstrated success in infectious diseases (e.g. COVID-19), their use in cancer has become increasingly popular with mRNA vaccines demonstrating effectiveness in melanoma, glioblastoma, and other tumors.

  3. **Dendritic Cell (DC) Vaccines:** Dendritic cells are professional antigen-presenting cells that are able to prime strong T-cell responses. Under the process, dendritic cell are cloned and removed out of the patient, loaded with tumor neoantigens (peptides, RNA or tumor lysates), and returned. This augments T-cell activation and produces a stronger antitumor immune response.

Clinical Significance

Cancer vaccines Personalized cancer vaccines are an emerging immunotherapeutic modality aiming to induce the patient or his/her own immune system to identify and kill tumor-specific antigens, especially those found with somatic mutations as neoantigens. These vaccines are being clinically pursued in a broad range of clinical trials and have demonstrated promising results, particularly in highly mutated cancers like melanoma, glioblastoma and non-small cell lung cancer (NSCLC). Neoantigens are highly concentrated in these tumours offering a good target to be taken up by immunity without posing a risk of off-target toxicities.

Initial preclinical studies have shown that personalized vaccines can effectively result in robust and durable T-cell responses, which are typically associated with clinical outcomes like tumor regression, slowed progression or extended survival. Notably, the given vaccines are not produced as monotherapy but are being progressively used together with immune checkpoint inhibitors (e.g. anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) to conquer the intensive immunosuppressive processes within the tumor microenvironment (TME). These combinations have also led to synergistic effects, increasing the persistence of vaccine-primed T-cells by reducing T-cell exhaustion and into a durable and clinically meaningful response.

Clinical relevance of personalized cancer vaccines goes beyond the therapeutic effect. They are a paradigm shift to precision medicine when the therapies are specific to the mutational profile or the specific tumor in a person. It is not only more efficacious but also lowers the chances of systemic toxicities as opposed to conventional chemotherapies or generalized immunotherapies. In addition, current developments in next generation sequencing, bioinformatics pipelines, and algorithmic neoantigens predictive methods are cutting down the vaccine design and manufacturing schedules, and these therapies are becoming more practical to implement into practice.

Although there are obstacles including the expense and time involved in designing personalized vaccines, the inconsistency of immune competence across patients, and difficult amino acid combinations to predict as really immunogenic neoantigens, the accumulating clinical data overwhelmingly points to their potential. When optimized, personalized cancer vaccines have the potential to be an essential part of the next-generation oncology, providing the patient with the option to treat cancer with durable, highly specific, and less toxic treatment and personalized cancer vaccines.

7.3. ADOPTIVE CELL THERAPIES (CAR-T, TCR-T)

Adoptive Cell Therapy (ACT) is a game-changing technology in cancer therapy, which uses the immune system of the body to attack and kill malignant cells with great accuracy never seen before. At the heart of this strategy is the isolation of T-lymphocytes, be it off the peripheral blood of the patient or directly off the tumor microenvironment and activated and then expanded in vitro in the laboratory under controlled conditions. Such cells can be further modified to increase their anti-cancer property. Regarding Chimeric Antigen Receptor T-cell (CAR-T) therapy, T-cells are engineered to produce artificial receptors that target antigens on tumors that make them target and destroy cancer cells more efficiently. Likewise, T-cell receptor-engineered T-cell (TCR-T) therapy T-cells are modified to recognize the presence of particular peptides on tumor cell major histocompatibility complex molecules which increases their specificity and cytotoxicity to tumors. The reinfusion of these powerful, tumor-targeted immune cells into the patient may lead to a powerful anti-tumor response, even to the extent of complete remission, particularly in hematological malignancies, like acute lymphoblastic leukemia and in some cases of lymphomas that have become resistant to conventional treatment.



Figure 3: Adoptive Cell Therapy

Source: (https://www.mdpi.com/2073-4409/10/4/808)

Adoptive Cell Therapy (ACT) is a game-changing technology in cancer therapy, which uses the immune system of the body to attack and kill malignant cells with great accuracy never seen before. At the heart of this strategy is the isolation of T-lymphocytes, be it off the peripheral blood of the patient or directly off the tumor microenvironment and activated and then expanded in vitro in the laboratory under controlled conditions. Such cells can be further modified to increase their anti-cancer property. Regarding Chimeric Antigen Receptor T-cell (CAR-T) therapy, T-cells are engineered to produce artificial receptors that target antigens on tumors that make them target and destroy cancer cells more efficiently. Likewise, T-cell receptor-engineered T-cell (TCR-T) therapy T-cells are modified to recognize the presence of particular peptides on tumor cell major histocompatibility complex molecules which increases their specificity and cytotoxicity to tumors. The reinfusion of these powerful, tumor-targeted immune cells into the patient may lead to a powerful anti-tumor response, even to the extent of complete remission, particularly in hematological malignancies, like acute lymphoblastic leukemia and in some cases of lymphomas that have become resistant to conventional treatment.

Types of ACT:

1. **CAR-T Cell Therapy (Chimeric Antigen Receptor T-cells)**

CAR-T cell therapy is among the most innovative and clinical success stories of adoptive cell therapy (ACT). In this method, the T-cells of a patient are harvested and genetically engineered ex vivo to produce chimeric antigen receptors (CARs)- artificial receptors to identify and attach to certain antigens on tumor cells. As opposed to natural T-cell receptors, CARs do not rely on major histocompatibility complex (MHC), which means that they can overcome tumor mechanisms aimed at avoiding immune rejection in the form of downregulating the major histocompatibility complex. The special characteristic of CAR-T cells enables them to be used effectively in antigen delivery against tumor-specific or tumor-associated antigens.

One of the most remarkable targets is CD19, which is persistently expressed in malignant B-cells in leukemias and lymphomas. Anti-CD19 CAR-T cell therapies have proven to be more successful than ever in blood cancers, especially in patients with refractory or relapsed disease that had exhausted all forms of conventional treatments, including chemotherapy, radiation and stem cell transplantation. Innovative FDA-approved therapies in this area are tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta). There have been impressive clinical trial

and real-world results such as high response rates in general and long-lasting remissions in patients who were considered untreatable.

The therapeutic benefit of CAR-T cells is not only in their capacity to cause a quick tumor clearance, but also in their possibility to be maintained in the human body over a long period and, thus, provide immunosurveillance and decrease the risk of the recurrence. Significantly, CAR-T therapy has revolutionized the management of pediatric and adult patients with B-cell acute lymphoblastic leukemia (ALL), and in adults with large B-cell lymphomas, and has established itself as an essential part of the treatment paradigm in treatment-resistant environment.

Outside of CD19, development of CAR-T applications is underway to incorporate other antigens like BCMA (B-cell maturation antigen) in multiple myeloma and CD22 in B-cell malignancies, which expands the therapeutic clinical program. Additionally, designs of CAR are being explored to counter resistance, improve on efficacy, and address toxicities such as cytokine release syndrome (CRS) and neurotoxicity via CAR-based innovations, including dual-target CARs, armored CAR-T cells that express cytokines and safety-switch systems.

Overall, CAR-T cell therapy has emerged as a shift in paradigm in cancer immunotherapy, providing sustained responses where traditional therapies have been unable, and platforming the development of next-generation engineered T-cell therapies to increase the spectrum of ACT into hematologic and, ultimately, solid tumor.

2. TCR-T Cell Therapy (T-cell Receptor Therapy)

Another sophisticated adaptive cell therapy (ACT) that is not similar to CAR-T treatment is TMC-T cell therapy. TCR-T therapy does not require the introduction of synthetic receptors but includes a genetic modification of T-cells of a patient to express tumor-specific T-cell receptors (TCRs). These engineered TCRs can identify intracellular tumor-associated antigens that are processed and shown on the tumor cell surface within major histocompatibility complex (MHC) molecules. This renders TCR-T therapy distinctly potent, since it increases the repertoire of possible targets beyond superficial antigens to a far broader one that encompasses both cancer-testis antigens (e.g., NY-ESO-1, MAGE-A3) and viral antigens in viral-related malignancies.

This is unlike CAR-T therapy, which is restricted to the ability to identify antigens on the surface of the cell, TCR-T therapy takes advantage of cell-native antigen-processing

mechanism. This implies that TCR-T cells are capable of recognizing and destroying tumor cells on the basis of intracellular protein fragments displayed by MHC molecules. Consequently, the method has specific potential in solid tumor therapy, in which appropriate surface antigens are scarce and antigen diversity is a significant concern.

TCR-T Therapy TCR-T therapy has shown promise in clinical trials in synovial sarcoma and multiple myeloma with tumor regression and long-lasting responses reported in early-phase trials (NYESO-1) with TCR-T therapy. Likewise, engineered TCRs targeting viral antigens, including the HPV E6 and E7 proteins have shown promise in HPV-related cervical and head-and-neck cancers. These results highlight the usefulness of TCR-T therapy in the treatment of both hematologic and solid cancers.

The benefits of TCR-T therapy are that it has wide antigen-binding properties and that it can penetrate intracellular tumor weaknesses inaccessible to CAR-T cells. Nonetheless, it is also associated with certain issues including rigid reliance on MHC-restricted antigen presentation, patient HLA proteomic variability and risk of off-target toxicities in case engineered TCRs cross-react with normal tissue antigens.

Regardless of these shortcomings, continued efforts in TCR affinity engineering, safety switch and customized approaches to HLA matching are enhancing the safety and effectiveness of TCR-T therapy. Collectively, these discoveries make TCR-T cell therapy a highly potential direction in the ACT landscape to complement CAR-T therapy, by expanding the therapeutic scope of most tumor types.

Challenges and Limitations of ACT

Despite the proven potential of adoptive cell therapy (ACT) in the transformative immunotherapy of cancer, there are various issues that still limit its wider clinical use. Cytokine Release Syndrome (CRS) is one of the most serious and possibly even life-threatening complications. CRS is caused by the huge discharge of pro-inflammatory cytokines in the aftermath of engaging engineered T-cells in tumor cells. In clinical terms, it presents itself as high fever, hypotension, hypoxia, dysfunction of multiple organs, which in extreme cases can result in death unless timely medical intervention is undertaken. The existing treatment methods, including the use of IL-6-blockers (e.g., tocilizumab) and corticosteroids, have resulted in better control; nevertheless, the challenge of suppressing the immune system without interfering with treatment efficacy is a fine balancing act.

Neurotoxicity, which is also referred to as immune effector cell-associated neurotoxicity syndrome (ICANS) is another significant toxicity. The spectrum of neurological manifestations of this complication is quite broad and includes confusion, disorientation, seizures, cerebral edema, and encephalopathy. In contrast to CRS, the specific mechanisms of neurotoxicity remain not yet fully studied, but they may be the endothelial activation, the breakage of the blood-brain barrier, and the neuroinflammation caused by cytokines. Neurotoxicity is not predictable, which further complicates the treatment regimens of ACT.

Besides toxicities, ACT, and especially chimeric antigen receptor T-cell (CAR-T) therapies, have limited efficacy in solid tumors relative to hematological malignancies. This disparity can be explained by several biological and structural obstacles:

- **Immunosuppressive Tumor Microenvironment (TME):** The TME is full of the inhibitory cytokines (e.g., TGF-B, IL-10) and immune checkpoint proteins (e.g., PD-L1), which together inhibit T-cell activity and growth.
- **Physical Barriers:** The thick extracellular matrix and stromal architecture surrounding many solid tumors is physically associated with hindering T-cell infiltration and limiting their cytotoxic capability.
- **Heterogeneity of Antigen:** In contrast to hematological cancers, solid tumors are heterogeneously antigen-expressive. In the treatment process, the targeted antigens may be down-regulated or even lost by the tumor cells and this allows the tumor cells to escape immunity and eventually causes a relapse.

More so, the complexity of manufacturing, high cost and the logistic problems of producing patient specific engineered T-cells also restrict the universal access of ACT. The procedure involves harvesting of autologous T-cells, genetic engineering, cell culture in strict requirements and reinfusion in time, all of which is resource-consuming.

Collectively, these constraints suggest the necessity of next-generation design, such as enhancement of safety-switch designs to regulate toxicities, engineering T-cells with a better homing and infiltration potential, developing allogeneic off-the-shelf ACT products, and combining ACT with checkpoint blockade or oncolytic agents to overcome the immunosuppressive environment of solid tumors. It is only in response to these challenges that ACT can become a genuinely long-term and multi-modal therapeutic agent against a wide range of cancers.

7.4. PRECISION CHALLENGES IN IMMUNOTHERAPY RESPONSE PREDICTION

Immunotherapy has transformed treatments in cancer, yet one of its greatest shortcomings is that it only a fraction of patients responds with durable meaningful responses. It is hard to predict that a patient will be benefited as both the tumor and the host immune system are highly heterogeneous and dynamic. Precision oncology is an innovative approach to personalize immunotherapy, but there are important obstacles that make response prediction difficult.

1. **Tumor Heterogeneity:** Cancers are not homogenous but are comprised of a number of subclones that have varying genetic and phenotypic profiles. In the same tumor, cells can contain target antigens that immunotherapy can recognize but others can have them or down-regulate them. Such clonal diversity may cause partial responses or relapse, with the growth of resistant clones. Besides these, inter-patient heterogeneity, which is variation between tumors of the same type in different patients also complicates prediction models.
2. **Dynamic Immune Microenvironment:** The tumor microenvironment (TME) does not remain stable, but it is modified by the response to therapy and disease progression. The immune cell infiltration (T-cells, NK cells, macrophages), cytokine signals, and checkpoint molecule expression (e.g. PD-L1, CTLA-4) differ by time and between tumor regions. The initially hot (full of immune infiltration) tumor can become cold (immune exclusion) and real-time monitoring becomes necessary but challenging.
3. **Limitations of Biomarkers:** PD-L1 expression and tumor mutational burden (TMB) are the two most commonly used biomarkers at the present to inform immunotherapy. Nonetheless, they are deficient in several aspects: PD-L1 expression may be focal and transient, and TMB is not necessarily associated with immune responsiveness. Other prospective biomarkers, including microsatellite instability (MSI), neoantigen load, and circulating immune signatures are being studied, but none given alone can provide a full forecasting picture.
4. **Mechanisms of Resistance:** Tumors commonly develop resistance mechanisms even at the time of initial response on the part of the patient. These are loss of antigen presentation machinery (e.g. mutations in MHC class I), release of immunosuppressive cytokines and recruitment of regulatory T-cells (Tregs) and myeloid-derived suppressor

cells (MDSCs). The adaptations produce an immunosuppressive niche that mitigates the efficacy of immunotherapy.

Future Directions

- **Multi-omics Approaches:** by integrating genomics, transcriptomics, proteomics, and metabolomics a complete picture on tumor-immune system interaction is provided. In contrast to single-dimensional biomarkers, multi-omics analyses enable biologically layered information and correlate genetic changes, expression changes, protein changes, and metabolic changes. This comprehensive system is able to discover new predictive biomarkers, discover disease pathophysiology, and monitor dynamic alterations in tumor development and immune responses. Finally, it could be possible that multi-omics would allow the use of precision oncology methods as molecular signatures can be associated with therapeutic sensitivity and resistance.
- **Artificial Intelligence (AI) and Machine Learning Models:** AI and machine learning are potent instruments to handle complexity and volume of clinical, pathological, and molecular data. The AI-based predictive algorithms also can help formulate the correct patient stratification systems by identifying nonlinear and subtle patterns that cannot be seen through the traditional statistical methods. Such models have the potential not only to predict responses to treatment, track disease progression, and provide adaptive therapeutic responses in real time, but also to forecast them. Moreover, AI has potential to improve the discovery of biomarkers, clinical trial design, and clinical decision making to drive therapy personalization.
- **Combination Therapies:** Although immune checkpoint inhibitors have been successful in treating patients, resistance or diminished responses are common in many patients, underscoring the need to implement combinatorial approaches. Combination of immune checkpoint blockade with targeted therapy, chemotherapy, radiation therapy, or new immunomodulators will be applied synergistically to recondition tumor microenvironment (TME), stimulate immune activation and evade adaptive resistance mechanisms. Such methods are effective not only in increasing the number of responders, but they also enhance clinical benefit durability. Mechanism-driven and biomarker-driven rational design of combination regimens is an avenue with potential to promote immuno-oncology.

REFERENCES

1. Wang, Y., Wang, M., Wu, H. X., & Xu, R. H. (2021). Advancing to the era of cancer immunotherapy. *Cancer Communications*, *41*(9), 803-829.
2. Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., ... & Genova, C. (2020). Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient. *Cancers*, *12*(5), 1125.
3. Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., ... & Maiello, E. (2022). Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives. *International Journal of Molecular Sciences*, *23*(2), 820.
4. Paucek, R. D., Baltimore, D., & Li, G. (2019). The cellular immunotherapy revolution: arming the immune system for precision therapy. *Trends in immunology*, *40*(4), 292-309.
5. Chowdhury, K. H., & Khan, S. S. (2022). Individualized Immunotherapy Approaches in Precision Medicine. *Journal of Precision Biosciences*, *4*(1), 1-10.
6. Adamaki, M., & Zoumpourlis, V. (2021). Immunotherapy as a precision medicine tool for the treatment of prostate cancer. *Cancers*, *13*(2), 173.
7. Incorvaia, C., Ridolo, E., Bagnasco, D., Scurati, S., & Canonica, G. W. (2021). Personalized medicine and allergen immunotherapy: the beginning of a new era?. *Clinical and Molecular Allergy*, *19*(1), 10.
8. Ye, L., Ma, S., Robinson, B. W., & Creaney, J. (2019). Immunotherapy strategies for mesothelioma–the role of tumor specific neoantigens in a new era of precision medicine. *Expert review of respiratory medicine*, *13*(2), 181-192.
9. Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022). Neoantigens in precision cancer immunotherapy: from identification to clinical applications. *Chinese medical journal*, *135*(11), 1285-1298.
10. Bair, S. M., Brandstadter, J. D., Ayers, E. C., & Stadtmauer, E. A. (2020). Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy. *Cancer*, *126*(9), 1837-1855.
11. Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., ... & Guerrisi, A. (2021). Precision medicine and melanoma: multi-omics approaches to

monitoring the immunotherapy response. *International journal of molecular sciences*, *22*(8), 3837.

12. Groisberg, R., Maymani, H., & Subbiah, V. (2018). Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. *Expert review of precision medicine and drug development*, *3*(3), 205-213.
13. Sajjadi, E., Venetis, K., Scatena, C., & Fusco, N. (2020). Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. *Ecancermedicalscience*, *14*, 1150.
14. Steuer, C. E., & Ramalingam, S. S. (2018). Tumor mutation burden: leading immunotherapy to the era of precision medicine?. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, *36*(7), 631-632.
15. Zhang, J., Wolfgang, C. L., & Zheng, L. (2018). Precision immuno-oncology: prospects of individualized immunotherapy for pancreatic cancer. *Cancers*, *10*(2), 39.

Chapter 8…

ARTIFICIAL INTELLIGENCE AND BIG DATA IN ONCOLOGY

Dr. NADESWARI GUNTUPALLI
M.D Assistant Professor, Department of General pathology,
Sri Balaji Medical College and Hospital, Renigunta Road, Tirupati, Andhrapradesh.
Email: nadeswari.guntupalli@gmail.com

Dr. PARIDHI AGARWAL
Postgraduates Student, Department of Oral Medicine and Radiology
Kothiwal Dental College and Research Centre, Moradabad, Uttar Pradesh.
Email: pariag58@gmail.com

Dr. SUMIT BHATT
BDS, MDS, PhD Scholar, Assistant Professor,
Department of Oral and Maxillofacial Surgery, Rajasthan Dental College & Hospital,
Nirwan University, Jaipur, Rajasthan.
Email: sumittbhatt22@gmail.com

Dr. KANIKA SINGH DHULL
PhD Scholar, Department of Pedodontics & Preventive Dentistry, Kalinga Institute of Dental Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha.
Email: kanikasingh.dhull@gmail.com

Dr. ROHIT NARENDRA RATHOD
(F.I.B.O.M.S, M.D.S, F.F.A.S, F.H.N.O, F.H.N.S, P.D.C.R, AOCMF-G.O.C.D, G.F.P.M, F.P.F.A, F.I.C.S.), Consultant in Department of Head & Neck Oncology & Skull Base Surgery at Shakus Medicity, Meshana, Ahmedabad, Gujrat.
Email: drrnromfs@gmail.com

Oncology is one of the fields that are undergoing transformation due to artificial intelligence (AI) and big data, which is changing the manner in which cancer is identified, diagnosed, and treated. Machine learning and deep learning algorithms allow learning to be analyzed with vast and high-dimensional datasets- medical imaging, genomics, pathology slides, electronic health records (EHRs), and wearable devices. Such technologies make it possible to extract the hidden patterns that human specialists can hardly notice, facilitating earlier and more correct cancer detection. As an example, AI-based image recognition can detect suspicious radiology scans or histopathology slides, and multi-omics integration (genomics, transcriptomics, proteomics, metabolomics) can help improve the knowledge base in tumor biology and inform individualized treatments. The AI systems also enhance the predictions of prognoses by integrating data between registries and actual clinical practice to enable clinicians to predict disease progression and intervene.

The clinical accuracy of AI and big data in oncology is not the only area of promise to make it efficient and accessible to cancer care. Automatic workflows have the potential to save clinicians time in which they can focus on complicated decision-making and interacting with patients. Such predictor models will be used based on large-scale data to prescribe personalized treatment regimens, such that each patient is provided with a treatment regimen that is expected to be most effective and reduce potential harmful side effects. Wearables and remote monitoring also increase the scope of oncology care and allow continuous monitoring of patients and providing real-time adjustment of their treatment. Nevertheless, to achieve these advantages, one will have to face significant issues: technical barriers of data standardization and interoperability; clinical-related problems with reliability, bias, and generalizability of AI models; and legal and ethical concerns of patient privacy, responsibility, and the danger of over-reliance on algorithms.

Finally, the merger of AI and big data in the field of oncology should not be concerned with the substitution of the clinician but rather with the abilities. Strict validation with different patients, open model development, and collaboration between humans and AI are needed to make adoption safe and fair. Oncology is headed to a future in which precision medicine is not only aspirational but also operational, in which the treatment of each patient is directed by real-time, data-driven insights that enhance outcomes and quality of life. Though promising, this paradigm shift relies on the balance between innovativeness and responsibility, and makes sure

that the power of AI can be used to complement human expertise and provide cancer care that is truly personalized.

8.1. MACHINE LEARNING MODELS FOR DIAGNOSIS AND TREATMENT PLANNING

Machine learning in oncology combines a variety of methods: supervised to recognize tumors and classify them, unsupervised to identify subtle subtypes, semi-supervised to learn scarce labels, reinforcement learning to adaptive treatment plans, and graph-based learning to learn complex biological interactions. These models are based on multi-modal inputs (such as medical imaging, digital pathology slides, molecular omics, clinical records and longitudinal time-series data). Radiomics, deep learning, and sophisticated NLP methods enable AI to improve the diagnosis, prognosis, personalization of treatment, and matching of the trial, greatly enhancing precision medicine.

The construction of AI systems in oncology has a workflow: sources such as EHRs, imaging archives, and genomics are gathered and refined; preprocessing operations are used to clean and standardize the data; experts are labeled; and representation learning happens using hand-crafted or deep features. Cross-validation is used to train and validate the models and test them against clinically relevant metrics, then implemented in clinical workflows with continuous monitoring. Nevertheless, there are still challenges such as the imbalance in classes, changes of domains between institutions, noisy labels, the overfitting risks, and interpretability. Harmonization, domain adaptation, explainable AI, and rigorous validation are essential to tackle such problems and develop trustworthy generalizable systems that can really change the face of cancer care.

- **Kinds of Machine Learning Used**

Machine learning in oncology cuts across several different directions: supervised learning on labeled tasks such as tumor classification, unsupervised learning on the hidden patient subtypes, and semi-supervised learning that uses limited labels. Reinforcement learning is used to maximize dynamic treatment plans and graph-based learning is used to model the intricate biological and patient interactions in order to forecast and tailor care.

- **Supervised learning:** The most widely used form of machine learning in oncology is supervised learning, in which models are trained on labeled data (where labels correspond to the outcome e.g., a benign or malignant tumor). Supervised models are

models trained to map input features to target labels. Standard algorithms can be logistic regression and support vector machines (SVMs) on structured clinical data, random forests and gradient-boosted trees (XGBoost, LightGBM) on tabular or heterogeneous data, and deep learning models such as convolutional neural networks (CNNs) on imaging (e.g., tumor detection in CT scans) and transformers on sequential or textual data (e.g., mining information in electronic health records).

- **Unsupervised learning:** This method can be applied in case explicit labels are not available. It identifies latent patterns in data, e.g., how to cluster patients into new subtypes or dimensionality of high-dimensional data (e.g. gene expression profiles). Patient stratification can be achieved with such methods as clustering (k-means, hierarchical clustering) and dimensionality reduction (PCA, t-SNE, UMAP), which can be used to identify possible biological mechanisms and formulate new hypotheses on cancer progression and therapy.
- **Semi-supervised / weakly supervised learning:** Medical data are costly to label, and detailed labels are often unavailable, so semi-supervised models use small labeled amounts of data with large quantities of unlabeled data. As an illustration, pathology slides can be simply labeled only at the slide-level (cancerous vs. non-cancerous), and not pixel-by-pixel. Weak label methods such as Multiple Instance Learning (MIL) and pseudo-labeling enable the model to utilize weak labels in generating higher accuracy.
- **Reinforcement learning (RL):** One of the recent research fields in the field of oncology, RL is concerned with decision-making in sequences. An RL agent tries to learn policies that maximize long-term goals, by planning actions, i.e., sequences of interventions, i.e., switching chemotherapy doses or radiation schedules, or adaptive treatment schedules. RL is able to model treatment as a dynamic process to personalize strategies to optimize survival or reduce toxicity.
- **Graph/relational learning:** Biological systems and the relationship between patients are graphs by nature. Graph neural networks (GNNs) are employed to learn graph models of molecular interaction networks (proteinprotein, gene regulatory), tumor microenvironmental celldynamics, or patient similarity graphs. This enables learning of relationships and not only individual features to predict drug response and patient outcomes.

➢ Input Data Types and Representations

Oncology makes use of varied sources of data: medical imaging and digital pathology to characterize tumors, multi-omics to provide molecular information and clinical/EHR to provide patient context. Longitudinal time-series data also represent the trajectories of disease, and the models of AI use these modalities together to enhance the process of diagnosis, prognosis, and treatment personalization.

- **Core inputs include medical imaging (CT, MRI, PET, and ultrasound):** They can be explored as is in 2D/3D arrays (voxels) or converted into radiomics features of tumor morphology, intensity distributions, and textural characteristics. Deep learning methods commonly operate on raw imaging, whereas radiomics-based methods operate on handcrafted descriptors.
- **Digital pathology:** Whole-slide images (WSIs) are gigapixel scans of tissue sections, which are extremely large. They are normally divisible into small areas to be analyzed computationally. Multiple Instance Learning combines patch-level features in making diagnoses at slide-level. Methods such as stain normalization minimize variability caused by the various labs or scanners.
- **Molecular data (omics):** molecular-level data include genomic (abnormalities in DNA mutations, copy-number variations), transcriptomic (RNA expression), proteomic, and epigenomic (DNA methylation) data. These datasets can be highly dimensional and hence dimensionality reduction, feature selection or embedding methods are performed prior to modeling.
- **Clinical data:** Consists of structured information, e.g. demographics, comorbidities, medications, lab findings, etc. Electronic health records are converted to unstructured notes which are then transformed into structured features by natural language processing (NLP), frequently through transformers (e.g., Bio BERT, Clinical BERT).
- **Longitudinal/time-series data:** Patient journeys are series of measures, such as follow-up imaging, lab values, treatment schedule. RNNs, temporal convolutional networks (TCNs), transformers learn temporal dependencies to forecast progression, recurrence or treatment outcomes.

➢ Typical Tasks in Oncology

AI in oncology supports diagnosis, tumor subtyping, prognosis modeling, and prediction of treatment response or toxicity. It also automates treatment planning tasks and enables precise clinical trial matching, driving more personalized and efficient cancer care.

- **Diagnosis and detection:** AI systems can assist in identifying suspicious lesions on medical imaging scans or detecting cancer cells in pathology slides. By automating initial screening and highlighting areas of concern, these tools improve diagnostic efficiency, reduce human error, and support early detection of malignancies.
- **Classification and subtyping:** Algorithms can distinguish histological or molecular subtypes of tumors, which is critical for guiding targeted therapies. Accurate subtyping enables clinicians to select the most effective treatment strategy, avoiding unnecessary interventions and aligning therapy with the underlying tumor biology.
- **Prognosis modeling:** AI can predict survival times, recurrence risk, or other time-to-event outcomes using approaches such as Cox proportional hazards models, survival forests, or deep learning-based survival models. These prognostic predictions support risk stratification, patient counseling, and prioritization of care interventions.
- **Treatment response prediction:** Predictive models estimate which patients are likely to respond to specific treatments—including chemotherapy, targeted therapies, or immunotherapies—allowing clinicians to personalize treatment selection and improve therapeutic efficacy while reducing exposure to ineffective interventions.
- **Toxicity prediction:** AI can forecast potential adverse effects, such as chemotherapy-induced cardiotoxicity or immune-related side effects, based on patient-specific clinical and molecular data. Early identification of high-risk patients facilitates preventative strategies and improves patient safety and quality of life.
- **Treatment planning automation:** AI streamlines labor-intensive clinical tasks, such as contouring tumor regions in radiotherapy or optimizing radiation dose schedules. By automating these processes, clinicians save time, reduce variability, and increase the precision of treatment delivery.
- **Clinical trial matching:** Integrating multi-modal patient data including genomic profiles, imaging, and clinical characteristics AI can match patients with suitable clinical trials. This accelerates enrollment, expands access to experimental therapies, and ensures that patients receive interventions most relevant to their disease profile.

➢ **Modeling Workflow (Practical Steps)**

The process of AI development in oncology can produce multi-source data, standardize it, pre-process and label the data, and finally run the feature engineering or deep learning to represent the data. Clinically relevant metrics are used to train, validate and evaluate models, and then deployed into workflows, with continuous monitoring and retraining of the model maintained to ensure reliability.

1. **Information gathering and management:** Use a variety of data sources on patients, such as electronic health records (EHRs), imaging repositories, and genomic or proteomic databases. Normalize data formats- like the use of DICOM in imaging to provide uniformity. Anonymize sensitive data about a patient to achieve privacy and compatibility of datasets in different institutions to conduct multicenter research and enhance the ability of a model to be generalized across institutions.

2. **Preprocessing:** Clean up and make ready raw data to be analyzed, using domain-specific normalization and cleaning. In imaging, image intensity values can be normalized, stain can be normalized in pathology slides, tiles can be patched whole-slide images (WSIs), and artifact removal can occur. In the case of omics data, counts should be normalized, batch effects corrected and missing values should be addressed to ensure that downstream analyses are those that capture biology as opposed to technical noise.

3. **Labeling:** label datasets with clinically validated outcomes, pathology reports, or expert-reviewed labels. Labeling is also time consuming and can be influenced by inter-observer errors, such that consensus review, quality control and standard annotation protocols are important in ensuring consistent model training.

4. **Feature engineering / representation learning:** Derive meaningful features of inputs in a manual or automatic way. Radiomics metrics, clinical scores, or lab values can be used as handcraft features, and hierarchical representations may be learned directly by deep learning models using raw data. Pre-trained model transfer learning can be especially useful when training data is scarce and the large labeled data is not necessary and it takes less time to develop models.

5. **Training and validation:** Split data into training, validation and test sets to construct and evaluate model behaviour. Use cross-validation or nested cross-validation to find

the best hyperparameters and decrease overfitting. Test models in external, independent cohorts to prove the strength and applicability across a variety of patient groups and clinical environments.

6. **Measurement metrics:** Measure performance of the models based on clinically relevant metrics, especially in the case of class imbalance. The metrics are sensitivity, specificity, precision, recall, and F1-score, AUC-ROC, AUPRC, Brier score, calibration curves, and decision curve analysis used to assess the net clinical benefit of the model. The correct choice of metrics guarantees that the results of the model will be sensible and applicable to a practical application.
7. **Deployment and monitoring:** Implement accepted AI models into clinical practice-such as into PACS systems as radiology models or EHR-based decision support systems. Track model performance on drift over time, retraining and updating models when needed to ensure accuracy and clinical reliability in dynamically changing healthcare settings.

➢ **Key Technical Challenges**

Oncology AI is associated with issues such as class imbalance, domain shift, label noise, overfitting, and low interpretability. The solutions to these involve the strong validation, alignment of data, weak supervision and explainable AI techniques to promote reliable, generalizable, and trustworthy clinical use.

- **Class imbalance:** Rare cancers or unusual clinical outcomes may biase the model training, resulting in low performance on low-represented classes. The measures that may be taken to mitigate this problem are resampling (oversampling those few classes that are hard to classify or under sampling those common classes that are easy to classify), class weighting when computing losses, focal loss functions that tend to emphasize those hard to classify examples, and selecting evaluation metrics carefully that can accommodate the imbalanced data. Those methods can be used to make sure that models are effective at generalizing to common and rare cases.
- **Domain shift:** The portability of trained models to new clinical settings may be reduced by changes in imaging equipment, pathology staining protocols or differences in patient populations. Such methods as domain adaptation, data harmonization, and federated

learning can be used to reduce such changes so that a model can be effective across a variety of healthcare settings without overlooking data privacy.

- **Label noise and inter-observer variability:** The variation among expert labels may induce label noise, particularly in problems such as histopathology or radiology interpretation. General approaches to dealing with this comprise consensus annotations with multiple experts, weak supervision methods that exploit partially labelled or noisy data, and probabilistic modeling to directly model the uncertainty of labels and enhance model robustness and reliability.
- **Data leakage and overfitting:** large-capacity models learned on small datasets will tend to memorize and not generalize. Strict validation procedures such as external test sets and cross-validation procedures and cautious experimental design are necessary to prevent overfitting and to make sure model performance is indicative of real-world applicability.
- **Interpretability:** Clinicians need clear explanations and uncertainty estimates which are calibrated in order to trust AI predictions. Saliency maps, attention mechanisms, Shapley values, and counterfactual reasoning are methods that offer insights into how a model makes decisions, i.e. which features or situations are relevant (and also influencing) to a prediction. These approaches contribute to clinician confidence by increasing interpretability and enabling a safe implementation of AI tools in clinical practice.

8.2. AI IN HISTOPATHOLOGY AND RADIOLOGY

The machine learning approach to histopathology is based on the whole-slide images (WSIs) High-resolution scans of tissue samples that are split into smaller patches to be examined by convolutional neural networks (CNNs). The output of these patches is aggregated with multiple instance learning (MIL) to produce slide- or patient-level diagnoses. The major tasks that AI assists with are tumor identification, grading (e.g., Gleason score), mitosis rate, TIL, and anticipation of molecular changes on the basis of H&E slides. Such techniques as attention mechanisms, cell segmentation (U-Net), clustering, and spatial analysis can boost the performance of the models, whereas preprocessing steps, in particular, stain normalization, artifact detection, and efficient tiling, provide the robustness. In clinical practice, AI accelerated slide triage, decreased inter-pathologist variability, offered second opinions and quantitative

biomarkers to inform precision medicine, but there are issues with large file sizes, inter-scanner generalizability, expensive annotations, and regulatory barriers.



Figure 1: AI Integration in Digital Pathology Workflow

Source: (https://www.mdpi.com/2075-4418/12/11/2794)

In radiology, AI enhances diagnostic accuracy, efficiency and quantitative measurements by the detection of lesions, automated tumor/organ segmentation, radiomic feature mining, RECIST-based response evaluation, prognostic modeling and optimization of radiation dosing. Models include 2D/3D CNNs, encoder-decoder models (U-Net) to vision transformers and multi-modal fusion models that combine PET-CT information. Radiomics provides interpretable, engineered features, whereas deep learning provides hierarchical patterns; a combination between the two improves predictive power and clinical transparency. PACS integration also facilitates triaging, follow-up and workflow, and interpretability (Grad-CAM, saliency maps) and uncertainty estimation (Bayesian networks, Monte Carlo dropout) are used to guarantee reliability so that AI can supplement, and not replace, radiologists in clinical practice.

AI in Histopathology:

- **Digital Pathology Pipeline:** The healthcare sector is starting to implement AI in histopathology with whole slide images (WSIs), which are very high-resolution scans of tissue samples in digital format. WSIs are huge in size, thus they are cut down into smaller tiles or patches. A patch-level model (typically a convolutional neural network

(CNN)) processes every patch and is capable of detecting subtle tissue features (e.g. abnormal cells, mitoses or tumor regions). Individual patch predictions are then combined via techniques, such as multiple instance learning (MIL) to generate a slide-level or patient-level diagnosis. This pipeline allows the analysis of whole tissue slides to be done with the efficiency and accuracy of AI so that they can assist pathologists in their clinical workflows.

- **Histopathology AI Tasks:** AI models are used in various major pathology tasks. Tumor detection assists in localizing cancerous areas in a short time, and tumor severity is determined by the use of grading system like the Gleason score in the case of prostate cancer. Mitosis can as well be detected using AI to determine the presence of dividing cells that can be used to gauge proliferation rates in tumors. The other important application is the quantification of tumor-infiltrating lymphocytes (TILs) that can be used as a prognostic biomarker. Also, AI is able to detect molecular changes, like mutation status or microsatellite instability, on H&E-stained slides, potentially saving the cost of costly genetic testing.
- **Techniques:** A number of AI techniques can improve the analysis of histopathology. CNNs learn to extract image patches; MIL de-patchify patch predictions and slide-level predictions. The model can be focused on clinically significant areas by attention mechanisms. Models of cell segmentation (typically variants of U-Nets) are used to label individual cells, and clustering algorithms are used to separate cells into phenotypes using morphological features. The spatial analysis methods are used to study cellular neighborhoods and tumor microenvironment to get further prognostic data.
- **Preprocessing Requirements:** Model performance is highly dependent on the strength of preprocessing. Normalization of stains decreases the variation of various scanners and staining conditions. The size of WSIs needs to be addressed with an efficient tiling strategy. Artifacts like a fold in tissue, pen marks or debris that can disrupt analysis are also detected by AI pipelines. Lastly, high quality labelled data to train in a supervised fashion must be generated using annotation tools, but these annotations are costly in terms of time to generate and must be annotated by trained pathologists.
- **Clinical Value:** AI has a significant clinical value in histopathology. With AI, the triage of slides is quicker, with urgent cases given priority and the time taken is minimized. It may be used as a second-opinion system, which reduces the differences in the opinion

of pathologists. AI also supplements pathologist workflow instead of substituting it with quantitative biomarker outputs (e.g., TIL counts and measures of heterogeneity) to inform treatment decisions. These understandings aid in the field of precision medicine and should improve the accuracy of diagnoses.

- **Limitations:** AI in histopathology has a number of obstacles to its potential. WSIs are very large in file sizes, which require large amounts of storage and computing resources. Models should be general to various staining protocols and scanners and this is not always easy. Annotations of high quality are expensive and time consuming and need trained pathologists. Lastly, acceptance by regulatory bodies is another challenge since medical implementation must be strictly validated and adhered to medical regulations.

AI in Radiology:

- **Usual Processes:** AI in radiology is oriented toward better diagnostic accuracy, efficiency, and quantitative measurements. Applications are lesion and characterization, automated segmentation of tumors and organs, and quantitative imaging biomarkers (radiomics) to provide shape, texture, and intensity biomarkers. Assessment of responses can also be enhanced using AI to automate the RECIST result, create prognostic signatures to predict outcomes, and optimize the radiation dose to reduce patient exposure.
- **Types of models:** AI in radiology utilizes a variety of architectures. 2D and 3D CNNs are popular in image classification and segmentation. Encoder-decoder designs like U-Net do automate high quality segmentation. Multi-modal fusion brings together data of modalities such as PET and CT to enhance diagnosis. Vision transformers have recently been used on large scale imaging data sets, which offer strong feature extraction functionality.
- **Radiomics vs Deep Learning:** Radiomics entails mining engineered characteristics of images, including tumor shape, texture, and intensity, and such features can be read-out in clinical terms. Deep learning (as opposed to it) learns features hierarchically automatically but is not always interpretable. Integrating the two methods can help in balancing predictive power and explainability that can be used in clinics.
- **Clinical Workflow integration:** AI tools may be integrated in PACS (Picture Archiving and Communication Systems) as CAD-like assistants, triaging radiologists scans by highlighting high-risk images and workloading scans. The follow-up can be

monitored with automated measurements that will allow managing patients more efficiently. Multi-centric research and compliance with the DICOM standards guarantee the generalizability of AI tools between the population and imaging devices.

- **Interpretability and Uncertainty Estimation:** To be clinically adopted safely, AI should be interpretable and reliable. Such visual explanation methods as Grad-CAM, saliency maps, and attention heatmaps accentuate parts of images that contributed to model predictions, enhancing transparency. Bayesian networks, Monte Carlo dropout, or ensemble methods, called uncertainty estimation, give confidence intervals on the predictions of the use of Bayesian networks. The cases with lower confidence could be sent to human review, so the AI would assist instead of substitute the clinical judgment.

8.3. PRECISION TREATMENT PATHWAYS DRIVEN BY PREDICTIVE ALGORITHMS

Accuracy of therapy pathways can be seen as a paradigm shift in oncology, shifting away from the generalized treatment plans in the favor of the personalized data-based care. The pathways combine in-depth molecular-profiling of a patient with a tumor with clinical data including the stage of the disease, comorbid conditions and previous treatment outcomes. Using this detailed data, clinicians can determine treatments that are most likely to work with a particular patient, decide on the best order to use, and think about combination approaches that increase efficacy and minimize possible side effects. The given approach is necessary to make sure that the treatment decisions are not made on the basis of population averages only but depend on the individual biology and clinical circumstances of the patient.

In addition to the optimization of therapy, precision treatment pathways to patients refer them to suitable clinical trials and provide access to new therapies that are focused on their tumor features. These pathways promote the concept of shared decision-making, including patient preferences, values and quality-of-life issues in the care plan. Through a systematic integration of molecular understanding, clinical experiences, and patient-centered considerations, precision treatment pathways can maximize treatment results, reduce unnecessary treatments and develop a more effective, focused, and personalized approach to cancer management.



Figure 2: Precision Treatment Pathways

Source: (https://www.researchgate.net/figure/Precision-medicine-and-personalized-treatment-process-for-immunotherapies-The-diagram_fig5_383037818)

➢ **How Predictive Algorithms Support Precision Pathways**

As the most important role, predictive algorithms are designed and implemented to implement precision treatment pathways in oncology, which will allow providing more personalized care to patients more effectively and safely:

- **Biomarker discovery/prediction:** Machine learning, statistical models could be used to study large-scale genomic, transcriptomic, or proteomic data to predict biomarkers that predict therapeutic efficacy or resistance. Such predictive markers are used to assist clinicians in choosing the most appropriate treatments based on the molecular profile of the patient tumor, where the choice of therapies is evidence based and patient-specific.
- **Treatment response models:** Predictive algorithms can be used to estimate response to certain therapies by patients, including immunotherapy compared to conventional chemotherapy. Stratifying patients based on predicted response enables clinicians to

focus on the most likely-to-succeed treatments, reducing avoidable exposure to unhelpful lines of intervention, and maximizing overall results.

- **Toxicity models:** Algorithms are able to forecast the risk of severe adverse events in individual patients depending on molecular, clinical and demographic data. Such models facilitate safer therapy choice, which can prevent regimens that could impair patient safety or quality of life, and proactively manage possible toxicities.
- **Trial matching/prioritization:** AI systems can be able to match patients to ideal clinical trials by combining molecular profiles, disease stage, and eligibility criteria. This broadens exposure to experimental treatments, hastens enrollment of patients in trials and facilitates more effective assessment of innovative treatment.
- **Treatment sequencing and optimization:** Advanced predictive algorithms, reinforcement learning and causal inference models, can prescribe the ideal order of treatment. This involves choices on adjuvant or neoadjuvant therapy, choice of chemotherapy regimen, addition of targeted agents, or combination of all of these so as to maximize clinical benefit and reduce unnecessary interventions.
- **Besides that, predictive algorithms can also be used in drug repurposing:** With big datasets in biomedical science, new opportunities of available drugs can be identified, even if they have not been previously known to have a drug-tumor fit. This will aid in drug repurposing plans, which will provide economical alternatives and hasten the transfer of the existing treatments to serve certain patient groups.

Modeling Approaches:

Several computational strategies are employed to generate precision treatment pathways in oncology:

- **Multi-omics integration:** Integrating multiple layers of biological data—including genomic, transcriptomic, and proteomic information—enables a more comprehensive understanding of tumor biology. Strategies include early fusion, where features from different omics datasets are concatenated into a single input for modeling; late fusion, which combines outputs from separate models in an ensemble approach; and hybrid approaches that blend the two. Additionally, graph-based models can represent molecular pathways, interactions, and network effects, capturing the complex

relationships among genes, proteins, and signaling networks to inform therapy selection.

- **Causal inference:** To distinguish true treatment effects from spurious correlations, causal inference methods such as Average Treatment Effect (ATE) and Conditional Average Treatment Effect (CATE) are used. These approaches estimate the direct impact of a specific therapy on patient outcomes, accounting for confounding variables and heterogeneity in patient responses. By quantifying causal relationships, these methods strengthen the reliability of treatment recommendations derived from predictive models.
- **Counterfactual explanations:** Counterfactual reasoning techniques simulate how patient outcomes might differ under alternative treatment scenarios. By demonstrating "what-if" outcomes, these methods provide a transparent basis for shared decision-making between clinicians and patients, helping to explain why a particular therapy is recommended and what potential benefits or risks may arise under other treatment options.
- **Clinical Decision Support (CDS):** Predictive model outputs can be integrated into clinical decision support systems, often accompanied by evidence summaries, confidence scores, and visualizations of expected outcomes. These systems assist tumor boards and clinicians in making informed, evidence-based decisions while emphasizing that AI serves to augment not replace human judgment. By presenting actionable insights alongside uncertainty estimates, CDS tools enhance decision quality and facilitate personalized care.

Validation and Evidence:

To make precision treatment algorithms reliable for implementation in clinical practice, they have to be rigorously vetted so that their safety, effectiveness, and applicability can be ensured in a wide range of patient populations. Validation is usually initiated by retrospective analyses, in which we test the predictions made by an algorithm using available patient data to determine possible limitations. This will be complemented by a prospective observational research that assesses the efficiency of the algorithm in clinical practice, which will give information about the performance of the algorithm with respect to the current patient care. Finally, most validity should be provided by randomized trials or prospective real-world studies which check whether

the algorithm can lead to a significant increase in clinical results and represent strong and reproducible evidence of its value.

More importantly, validation is not just the ability to show predictive accuracy. An algorithm can be able to predict disease progression or respond well to treatment, but when used in clinical practice, is it likely to make tangible clinical improvements, such as longer survival or lower toxicity or higher quality of life? Making clinical utility will also make sure that the algorithm produces actionable insights that decision-making is informed and that the treatment selection is guided meaningfully. Through strictly validating precision treatment algorithms in a series of steps of algorithm evaluation, clinicians and researchers can be assured that in addition to predicting, these tools can make a positive contribution to patient care and thus close the gap between computational prediction of outcomes and clinical influence in practice.

Practical Barriers:

Although predictive algorithms promise utility in oncology, there are a number of obstacles that still restrict their application:

- **Heterogeneous data and silos:** Patient data is commonly spread across various systems, which include electronic health records (EHRs), laboratory information systems, imaging archives and genomic databases. This discontinuity introduces obstacles to complete data integration and it is challenging to provide predictive algorithms with the entire range of useful clinical, molecular, and imaging data required to support risk stratification or treatment recommendations with accuracy.
- **Interoperability concerns:** Although some standards like FHIR (Fast Healthcare Interoperability Resources) are aimed at supporting the sharing and exchange of healthcare information, their implementation is not uniform in institutions. The disparity in data format, software platform, and local usage practices may impede the effortless integration and lowers the effectiveness and dependability of AI-based predictive instruments.
- **Cost and access:** Not every healthcare facility has the capacity to conduct a complete molecular testing or offer access to specific therapeutics. Such constraints make precision medicine pathways more applicable in under-resourced environments and, when combined, may produce disparities in patient care by denying certain individuals access to high-quality predictive analytics.

- **Tumor evolution and sampling bias:** Biopsies are usually only a single snapshot of tumor at a given point in time. Tumors are however dynamic and may evolve to respond to treatment pressures, acquire resistance or display intratumoral heterogeneity. This renders continuous evaluation, recurring sampling and revision of forecasting treatment routes vital in safeguarding accuracy and performance in clinical determination.

8.4. ETHICAL ISSUES AND INTERPRETABILITY IN AI DECISION-MAKING

AI in oncology also poses a major ethical concern, which should be overcome to enable safe, fair, and reliable implementation. The main issues are bias and fairness because models trained on non-representative datasets can perform poorly on a particular group of patients, worsening the situation of healthcare disparities. Genomic and imaging data are sensitive and, as a result, face a problem of privacy and data protection as informed consent and safe processing should be enforced. The transparency and explainability are also needed because the black-box predictions may lead to mistrust in clinicians and patients. Liability and accountability are still ambiguous, and there is no clear responsibility among AI-based errors, and automation bias and de-skilling are the further threats. Another issue is the problem of access and equity in case only well-equipped centers can launch validated AI systems.



Figure 3: AI in Oncology

Source: (https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-025-02369-9)

These risks need to be mitigated with strong interpretability, governance and best practices. Optimistic interpretability and after-the-fact explanation techniques (e.g., LIME, SHAP, saliency maps) allow clinicians to interpret model choices, and model cards, datasheets, and uncertainty reporting enhance transparency and responsibility. Federated learning and differential privacy are privacy-preserving methods that secure patient information. It must be ethically deployed with standardized reporting structures (TRIPOD-AI, CONSORT-AI, SPIRIT-AI), external validation and human-in-the-loop processes to make sure AI remains an aid to clinicians instead of a replacement. Oncology Multidisciplinary team, ongoing auditing and documentation are also effective in ensuring dependable, equitable and clinically valuable AI adoption.

- ***Key Ethical Concerns***

Oncology AI systems raise some ethical concerns that will have to be eliminated to make sure their implementation is safe and fair. Discrimination and equality are major issues: models that were trained on non-representative data might not perform well on underrepresented groups, such as patients who are differentiated on the basis of sex, race, or socioeconomic status. These biases may have an adverse impact on care disparities and treatment outcomes in oncology.

Privacy and data security are also paramount, because the genomic and imaging data can be identified in itself. Patients should be assured of their consent in regards to reusing, secondary analysis, and sharing of their data, which needs to be approached carefully. Trust is impossible without transparency, explainability; clinicians and patients require reasons that are understandable to AI-driven recommendations since black-box results can make confidence in clinical decision-making less than certain.

Another problem is accountability and liability: in case an AI recommendation causes harm, it might be unclear who is to bear the liability: the software vendor or the hospital or the treating clinician. The legal aspects of AI-driven care are in the process of development. Other risks are automation bias and de-skilling since with time, too much use of AI might cause clinician complacency or loss of necessary skills. Lastly, there might be the problem of access and equity, since only well-funded centers might be able to implement validated AI systems, which could escalate the existing healthcare disparities.

- ***Interpretability Strategies***

AI models have to be explainable to reduce ethical risks. Intrinsic interpretability Intrinsic interpretability uses simpler, human-readable models like Generalized Additive Models

(GAMs) or decision trees where possible and enables clinicians to get a direct insight into the decision logic. Post-hoc explanation methods include LIME, SHAP, counterfactuals, and saliency maps which give information on how the model has made these specific predictions.

Model cards and datasheets are a standardized documentation, describing the intended use of a model, limitations, datasets and performance metrics in different patient subgroups. Moreover, uncertainty reporting is essential: AI predictions ought to come with a confidence or uncertainty score, and the low-confidence predictions ought to be forwarded to human inspection to avoid any possible errors.

- ***Governance and Reporting Standards***

Use of AI in the clinical practice must comply with strong governance and reporting practices. Clear reporting of model development and clinical AI trials is directed by the established frameworks, including TRIPOD-AI, CONSORT-AI, and SPIRIT-AI. It is suggested that continuous auditing and monitoring of production be implemented with periodic bias evaluations and governance by governance committees made up of clinicians, patients and ethicists.

Privacy-sensitive approaches, like federated learning, differential privacy and secure multi-party computation, can enable AI models to be trained on distributed data, without revealing raw patient information, thus preserving privacy. Informed consent and patient communication are also essential: patients are to know each time AI tells their care and to know how much AI affects their decision-making.

- ***Practical Best Practices***

To ensure ethical and reliable deployment of AI, several actionable best practices should be followed. AI models should be trained on diverse, well-documented datasets, with subgroup performance reported to detect disparities. External and prospective validation is essential before clinical deployment. AI should function within human-in-the-loop workflows, augmenting but not replacing clinician decisions. Transparent documentation, including model cards and dataset provenance, supports accountability and reproducibility. Uncertainty thresholds and fail-safe rules ensure that ambiguous cases are automatically routed to human review. Finally, AI development and deployment should involve multidisciplinary teams combining expertise from data science, clinical medicine, ethics, and law.

- **Short Takeaway Bullets**
  - **AI is good at recognizing patterns in pictures and multimodal data:** Artificial intelligence, especially deep learning algorithms, has demonstrated impressive capacity to identify complex patterns in medical images, genomic data, electronic health records among other complex multimodal data. These systems are however dependent on massive, heterogeneous and well-labeled datasets to be highly accurate and generalizable. In the absence of adequate data quality and diversity, artificial intelligence models may be subject to bias or low-performance in clinical environments.
  - **Clinical utility requires external prospective validation:** To make AI tools have significant influence in healthcare, their performance has to be shown to be valid beyond the original training data. External and prospective validation guarantees that AI forecasts are strong when using them with varied patient groups and clinical environments. Also, it is necessary to show that patient outcomes and diagnostic accuracy or net clinical benefit can be measured, and that improvements are being made.
  - **Interpretability, quantification of uncertainty, and ethical governance:** To deploy AI safely in the health sector, transparency should be created in decision-making processes by the algorithms. Interpretability enables clinicians to interpret and be confident to AI recommendation, whereas uncertainty quantification assists in estimating confidence in predictions. Furthermore, it is essential to have ethical oversight such as fairness, accountability, and privacy concerns to avoid hurt, prejudice, and unfair treatment of patients.
  - **Human-AI partnership as the realistic course to clinical implementation:** AI is best adopted by complementing, not substituting clinicians. AI can improve clinical judgment and efficiency by aiding the decision-making process, identifying pertinent patterns, and simplifying the working process. It is a collaborative model that makes the best of human experience and computational intelligence to achieve more safer, more productive and clinically actionable results.

REFERENCES

1. Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020). Artificial intelligence (AI) and big data in cancer and precision oncology. *Computational and structural biotechnology journal*, *18*, 2300-2311.
2. Wu, X., Li, W., & Tu, H. (2024). Big data and artificial intelligence in cancer research. *Trends in cancer*, *10*(2), 147-160.
3. Charalambous, A., & Dodlek, N. (2023, June). Big data, machine learning, and artificial intelligence to advance cancer care: opportunities and challenges. In *Seminars in oncology nursing* (Vol. 39, No. 3, p. 151429). WB Saunders.
4. Zhu, S., Ma, S. J., Farag, A., Huerta, T., Gamez, M. E., & Blakaj, D. M. (2025). Artificial intelligence, machine learning and big data in radiation oncology. *Hematology/Oncology Clinics*, *39*(2), 453-469.
5. Shimizu, H., & Nakayama, K. I. (2020). Artificial intelligence in oncology. *Cancer science*, *111*(5), 1452-1460.
6. Kann, B. H., Hosny, A., & Aerts, H. J. (2021). Artificial intelligence for clinical oncology. Cancer Cell, 39(7), 916-927.
7. Kann, B. H., Thompson, R., Thomas Jr, C. R., Dicker, A., & Aneja, S. (2019). Artificial intelligence in oncology: current applications and future directions. Oncology, 33(2), 46-53.
8. Luchini, C., Pea, A., & Scarpa, A. (2022). Artificial intelligence in oncology: current applications and future perspectives. British Journal of Cancer, 126(1), 4-9.
9. Hamamoto, R., Suvarna, K., Yamada, M., Kobayashi, K., Shinkai, N., Miyake, M., ... & Kaneko, S. (2020). Application of artificial intelligence technology in oncology: Towards the establishment of precision medicine. Cancers, 12(12), 3532.
10. Azuaje, F. (2019). Artificial intelligence for precision oncology: beyond patient stratification. NPJ precision oncology, 3(1), 6.
11. Huynh, E., Hosny, A., Guthier, C., Bitterman, D. S., Petit, S. F., Haas-Kogan, D. A., ... & Mak, R. H. (2020). Artificial intelligence in radiation oncology. Nature Reviews Clinical Oncology, 17(12), 771-781.
12. Thompson, R. F., Valdes, G., Fuller, C. D., Carpenter, C. M., Morin, O., Aneja, S., ... & Thomas Jr, C. R. (2018). Artificial intelligence in radiation oncology: a specialty-wide disruptive transformation?. Radiotherapy and Oncology, 129(3), 421-426.

13. Lipkova, J., Chen, R. J., Chen, B., Lu, M. Y., Barbieri, M., Shao, D., ... & Mahmood, F. (2022). Artificial intelligence for multimodal data integration in oncology. Cancer cell, 40(10), 1095-1110.
14. Iqbal, M. J., Javed, Z., Sadia, H., Qureshi, I. A., Irshad, A., Ahmed, R., ... & Sharifi-Rad, J. (2021). Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. *Cancer cell international*, *21*(1), 270.
15. Elemento, O., Leslie, C., Lundin, J., & Tourassi, G. (2021). Artificial intelligence in cancer research, diagnosis and therapy. *Nature Reviews Cancer*, *21*(12), 747-752.

Chapter 9…

PATIENT STRATIFICATION AND ADAPTIVE CLINICAL TRIALS

MONIKA KASHYAP
Assistant Professor
Institute of Pharmaceutical Sciences, IET Bhaddal
Pin - 140108
Email: mk32ei@gmail.com

Dr. B SABANA
Assistant Professor,
Department of Biochemistry and Bioinformatics,
Dr. MGR Janaki College for Women, Adyar

Mr. GADGE SHUBHAM CHANDRAKANT
Assistant Professor
Department of Pharmacology
Samarth Institute of Pharmacy, Belhe
On Nagar kalyan Highway At-Bangarwadi Post-Belhe, 412410
Email: shubhamgadge2208@gmail.com

Dr. P. SHOBANA
Assistant Professor
Sri Shanmugha college of Pharmacy, Sankari
Email: shobanaragavan949@gmail.com

Mr. JYOTIPRAKASH BHANJA
Assistant Professor
Department of Pharmacology
Akash Institute of Pharmaceutical Education and Technology
Mahipal, Kendrapara, Odisha, India. 754211
Email: jyotiprbhanja@gmail.com

Conventional clinical trials in oncology often adhere to a fixed design, such that patients are randomized to pre-specified treatment arms, efficacy or safety are only evaluated at the study conclusion. Although this has been a classical method in the development of drugs, it has its significant shortcomings. Cancer is a disease that is heterogeneous in nature and even within the same histology there is a wide range of molecular, genomic, epigenetic and immunological characteristics of the tumors. Therefore, those treatments which are found to be effective in one subgroup might prove ineffective, or possibly harmful, in another, causing trial inefficiencies, long timeline, and exposing patients to ineffective therapies. The difficulties related to these challenges underscore the importance of more flexible and patient/tumor-specific trial designs capable of considering patient and tumor heterogeneity.



Figure 1: Patient Stratification Using Genetic and Genomic Biomarkers

Source: (https://www.researchgate.net/figure/Patient-stratification-using-genetic-and-genomic-biomarkers-Top-panel-shows-the_fig1_270289152)

Patient stratification is a solution to this problem by splitting patients into subgroups according to molecular or clinical attributes of predicting treatment response. Stratification based on biomarkers enables the researcher to determine groups of populations that are most likely to respond to certain interventions to increase the statistical strength and clinical utility of trials. To illustrate, treating patients containing a genetic mutation, e.g. EGFR mutations in lung cancer or BRCA mutations in breast and ovarian cancer, with targeted therapies enhances

therapeutic effect and reduces non-response by unnecessary toxicity. Adding real-world evidence, such as data on electronic health records and registries, and past clinical trials, further streamlines stratification plans, offering information on variability in the response to treatment in larger groups of patients.

Adaptive clinical trial designs are used to complement stratification, and they permit dynamic changes in the study without affecting statistical rigor. Contrary to conventional fixed trials, adaptive trials are allowed to change things, e.g., sample size, treatment arms, or patient allocation, based on interim analyses. These real-time decisions are usually carried out using Bayesian and frequentism statistical models so that they can treat people ethically and make proper use of available resources. An example is that the expansion of promising treatment arms can be increased to recruit more patients, and ineffective arms can be minimized to reduced exposure to non-optimal treatment. Adaptive designs in oncology include seamless Phase II/III trials, umbrella trials that aim to test a single therapy across multiple molecular subtypes within a single tumor type as well as basket trials that test a single therapy in multiple cancers sharing the same mutation.

Combination of patient stratification and adaptive trial design is a paradigm shift in clinical oncology. These methods enhance the speed of clinical assessment of new therapies, maximize patient benefit, and personalized medicine by integrating molecular profiling, real-world data, and flexible trial structures. Also, they are more conducive to quicker regulatory decisions since adaptive trials are capable of producing strong evidence more effectively. All in all, the future of precision oncology and innovative trial methodology converging can allow revolutionizing the drug development of cancer not only in terms of efficiency of trials but also in terms of patient outcomes and reduced unnecessary exposure to ineffective treatment.

9.1. BASKET, UMBRELLA, AND PLATFORM TRIAL DESIGNS

Adaptive clinical trial designs have transformed the oncology research by matching therapies in patients based on their molecular and genetic features and the goal of optimizing their efficacy and efficiency. One of these methods includes basket trials, which have become an effective method to test one therapy in a variety of cancer types that have a common molecular change, like the BRAF V600E mutation. Rather than assessing the impact of therapy on the tissue of origin, basket trials assess the impact of therapy on mutation-driven processes, which allows drug development to be faster and studies rare mutations that otherwise would not have

ample patients to examine. This design is especially beneficial in pooling patients with different tumor types, which will allow recruiting them faster and generating more evidence. Nevertheless, there are still obstacles, especially in dealing with the heterogeneity of tumor microenvironments across tissues and intricacies of carrying out powerful statistical analyses in small and heterogeneous subpopulations. Such constraints suggest the fragility of the trade-offs between innovation and methodological rigor in basket trials.

Umbrella trials, by contrast, target one type of cancer but divide patients into subgroups according to particular molecular subtypes, giving targeted therapies to the subgroups. The design enables researchers to compare several treatment options in a single tumor type, which will promote precision medicine in a disease-specific environment. Indicatively, among a single cancer like non-small cell lung cancer, the patients can be assigned to various therapeutic arms based on their biomarker status. Umbrella trials therefore offer a feasible platform to also investigate the relative efficacy of various targeted therapies within a unified study setting. Nevertheless, they are not devoid of them: the demand to have molecular diagnostics of high accuracy can be resource-intensive, and subgroups can be small in question, lowering statistical power and making the results interpretation harder. Regardless of these limitations, umbrella trials are an effective and patient-centric methodology, which allows optimizing the choice of therapies and enhancing clinical outcomes in a single cancer population.

Platform trials take the concept of adaptive trial to an even greater extent by using ongoing master protocols, which provide room to keep on changing trial arms in response to interim results. In contrast to traditional, non-perpetual, trials, platform trials are constructed to be continuous, where the non-effective treatments can be removed and new investigational therapies are added without distracting the trial structure. One of the most striking examples is the I-SPY 2 trial of breast cancer, whereby unproductive treatment arms are quickly abandoned and promising treatments are added in real-time, thus saving time and money and accelerating the identification of effective treatments. This very versatile model enables real life learning and adaptive decision-making and is therefore one of the most effective tools to use in the current oncology research. Nevertheless, the logistics of platform trials are large: they require complex statistical modeling, powerful trial management systems, and effective regulatory controls to guarantee validity and interpretability of outcomes. The practical and logistical issues highlight the importance of immense infrastructure, partnership, but when done properly, platform trials are a groundbreaking strategy of speeding up the development of cancer therapy.

1. Basket Trials

- **Idea:** Basket trials the concept of basket trials is designed to test one therapeutic agent in a group of tumor types with a common molecular alteration, e.g. a particular genetic mutation. In contrast to classical trials involving the grouping of patients by the tissue that the tumor originates, basket trials are based on the common molecular target to all cancers and investigates whether the drug can generate an effect regardless of the anatomical origin of the tumor. This strategy relies on the concept of precision oncology in which molecular features, instead of histology are used to select therapy.
- **Bonus:** The ultimate aim of basket trials is to determine which tumors are sensitive to a directed treatment irrespective of their tissue of origin. Through this, researchers will be able to decide on whether a molecularly focused agent could be efficient on different types of cancer, indicating wider clinical signs of rare mutations.
- **Example:** A typical example is a drug targeting the BRAF V600E mutation that can be used along with melanoma, colorectal cancer, and non-small cell lung cancer. This design will give the trial the opportunity to assess whether the presence of the mutation is correlated with therapeutic response in these different tumor types, to emphasize the mutation-driven and not tissue-driven treatment model.
- **Benefits:** Basket trials are especially effective when it comes to researching rare mutations that take place in various types of cancers, and in these cases, it is possible to pool patients with diverse cancers. This design saves on time; patient numbers and resources as opposed to the use of independent clinical trials per type of cancer.
- **Challenges:** The tumor microenvironment may impact a drug's efficacy, and these differences may occur in different tissues, resulting in different responses. In addition, statistical interpretation can be complicated because treatment effects can vary depending on the tumor subgroups and thus close subgroup analyses and strict interpretation of results are necessary.

2. Umbrella Trials

- **Concept:** The principle of umbrella trials is meant to test a number of targeted therapies in a single tumor type. Patients are divided into molecular subtypes of the disease; a therapy is given to each subgroup which is expected to be effective on the basis of the molecular profile of their tumor. The method will enable the concurrent testing of multiple therapies and still focus on a single type of cancer.

- **Goal:** The overall objective is to pair every patient with a therapy that is likely to be effective against his or her particular molecular subtype, allowing a very specific treatment approach even within an individual disease. Umbrella trials will improve precision oncology across a single cancer type by linking treatment with molecular properties of that cancer type.
- **Examples:** In lung cancer, the EGFR, ALK, KRAS and ROS1 can be stratified with each subgroup undergoing a specific targeted therapy based on their molecular alteration. This allows the trial to be a test of several therapies at the same time under a single umbrella protocol, simplifying the assessment and resource consumption.
- **Benefits:** Umbrella trials allow personalized medicine in one tumor type and allow the efficient utilization of patient cohorts and trial infrastructure, as more than one treatment regimen can be evaluated in parallel instead of in series.
- **Challenges:** The only way to do umbrella trials is to have a very powerful molecular diagnostics in order to categorize the patients properly under the corresponding subgroups. Moreover, certain subgroups might be of small size and this can reduce statistical power and reduce the ability to detect high treatment effects.

3. Platform Trials

- **Concept:** Platform trials are based on master protocols that permit treatment arms to be added or taken away as interim analyses occur. In such adaptive trials, several therapies or combinations are continuously tested in the course of time without the necessity to start a trial with each new intervention.
- **Goal:** The goal is to maximise flexibility and efficiency, such that multiple therapies can be assessed in real time and promising new treatments can be incorporated and unsuccessful ones discontinued fast. Platform trials especially are best adapted to assessing changing treatment opportunities and to expedite therapeutic discovery.
- **Example: I**-SPY 2 trial in breast cancer is a famous platform trial which presents several investigational drugs in parallel. Ineffective treatment arms are not retained long enough and new agents can be initiated without initiating a new protocol, resulting in faster identification of effective therapies.
- **Strengths:** Platform trials save money and time of trial because they use one master protocol. They enable real time learning by continuous data and permit quick

incorporation of novel medicines, enhancing proficiency in clinical advancement and permitting adaptive judgment depending on early outcomes.

- **Challenges:** Platform trials require intricate study design, advanced statistical modelling, and legal control. These trials demand sophisticated infrastructure and trial management systems to manage dynamic changes in arms of treatment, interim analysis and adaptive rules, and therefore are operationally more difficult than traditional trials.

9.2. STRATIFYING PATIENTS BASED ON MOLECULAR ALTERATIONS

The key concept of precision oncology is patient stratification according to the molecular features of the specific tumor, and the treatment can be adapted to each individual biological profile. Although tumors might look like each other when viewed under a microscope, they may contain different genetic, transcriptomic, or proteomic differences, which determine how they respond to treatment. Molecular profiling Molecular profiling (i.e. genomic sequencing, RNA expression analysis, proteomics etc.) enables clinicians to determine predictive biomarkers, identifying those patients with the highest likelihood of response to treatment. This strategy guarantees that the treatment is guided, directed to responsive patients and other patients are spared unnecessary treatment which may be ineffective or even harmful and finally lead to better outcomes and avoid toxicity which is not necessary.

In addition to personalized therapy of the patient, molecular stratification is also important in the design of clinical trials. The trials could now be more accurately able to assess the investigational therapy efficacy by grouping patients based on biologically relevant characteristics, in well defined subpopulations. This focused structure will maximize the chances of observing significant therapeutic effects and resource use, and hasten the creation of novel treatment. Moreover, stratification can be used to identify knowledge about tumor biology, drug resistance mechanism, and possible combination approaches, which can ultimately bring the field of oncology closer to personalized and effective care.

➢ Common Stratification Approaches

- **Genomic Alterations:** The DNA level alteration which influences tumor behavior can be used to stratify patients. Drug sensitivity or resistance can depend on somatic mutations in important oncogenes or tumor suppressor genes (including KRAS, BRAF, or TP53). Variations in copy number can help to understand the dose effect of genes that could influence the response to the treatment, and gene fusions such as ALK and

NTRK rearrangements tend to become actionable targets that can be targeted with a given inhibitor. These genomics attributes have effectively acted as directing agents in therapy selection and enrolment in clinical trials.

- **Transcriptomic and Proteomic Signatures:** It is also possible to stratify using transcriptomic and Proteomic Signatures which reflect functional tumor behavior at levels beyond those of DNA sequence alone. An example is the expression signature of the PAM50 gene in breast cancer that is used to categorize tumors into intrinsic subtypes that have different prognoses and different sensitivities to therapy. Likewise, protein abundance and activation states, measured by proteomic analysis, such as phosphoproteomics, give information about signaling pathways, which can be used to guide selection of targeted therapies.
- **Epigenetic Markers:** Molecular stratification may also be enriched with epigenetic features, including the patterns of DNA methylation, which have proven to predict the response to some therapies. The markers are used to give further layers of information, which is complementary to the genomic and transcriptomic data, and enable clinicians to target treatment solutions to achieve improved patient-specific outcomes.
- **Immunological Profiles:** In immunotherapy-based therapies, immunotherapy is often stratified based on the following markers: tumor mutational burden (TMB), microsatellite instability (MSI) and the level of PD-L1 expression. Such immunological characteristics aid the detection of patients who are likely to respond to checkpoint inhibitors or other immunomodulators to initiate a targeted distribution of immunotherapy and greater clinical effects.

➢ **Workflow for Stratification**

Molecular stratification uses a workflow of steps to achieve appropriate and practical classification of patients:

1. **Collection of the sample:** Patient samples may be obtained by a standard tissue biopsy or by such a non-invasive approach as a circulating tumor DNA (ctDNA). Liquid biopsies have the benefit of longitudinal monitoring of tumor evolution, identifying new mutations, and characterizing tumor heterogeneity that can arise during therapy, with the benefit of repeated sampling over time.

2. **High-Throughput Profiling:** The samples are high-throughput profiled using molecular profiling methods after they have been obtained. They are next-generation

sequencing (NGS) DNA analysis, RNA sequencing (RNA-seq) to understand gene expression pattern, and proteomic studies to assess protein-level changes. Combined, these methods produce extensive molecular data sets, which allow in-depth insights into the biological landscape of the tumor.

3. **Bioinformatics Analysis:** The molecular datasets undergo a high-level set of computation pipelines. Bioinformatics tools are used to identify mutations that can be acted upon, describe the expression characteristics, and identify patient subgroups or clusters which may respond variably to treatment. This analysis transforms raw molecular data into clinically useful information, to support informed decision-making in order to adopt personalized treatment plans.

4. **Treatment Assignment:** The individual patients are matched to a particular treatment arm or targeted therapy through the molecular analysis that most effectively matches with the biological features of the tumor. This will allow customizing the selection of therapy and, to the greatest extent, increase the chances of a clinical effect and reduce the exposure to non-effective treatments in accordance with the principles of precision medicine.

➢ **Challenges**

Although promising, molecular stratification has a number of serious issues:

- **Tumor Evolution and Heterogeneity:** Tumor is not intended to be a fixed set of mutations; it is a dynamic entity that continually changes. It is possible that mutational profiles can change with time, as a consequence of intrinsic tumor evolution, or by the selective forces of therapy. Such alterations can undermine molecular stratification accuracy because a patient can no longer have a tumor that matches the profile that was initially applied in the treatment decisions, which may impact the efficacy and clinical outcome of the treatment.

- **Technical Limitations:** Technical performance of the assays used is very crucial to the efficacy of molecular stratification. The sensitivity of detection methods, sequences coverage, and depths can also be a limitation to identify low-frequency mutations or infrequent molecular events. Such technical limitations can affect appropriate patient referral to specific treatments and the success of precision oncology treatments in general.

- **Publications:** The Advanced molecular testing is not universally available, and its application in precision oncology also raises some ethical issues that pertain to fairness, equity, and inclusivity. The differences in access may deny some groups access to personalized treatment strategies. Fair access to molecular diagnostics is one significant challenge to harnessing precision oncology out of the research context and into the general clinical practice.

9.3. REAL-WORLD EVIDENCE AND DATA-DRIVEN TRIAL DESIGN

Real-world evidence (RWE) refers to clinical information gathered in the real-world, beyond the confines of the formalized procedures of randomized clinical trials (RCTs). In contrast to RCT that is meant to test efficacy and safety in highly controlled settings, RWE reflects the experience of patients in regular medical care, including those with comorbidities, different levels of adherence, or different demographic/socioeconomic characteristics. This renders RWE especially useful in the context of information about treatment performance across larger, more general heterogeneous populations, which counteracts the generalizability shortcomings that tend to be present in traditional clinical trials. RWE offers a reflection on the complexity of care in the real-life setting, giving insights into the treatment effectiveness, safety, and patient outcomes in situations that cannot be adequately reproduced in the RCT.



Figure 2: Sources of Real-World Data (RWD)

Source: (https://toolbox.eupati.eu/resources/patient-toolbox/real-world-data-rwd-real-world-evidence-rwe/)

RWE is obtained in various sources, such as electronic health records, insurance claims, patient registries, mobile health applications, and even wearable devices. These data enable the researcher and clinician to measure long-term outcomes, observe rare adverse events, and also measure the interventions in various healthcare contexts. Combined with RCT-based evidence, RWE can reinforce clinical judgment by providing additional supportive evidence to guide guideline development, policy-making, and personal patient care. Moreover, regulatory authorities are progressively appreciating the importance of RWE in not only justifying drug approvals, post-marketing surveillance, and health technology evaluations, but also playing an ever-increasing role in filling the gap between the controlled trial data and actual clinical practice.

Sources of RWE include:

- **Electronic Health Records (EHRs):** EHRs are a rich source of both structured and unstructured clinical information, such as diagnostic notes, imaging reports, prescriptions, laboratory results and longitudinal treatment histories. These datasets provide detailed information on the efficacy of therapies in the non-trial environments.
- **Registries and observational cohorts:** Disease-based registries and observational cohort studies follow patient outcomes in the long term. These sources are useful to learn the long term trends in the survival, trends in resistance to treatment, and differences in practice within institutions.
- **Claims/billing data:** Insurance claims are used to record the healthcare usage, treatment expenses, and hospital admissions. They are not clinically described in greater detail but are critical to large-scale epidemiological evaluation, economic evaluation, and health outcomes research.
- **Wearables and patient-report outcomes (PROS):** Digital healthcare tools including wearable devices, mobile applications and self-report platforms provide real-time and continuous data on lifestyle, quality of life, symptom burden and treatment side effects. Such contributions give a patient-focused view that is usually absent in standard clinical trials.

Uses in Trial Design

- **The use of Real-World Evidence (RWE) in Clinical Trials:** Evidence Real-world evidence is now a cornerstone in contemporary clinical trial designs, supplementing the

previous conventional randomized controlled trials (RCTs) and broadening the evidence-generating potential. RWE enhances hypothesis generation, trial performance, and post-approval observations through the use of data available electronically, via health records (EHRs), registries, claims databases, and other real-world data.

- **Hypothesis generation:** With RWE, researchers are able to search enormous, heterogeneous data in order to discover new patterns and derive new hypotheses to study clinical research. Indicatively, the retrospective EHR analyses might point to the fact that patients with a particular genetic mutation or demographic profile or a comorbidity do not react to a particular therapy. These observations are priceless in designing the targeted and precision-focused clinical trials that are more closely consistent with real-world treatment responses.
- **Patient selection and enrichment:** Trial populations can be selected and stratified on the basis of RWE to enrich and select individuals with the highest probability of responding to investigational therapies. An example is that biomarker-positive patients that may have a favorable response to a treatment can be identified in the registries and genomic databases, which can increase the efficiency of the trial, increase the statistical power and shorten the total sample size needs.
- **Historical controls:** In an environment like rare cancers or small groups of patients, it is not always feasible to recruit large and balanced control groups. RWE is a useful alternative as it will provide external control groups based on the historical patient outcome data. This method eliminates the participant overload, eliminates any ethical issue of withholding treatment, and is scientifically valid in the case of limited randomization.
- **Post-marketing surveillance:** After approval, RWE is important in the real-world application of the therapies during the long-term. It promotes the identification of uncommon or untimely adversarial incidents, measures ongoing effectiveness, and evaluates safety in larger and more heterogeneous groups of patients who might not have been reflected in pivotal research. This continuous generation of evidence facilitates regulatory decision-making and is informative of clinical practice guidelines.

Adaptive, Data-Driven Design

The real-world evidence (RWE) is progressively integrated into the modern clinical trial design together with adaptive methodology, providing flexible, responsive designs that are updated in accordance with the accruing data. The above paradigm shift increases the efficiency of trials, boosts ethics by ensuring fewer patients are exposed to ineffective therapies and boosts external validity by ensuring results are more representative of clinical practice in the real world. The essence of this strategy is.

- **Interim analyses:** Dynamic changes can be made without affecting scientific validity and regulatory compliance by pre-specified analysis at designated times in a trial. These analyses are necessary in making informed decisions and can include various forms of adjustments, which include:
    - **Dropping ineffective treatment arms:** Removing arms that exhibit low-efficacy to preserve patients against unreasonable risk and rationalize the resources of trials.
    - **Growing enrollment in promising subgroups:** Recruiting more patients into select groups that already indicate high response rates, thus hastening the production of evidence in select groups.
    - **Secondary Endpoint Adjustments:** Adjusting dose, schedule or primary/secondary endpoint in response to emerging clinical information in order to maximize therapeutic effects and match patient requirements.
- **Statistical and computational approaches:** The combination of developed statistical models and computing software has changed adaptive trial design into more powerful and predictive.
    - **Bayesian statistics:** Offer a very versatile model of continuous evidence updating, in which prior information is combined with data obtained recently. The methodology permits updating of decisions in real time during trial, not until full data lock, and keeps error rates under control.
    - **Machine learning models:** Machine learning methods can predict patient outcomes, optimize the utilization of participants in trial arms, and make adaptive changes in real-time, because they can handle high-dimensional and heterogeneous data-types, including imaging, genomic profiles, and electronic health records. These models increase the accuracy of clinical trials and allow conducting a more individual approach to the assessment of therapies.

- **Advantages of RWE-Driven Designs**
  - **Quicker drug assessment:** Placing clinical trials in a standard healthcare environment and utilizing the existing real-world data can help make drug assessment much quicker. This is because the method can lead to results much faster than conventional randomized controlled trials (RCTs), and thus promising therapies can reach patients within a shorter period and still be scientifically rigorous.
  - **Less patient exposure to ineffective treatments:** Adaptive trial designs enable an early identification and discontinuation of trial arms that are not demonstrating therapeutic value. It decreases patient exposure to non-effective or potentially detrimental treatment and improves patient safety and makes sure that resources are directed towards interventions with the best chance of success.
  - **Combination of heterogeneous data:** Trials that use real-world evidence (RWE) combine various data streams, such as electronic health records (EHRs), molecular and genomic data, imaging findings, and patient-reported outcomes. This holistic method offers a more holistic, patient-centered view of treatment performance in various patient groups that allow subtle information on effectiveness, safety, and treatment response variability.
  - **Improved generalizability:** Since RWE is developed by using the diversity in the real-world patient populations such as older adults, patients with multiple comorbidities, and generally underrepresented in traditional RCTs, the results of RWE-based trials are more generally applicable. This increases external validity of the findings and makes the conclusions applicable to the entire range of patients who ultimately will be subjects of the therapy.

9.4. REGULATORY CHALLENGES AND EVOLVING GUIDELINES

Basket, umbrella, and platform trials (adaptive and innovative trial designs) are novel concepts that provide more flexibility than ever before in oncology research and permit changes in treatment arms, dosages, and endpoints in response to interim results. Although these designs enhance efficiency and patient-centricity, they come with immense challenges, such as statistical complexity, operational issues, and ethical issues. Close supervision is necessary to maintain adequate control groups, to guarantee fairness in the allocation of patients and to address dynamic changes without undermining the validity of the trials. Moreover, the

algorithmic combination of various datasets, such as genomics, imaging, electronic health records, and real-world evidence poses the risk of standardization, reproducibility, and data quality that is critical to the attainment of credible results and regulatory compliance. The classic regulatory opportunities, which assume the use of fixed two-arm randomized trials, may not be able to fit such adaptive structures, requiring updated approval mechanisms and close attention to ethics.

The FDA and EMA regulatory agencies have acted with changing guidance to enable adaptive and real-world evidence-based trials. FDA promotes pre-specified adaptation regulations, Bayesian statistics to interpret an interim examination, and incorporation of real-world data, especially when rare cancer or post-marketing research is required. On the same note, the EMA encourages patient selection based on biomarkers, heterogeneous population master protocols and the adoption of surrogate endpoints in the absence of overall survival data. Regulatory compliance best practices focus on pre-specification of rules of adaptation, statistical rigor, transparent documentation and high-quality standards in all data sources. Interaction with regulators early is essential to align the objectives of the trials with approval expectations to lessen the uncertainty and increase the chance that adaptive trials can deliver credible actionable findings and protect patient safety and ethical considerations.

- **Key Challenges**
  - **Complexity of trial design:** Adaptive, basket, umbrella, and platform trials allow dynamic changes—such as adding or removing treatment arms, adjusting dosages, or redefining endpoints—based on interim results. While these designs increase efficiency, they introduce statistical and operational complexities. Regulatory bodies must ensure that frequent modifications do not compromise trial validity or introduce hidden biases. Establishing proper control groups and ensuring comparability across changing trial arms is particularly difficult.
  - **Data quality and reproducibility:** Integration of diverse datasets—including multi-center imaging, genomics, electronic health records, and real-world evidence (RWE)—poses challenges for standardization, reproducibility, and data harmonization. Regulators require data to be traceable, consistent, and validated. Incomplete or poorly curated datasets may undermine the reliability of results, making regulatory approval difficult.

- **Approval pathways:** Traditional regulatory frameworks, developed for classical two-arm randomized controlled trials, do not always align with adaptive trial structures. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have historically relied on fixed designs with predefined endpoints. Adaptive designs—by contrast—require continuous evaluation and updated decision-making, necessitating revised approval pathways and more flexible regulatory approaches.
- **Ethical oversight:** Dynamic allocation of patients to trial arms, dropping of ineffective treatments, or introduction of new therapies during the trial can create ethical concerns. Institutional Review Boards (IRBs) must ensure that patients are fully informed about potential changes and that informed consent documents are updated accordingly. Maintaining fairness in patient allocation while balancing scientific efficiency with patient protection is an ongoing challenge.

➢ **Evolving Guidelines**

FDA guidance (2019, 2020): In recent years, the FDA has issued more updated guidance documents to help meet the increasing complexities of adaptive trial approaches and the introduction of real-world evidence (RWE) into the regulatory process. These updates underscore how the agency strives to create innovation without sacrificing the scientific rigor and patient safety. The key points include:

- **Underpinning the adaptive trial designs:** The FDA acknowledges the value of flexibility in clinical trials and promotes adaptive designs where easily pre-specified adaptation rules are involved. These rules offer transparency, reduce bias and make sure that changes in the parameters of the trials, including sample size, treatment arms or endpoints, are guided by objective criteria instead of subjective decision-making.
- **The utilization of RWE:** To supplement the traditional randomized controlled trials (RCTs), the FDA has focused on the utilization of real-world evidence in regulatory submissions, especially in the spheres where RCTs are not possible to conduct. This is particularly applicable to rare cancers where a small number of patients will not allow the conduct of large-scale trials and post-marketing trials to monitor long-term safety and effectiveness.
- **Permitting Bayesian statistical approaches:** Bayesian statistical approaches in interim analyses are also promoted by the FDA guidance. The techniques aid in ongoing learning because they update probabilities when new information is received.

Simultaneously, they assist in the correct regulation of the number of errors, and thus better-informed decisions concerning the development of the trial, its amendments, or early termination in case of need.

EMA guidelines: The European Medicines Agency (EMA) has presented guidelines in support of more adaptive and dynamic regulatory frameworks, especially where the field of oncology research is in a complex and fast changing scenario. The recommendations are intended to strike a balance between scientific rigor and the necessity to be efficient in meeting urgent medical demands, in particular in rare cancers and heterogeneous patient groups. The key points include:

- **Master protocols:** The EMA encourages use of master protocol trial designs e.g. basket trials, umbrella trials, and platform trials to facilitate drug development. These techniques enable the study of several therapies or disease subtypes at the same time within one and broad umbrella and result in less and more efficient redundancy, time, and efficiencies in the analysis of therapies against rare cancers and diverse populations.
- **The focus on biomarker-driven patient selection:** The EMA lays a lot of emphasis on the use of biomarkers to direct patient selection taking into consideration the importance of precision medicine. Biomarker-based trials increase the likelihood of proving efficacy, minimize trials efficiency, and decrease non-responders' needless exposure to trial therapies by enriching the trials with individuals most likely to respond to a specific therapy.
- **Acceptance of surrogate endpoints and real-world outcomes:** To ideate access to potentially life-saving therapies, the EMA permits the use of surrogate endpoints, e.g., progression-free survival or objective response rates, to be used as appropriate measures in cases where overall survival data are not yet mature. Besides that, the agency recognizes the emerging significance of real-world outcomes, which are important to gain profound understanding of the effectiveness of treatment, quality of life among patients and their long-term safety in clinical practice settings.

➢ **Best Practices for Regulatory Compliance**

Researchers have an opportunity to adhere to the best practices to successfully navigate regulatory processes in adaptive and RWE-driven trials:

- **Pre-specify adaptation rules:** It is necessary to state clearly in the trial protocol the particular rules and criteria that may be used in any case of adaptation. This involves

the description of situations when trial arms can be dropped, added or changed. These rules can be set beforehand, thereby reducing the possibility of bias and making decisions transparent in a trial that preserves the integrity of study results.

- **Ensure statistical rigor:** Statistical rigor is important in adaptive trials, especially due to the fact that repeated adaptations may promote type I errors (false positives). With proper planning and application of the relevant statistical techniques, the validity of the findings can be maintained so that the results can be interpreted and reliable even when interim changes are made or complex trial designs are used.
- **Clear documentation:** This is essential in the adaptive trial process as it is well documented and transparent. These involve recording of the interim results, decision making procedure and reasons as to why there might be any modification made during the trial. Detailed documentation does not only justify regulatory review, but also exhibits accountability to institutional review boards (IRBs) and other control agencies.
- **Quality control:** High-quality data is the basis of all conclusions of trials. Strict validation processes are to be implemented in molecular assays, biomarkers, imaging modalities, and real-world evidence (RWE) sources. Making sure that data is accurate, reproducible, and reliable will help in enhancing the level of credibility of study findings and minimizing the chances of false interpretations.
- **Early cooperations with regulating agencies:** It is important to discuss with regulatory agencies, including FDA, EMA, and other agencies, the trial design process early. The benefits of early collaboration include harmonizing trial objectives and design with regulatory expectations, less uncertainty about what is needed to get the fictitious trial approved, and a higher likelihood that the results of the trial will be of regulatory acceptance standard.

REFERENCES

1. Brown, L. C., Graham, J., Fisher, D., Adams, R., Seligmann, J., Seymour, M., ... & FOCUS4 Trial Investigators. (2022). Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. *Clinical Trials*, *19*(2), 146-157.
2. Robertson, D. S., Lee, K. M., López-Kolkovska, B. C., & Villar, S. S. (2023). Response-adaptive randomization in clinical trials: from myths to practical considerations. *Statistical science: a review journal of the Institute of Mathematical Statistics*, *38*(2), 185.
3. Nimmagadda, V. S. P. (2024). Using AI to Improve Success Rates of Clinical Trials Through Advanced Patient Stratification Techniques. *American Journal of Data Science and Artificial Intelligence Innovations*, *4*, 342-379.
4. Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyoizumi, K., ... & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials–by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). *Orphanet journal of rare diseases*, *15*(1), 69.
5. Feng, M., Suresh, K., Schipper, M. J., Bazzi, L., Ben-Josef, E., Matuszak, M. M., ... & Lawrence, T. S. (2018). Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA oncology*, *4*(1), 40-47.
6. Garralda, E., Dienstmann, R., Piris-Giménez, A., Braña, I., Rodon, J., & Tabernero, J. (2019). New clinical trial designs in the era of precision medicine. *Molecular oncology*, *13*(3), 549-557.
7. Winter, S., Shoaie, S., Kordasti, S., & Platzbecker, U. (2020). Integrating the "immunome" in the stratification of myelodysplastic syndromes and future clinical trial design. *Journal of Clinical Oncology*, *38*(15), 1723-1735.
8. Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. *Genome medicine*, *14*(1), 101.
9. Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., ... & Northcott, P. A. (2021). Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). *Journal of Clinical Oncology*, *39*(7), 822-835.

10. Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., ... & Athey, B. D. (2018). Deep learning in pharmacogenomics: from gene regulation to patient stratification. *Pharmacogenomics*, *19*(7), 629-650.
11. Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., ... & Dubois, L. J. (2019). Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. *Clinical and translational radiation oncology*, *15*, 62-69.
12. Kiernan, M. C., Vucic, S., Talbot, K., McDermott, C. J., Hardiman, O., Shefner, J. M., ... & Turner, M. R. (2021). Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nature Reviews Neurology*, *17*(2), 104-118.
13. Hu, C., & Dignam, J. J. (2019). Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. *JCO Precision Oncology*, *1*, 1-12.
14. Gonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Chanan Khan, A. A., Dingli, D., ... & Roy, V. (2019). Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone marrow transplantation*, *54*(3), 353-367.
15. Rello, J., Van Engelen, T. S. R., Alp, E., Calandra, T., Cattoir, V., Kern, W. V., ... & Wiersinga, W. J. (2018). Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clinical Microbiology and Infection*, *24*(12), 1264-1272.

Chapter 10…

HOLISTIC AND PATIENT-CENTERED PRECISION ONCOLOGY

Dr. RAKESH SAHEBRAO JADHAV (PT)
Principal & Professor
Dept: MSK PT, Dr. Bhanudas Dere College of Physiotherapy,
Sangamner Dist. Ahilyanagar (Maharashtra)
E mail: drrakeshsj@gmail.com

Dr. PREETI DAGDUJI GHODGE (PT)
Associate Professor
Neuro Physiotherapy
Wellness College of Physiotherapy, Dharashiv (Maharashtra)
E mail: ghodgepreeti@gmail.com

Dr. KALPANA KRISHNARAO JADHAV
Designation: HOD & Professor
Dept: Swasthavritta & Yoga
Yashwant Ayurvedic College, PGT & RC Kodoli,
Tal Panhala, Dist Kolhapur (Maharashtra)
Email: kalpanajadhav70@yahoo.com

Dr. MILIND MOHAN GODBOLE
Dean & Professor
Swasthavritta & Yoga
Yashwant Ayurvedic College PGT & RC Kodoli,
Tal Panhala Dist Kolhapur (Maharashtra)
E mail: milindgodbole@gmail.com

Dr. SONAL S. WAGH
Principal & Professor
Streerog & Prasuti Tantra
Dr. Bhanudas Dere Ayurved College, Sangamner
Sangamner Dist. Ahilyanagar (Maharashtra)
E mail: sonaldere1@gmail.com

Precision oncology has long been based on treating tumor biology with the help of molecular profiling, genetic sequencing, and biomarker-based therapies. Although this method has resulted in the development of specific drugs and enhanced survival rates, it tends to perceive the patients mainly in terms of their cancer. There is a danger that this reductionist focus will cause an overlooking of important aspects of patient care: individual values, comorbidities, and quality-of-life considerations. The second step toward precision oncology should then not be the application of molecular customization but a much more holistic concept that incorporates the biological complexity of cancer with the lived experiences of patients.



Figure 1: Holistic Patient-Centered Precision Oncology

Source: (https://www.researchgate.net/figure/Overview-of-precision-oncology-From-the-patient-to-the-development-of-novel_fig2_349601136)

Precision model is patient centered and incorporates the person in the centre of treatment planning. This implies that treatment plans are not only based on the nature of the tumors, but also functional conditions, ability to withstand treatments and life ambitions. As an illustration, a weak patient with progressive illness may consider independence and symptom management to be more important than vigorous interventions whereas a young patient may seek aggressive treatments to achieve a long-term remission. Psychosocial support, family dynamics and patient preferences are important to be included in the oncology decision-making process so that the treatments are not only that best suited to the person, but also the disease.

Taking holistic precision oncology means a focus on interdisciplinary integration and digital health-tools to assist with continuous and patient-centered care. Wearables, remote monitoring systems, and mobile health applications can give real-time information about the symptoms, activity levels, and adherence to the treatment, which will give clinicians a more comprehensive picture of the patient well-being not limited by the hospital visits. The addition of psychosocial interventions, survivorship programmes and palliative care complement this framework to support the emotional, spiritual and social aspects of cancer care. Collectively, these approaches allow changing the oncology paradigm of disease-centeredness into a patient-centered ecosystem that is highly dynamic in its response to the needs of individuals.

Lastly, to achieve patient-centered precision oncology, healthcare systems need to be restructured and reshaped in terms of their culture. Not only should the clinicians be trained to incorporate the molecular and behavioral information to shared decision-making, but also the institutions need to adopt multidisciplinary models of care that connect oncology with psychological, rehabilitation, and primary care. Equitable access to molecular diagnostics, resources to support care, and digital health innovations are also crucial policies to promote inclusivity. The blending of biological accuracy and humanistic attention will not only prolong life but will make it more meaningful to the next generation of oncology as patients will be regarded as complete human beings and not disease vectors.

10.1. ROLE OF PATIENT PREFERENCES, LIFESTYLE, AND COMORBIDITIES

Role of Patient Preferences, Lifestyle, and Comorbidities in precision oncology highlights how the definition of personalization has to expand beyond tumor genetics on its own. Although molecular profiling and biomarker-based therapies have transformed the treatment of cancer, they can only treat the biological aspects of the condition. Personalization itself must be truly personal and it needs to be done within the context of complete patient, including not only physiological condition, but also psychosocial, economic, and cultural factors. The same tumor mutations can be interpreted differently by two people who have them based on their overall health, resilience and lived environment. Indicatively, the frailty score of a patient, comorbidity burden or psychological preparedness may determine whether a potentially useful therapy is tolerable or too harmful. Therefore these contextual factors must be incorporated in order to render treatment really patient-centered, and not merely disease-oriented.

The other important aspect is the contribution of lifestyle and daily functioning to treatment results and longevity. A history of smoking, exercise, nutrition, and psychosocial strength are the direct determinants of treatment tolerance, risk of complication, and recovery patterns. One patient who is physically well-conditioned and who has social structures in his favor might be able to tolerate intensive therapy more effectively, whereas another with unnutritious diet and frequent stress or with small social support can be challenged by even conventional protocols. In addition to physical strength, psychological strength and coping mechanisms frequently dictate compliance with multicomponent regimens and acceptance of long term therapies. Through this, lifestyle factors cannot be disregarded but rather be central in decision-making processes to enable clinicians strike a balance between medical advice and realistic outcome and quality of life expectations.

Lastly, patient values, and preferences should be incorporated in all the treatment planning stages especially where the choices would be based on a trade-off between survival and quality of life. A patient with severe comorbidities and with advanced age might reasonably seek comfort, autonomy, or meaningful time with their family than aggressive treatment that prolongs life at the cost of much suffering. In contrast, a younger, otherwise healthy patient would be ready to experience more toxicity in case it offers him/her an opportunity to have long-term remission or cure. The effect of neglecting these personal priorities can include over-treatment resulting in unneeded toxicity, financial and emotional overload, or under-treatment, which can be withholding potentially life-prolonging therapies. Both cases reduce patient satisfaction and deteriorate overall results. Oncology care can be made more equitable, ethical, and responsive to what actually matters to patients in their care path by systematically combining preferences, lifestyle factors, and assessments of comorbidity.

- **Key Components**

1. Systematic Assessment of Patient Context

Acknowledging the systemic review of the patient context is the basis of the holistic approach to cancer care, as it makes it impossible to make treatment decisions only based on the nature of the disease, but also on the health and functioning conditions of a patient and his/her life situation. This is initiated by a systematic review of the overall condition of the patient, which involves clinical as well as non-clinical elements. The Comprehensive Geriatric Assessment (CGA) is especially useful in older adults because it identically assesses cognitive function, mobility, nutritional condition, and social support systems. All these factors are good predictors

on the patient tolerance to treatment and reaction to therapy. Likewise, performance status scales (e.g., Eastern Cooperative Oncology Group (ECOG) scale or Karnofsky Performance Status (KPS)) are standard measures of physical functioning, and when clinicians evaluate patients regarding their tolerance to aggressive treatments, the scales enable them to determine whether patients are stable enough to continue the treatment or the treatment needs to be modified. Such formal instruments are used to personalize cancer treatment to balance the intensity of treatment with the functional reserve of the patient.

It is also crucial to evaluate comorbidities and vulnerabilities which might not be obvious. Such tools as the Charlson Comorbidity Index measure the weight of other diseases that accompany cancer, and frailty scores are used to determine patients who might be physically well but frail and more vulnerable to complications. Among medical and physical parameters, non-medical determinants of health are also found in systematic assessment. Health literacy, financial stability and social support need screening will help make sure that planning of treatment is based on realistic factors like comprehension of medical instructions, affordability of drugs, or access to treatment facilities. Through the combination of these clinical, functional, and social aspects, caregivers can develop practical, patient-focused treatment plans that increase adherence, better outcomes, and equity in cancer care.



Figure 2: Comprehensive Geriatric Assessment (CGA)

Source: (https://www.researchgate.net/figure/Comprehensive-geriatric-assessment-CGA-is-an-organized-evaluation-method-to-provide-a_fig2_346542805)

2. Patient-Reported Outcomes (PROs) and Goals Elicitation

Patient-Reported Outcomes (PROs) and Goals Elicitation are part and parcel of the process of making cancer care patient-centered, i.e. not just the biomedical aspect of the illness, but the lived experience, preferences, and priorities of patients. Regular treatment of cancer commences with a systematic examination of the general health of the patient alongside clinical examination and patient input. In elderly patients, such tools like Comprehensive Geriatric Assessment (CGA) come in handy especially since they offer an assessment of cognitive status, mobility, nutrition health and social support networks, which are highly significant in determining treatment options and general resilience. Moreover, the Eastern Cooperative Oncology Group (ECOG) and Karnofsky scales are another performance status scales that are still commonly used to predict the ability of a patient to withstand a therapeutic treatment. These measures, in combination with PROs, provide a more detailed perspective of the functional state of the patient, which guarantees that the treatment requests are based on physiological capacity as well as on patient-defined objectives.

In addition to performance and functionality, it is necessary to consider the context of the whole health of the patient and customize care. Such tools as the Charlson Comorbidity Index give a measurable value of the burden of coexisting diseases, whereas frailty scores reveal physiologic susceptibility that cannot be detected externally. These tools combined with patient-reported data on symptoms, emotional well-being, and quality of life can help clinicians to identify risk sooner and make changes to the treatment plan. In addition, the ideation of health literacy, financial and social needs screening into the assessment process will guarantee that practical obstacles like the inability to comprehend medical prescriptions, afford the treatment, or use healthcare facilities are properly tackled. This twofold approach to clinical signs and patient-reported outcomes helps to make shared decisions, promote realistic treatment expectations, and increase compliance, which leads to better patient survival and the quality of life in cancer care.



Figure 3: Patient-reported outcomes (PROs)

Source: (https://www.jprasurg.com/article/S1748-6815(23)00481-3/abstract)

3. Shared Decision-Making (SDM)

Shared Decision-Making (SDM) has become a fundamental part of the contemporary oncology practice that is no longer based on the paternalistic approach of care but is rooted in the collaboration between clinicians and patients. This is done through giving patients easy to understand balanced and accessible information regarding the absolute risks and benefits of different treatment alternatives. This does not necessarily involve only the standard aggressive treatment but also the less aggressive options like active surveillance, supportive treatment, or symptom management. Clinicians can enable patients to make decisions based on their own values, objectives, and risk tolerance, as well as their own understanding of complicated medical information by simplifying and clarifying complex health-related information. SDM builds trust, facilitates open dialogue, and makes sure that the care provided is not only warranted by the medical necessity, but the definition of quality of life as the patient defines it. Notably, it provides room to patients to share fears or cultural beliefs, or their own priorities that otherwise would have been hidden in a strictly biomedical practice.

Another crucial branch of SDM is advance care planning, which is especially important with patients of advanced illness, serious comorbidities, or indeterminate prognosis. Structured discussions will help patients express their care preferences and define outcomes important to them, as well as make a record of decisions related to future interventions. Such documented preferences serve as a protection, as they guarantee continuity and the preservation of the values of the patient even in case the situation changes or the patient cannot make decisions in the future. Advance care planning is not a single discussion but a tendentious dialogue, changing flexibly with the health condition of the patient and his/her changes in objectives. It allows reducing uncertainty and avoiding unwanted interventions and assures both the patients and the family as well as enhances value-concordant ethically based care. Combined, shared decision-making and advance care planning increase patient autonomy, both therapeutic alliance and dignity in cancer care.

4. Lifestyle and Risk Modification

Lifestyle and Risk Modification has an essential role in the development of the long-term outcomes of cancer patients as it is complementary to medical treatment with proactive approaches that improve health and overall resilience. Lifestyle change interventions have a direct impact on treatment tolerance, complication rates and survival. As one example, smoking cessation has been demonstrated to enhance wound healing, decrease complications associated with treatment, and decrease cancer recurrence or secondary malignancies. Likewise, with structured nutritional care, it is indemnified such that the patient keeps up with respect to strength, immunity as well as energy reserves during therapy and therefore, enhances compliance and decreases treatment breaks. Dietary consideration does not only help in the alleviation of the side effects of weight loss or malnutrition but also helps the body to recover the energy of the chemotherapy, radiations, or surgeries. When incorporated into the treatment plan, these lifestyle measures serve as crucial adjuncts to biomedical interventions that maximize patient adherence to their own treatment and remain a solid reinforcement of patient participation in self-management.

Physical and psychosocial support is equally important, as both are used to complement functional and emotional aspects of survivorship. Specialized physical activity strategies, including mild to moderate work, and systematic rehabilitation interventions have the potential to greatly lessen cancer-related fatigue, boost cardiovascular and muscular strength, and functional recovery. Simultaneously, psychosocial interventions such as counseling, stress

management and peer support directly reduce depression, anxiety and distress, which are frequent but not well-known obstacles to adherence to treatment and quality of life. Psychosocial support is resilience-strengthening and improves coping strategies by empowering the patient to cope with emotional well-being as well as physical health. Combined, these lifestyle-based interventions shift the conventional paradigm of oncology care not only to a reactive model, which is based mainly on disease treatment, but to proactive orientation, which pays more attention to the management of health and prevention over an extended period, as well as to long-term well-being.

5. Multidisciplinary Care Planning

The concept of Multidisciplinary Care Planning has become a necessity in the contemporary cancer treatment because cancer treatment is far more than biomedical. Oncologists offer their essential competence in the areas of disease biology, staging, and treatment options, yet to provide effective cancer care, it is necessary to cooperate with professionals in various areas to cover the entire range of patient needs. The standard tumor boards, usually consisting of just oncologists, radiologists and surgeons, are now being enlarged to include representatives of geriatrics, palliative care, rehabilitation medicine, psychology, social work and pharmacy. This expanded involvement means that the treatment plans are not only being based on eradication of tumors but rather on the basis of a holistic view of the health status, functional ability and circumstances of a life that the patient is in. Through the development of highly orchestrated cooperation, multidisciplinary planning reduces the risk of suboptimal care delivery, improves provider communication, and provides coordinated plans that address the medical effectiveness and patient-centered priorities.

The above approach will make treatment decisions both biologically sound and functional. As an example, a geriatrician can review frailty, comorbidities, and cognitive well-being to know that aggressive interventions can be used or changes are necessary. Social workers can assist patients in practical barriers such as having financial pressures, transport challenges, or access to community resources hence enhancing adherence and limiting inequities. Equally, a psychologist can offer coping mechanisms to deal with anxiety, depression, or adjustment difficulties, and the rehabilitation professionals can increase mobility and living quality throughout and after the treatment. Pharmacists can assist in their part by making sure that medications are well managed and drug interactions are accommodated. The combination of this contribution constitutes an integrated plan of care that seeks not just to treat the tumor but

the entire patient with the understanding that it has medical, emotional, social, and functional needs. This multidimensional model incorporates the elements of individualized oncology care, the maximization of the clinical outcomes and quality of life.

6. Clinical Impact and Measurement

Clinical Impact and Measurement patient-centered oncology transcends biomedical outcomes that are standard, including tumor shrinkage or overall survival. As important disease control indicators, these do not give a complete picture of the lived experience of treated patients. In a bid to fill the gap, clinicians should consider expanding evaluation metrics so as to incorporate parameters that capture safety, feasibility and daily functionality. As an example, detection of the toxicity rate is crucial to inform about the tolerance of treatment in patients and timely adjust the treatment to minimize the adverse effects and maintain the quality of life. Likewise, treatment adherence can be used in the evaluation of both the feasibility of prescribed regimens as well as the willingness and capacity of the patients to comply with the recommendations. Additional evidence of whether treatment enables patients to live with autonomy and dignity as opposed to biological outcomes is functional patterns, which include mobility, ability to live independently, and ability to remain at social roles.

Patient-level outcomes and system-level outcomes are also equally important, since they directly indicate patient values and system-level effectiveness. Quality of life (QOL) scores are theoretical insights into physical comfort, emotional well-being and social functioning that are standardized and have been validated, and assist clinicians in determining the overall effectiveness of therapy as seen by the patient. Indirect indicators of treatment safety, continuity and effectiveness in the management of non-acute complications are health-care utilization rates, such as hospitalizations and emergency visits. Lastly, the concordance rates, or the extent to which the preferences of a patient and the care provided to him comply with each other, perhaps the most significant indicator of patient-centered oncology because this demonstrates whether treatment really respects personal goals and values. Collectively, these extended measures enable clinicians to evaluate cancer care in a more integrated fashion, so that success is not solely defined by medical results, but also by the experience of the patient, his or her well-being, and satisfaction with care.

10.2. PRECISION PALLIATIVE CARE AND SURVIVORSHIP PROGRAMS

In the environment of the precise oncology, palliative care is no longer associated with end-of-life treatment. It is now conceived as the early, integrated and patient-centered approach aimed at improving the quality of life throughout the cancer continuum. Unlike the reactive model, this model is proactive and aims at dealing with the physical, emotional, and social burden since the time of diagnosis. Patients repeatedly face a set of issues that can be grouped as pain, side effects of treatments, anxiety, role disruption, and financial stress, and unchecked, these issues may lead to poor adherence to treatment and poor treatment results. Incorporating palliative care at the early stages of treatment or during the period of high risk allows clinicians to reduce pain, encourage adherence to the treatment process and maintain harmony between medical and patient values and personal objectives.

In line with this, survivorship programs take the care past active treatment since, in many cases, cancer may have long-term impacts. The programs are geared towards surveillance and treatment of long-term sequence, such as late toxicity such as cardiotoxicity, infertility, neuropathy, hormonal disorders and cognitive impairment. Other psychosocial issues that are taken care of by survivorship care include fear of recurrence, employment reintegration, and financial strain. Survivorship programs are able to customize follow-up according to treatment history, comorbidities and lifestyle factors, meaning that precision medicine is not just focused on curing the tumor, but the entire patient over the long term.

Models of Delivery

1. **Early Integrated Palliative Care**

Early Integrated Palliative care is an active concept in the field of oncology which focuses on introducing palliative activities at the time of diagnosis or even early in the development of known advanced illness. It is not the usual model where palliative care is considered only at the end-of-life stages, but a combination of the management of symptoms, psychological support, and care planning is combined at the very beginning. The constant monitoring and early management of pain, fatigue, nausea, and other uncomfortable symptoms are beneficial to patients to increase the level of comfort and normal functioning. Through the incorporation of palliative care and the curative or disease-modifying therapies, clinicians will guarantee that they will treat the needs of the patients holistically, which will include not just physical but emotional, social, and existential aspects as well. This premature intervention creates a

collaborative spirit where patients, families and health care teams get to make joint decisions assisting patients negotiate the complicated treatment options and match the care with their own values and preferences.

Clinical study results show that early comprehensive palliative care has salutary impacts on various outcomes. Patients have reported enhanced quality of life, less symptom burden and better psychological wellbeing and families have more support and reassurance during the care continuum. In addition to this, this model has also been linked to the decreased unnecessary hospitalization, emergency care, and intensive care that might not be in line with the objectives of a patient hence improving the sustainability and efficiency of care delivery. Notably, palliative integration in the early stage promotes goal-concordant care- where the treatment plans represent the patient values, preferences, and priorities-so as the interventions are warranted and contextual. Even some studies indicate potential survival advantages, presumably because symptoms are better controlled, there is less stress associated with treatment, and greater compliance with treatment. Altogether, early integrated palliative care is an example of a patient-centered evidence-informed care that fills the gap between treatment based on disease and holistic supportive care.

2. Co-Management Clinics

The Co-Management Clinics represent a team of multidisciplinary care delivery of cancer care such that oncology care is provided concomitantly with palliative care, rehabilitation, and primary care. Co-management clinics seek to avoid the discontinuity of care that patients usually feel as they move across several specialties to ensure that the services are integrated into a coordinated environment. Under this model, every team member brings his/her skills on board: the oncologists work on the disease-guided treatment, the palliative care experts handle the symptoms and offer emotional support, rehabilitation practitioners can improve physical functioning, and primary care providers can handle comorbidities and preventive health care. Such a team arrangement would make sure that patients get thorough, ongoing care on the physical and functional aspects of health, including the psychological and social aspects. Besides, co-management clinics enable immediate communication among the providers and allow making timely corrections to the treatment plans, as well as accommodate a smooth transition between care environments and improve patient safety and risk of medical errors or missed concerns.

The comprehensive system of co-management clinics also helps enhance the experience of patients through the stable system of support and eliminates the stress related to the work in complicated healthcare systems. Patients will enjoy integrated appointments, combined care plans, and multidisciplinary resources that will meet both short-term and long-term needs. Clinical interventions are provided along with emotional and functional support, which promotes resilience, autonomy, and treatment adherence. Research has shown that those models enhance patient satisfaction, decrease care gaps, and potentially have a positive impact on health outcome, as timely symptom management, rehabilitation, and follow-up are ensured. Moreover, co-management clinics also act as a safety net, especially with regard to vulnerable groups, by narrowing the gap between access to supportive services and by ensuring that patients have access to the full range of services that have the potential to lead to the best recovery and life.

3. Survivorship Care Plans (SCPs)

Survivorship Care Plans (SCPs) are patient-centered, structured documents that are designed to assist patients in their post-treatment phase of cancer care. The SCPs offer an in-depth account on the treatment history of the patient (surgery, chemotherapy, radiation, and other treatment), and so both the patients and medical professionals are well aware of what has been done. In addition to the description of the past care, SCPs anticipate possible delayed consequences of the treatment, describe the suggested screenings, and indicate the rehabilitation services, which can help the patient recover physically, cognitively, and emotionally. SCPs are a map to continued health care by pulling together this information to guide patients in their continued health care initiation to ongoing survivorship with clarity and confidence. Such plans also have the relevant contacts in case of emergency care and specialized services as their backup to ensure that the patients facing new or persistent health issues have a safety net.

Besides facilitating clinical continuity, SCPs enable patients to have an active role in health management. Patient-friendly summaries, which are often a part of electronic medical records, enable patients to read and consult their care plan effortlessly and enable them to self-manage and make well-informed decisions. Patient-centered SCPs allow providing recommendations that are applicable and will be implemented according to the needs of particular risks, lifestyle factors, and goals of the specific patients. Through the encouragement of involvement and awareness, SCPs assist survivors to become aware of the warning signs, follow-up schedules,

and supportive services as quickly as possible. This organized development is not only better health in the long term but is also better life quality because of the feeling of control, alleviation of anxiety about the unknown, and empowering the relationship between patients and their healthcare team in their survivorship period.

4. Risk-Stratified Survivorship

Risk-Stratified Survivorship is a discontinuity-based approach to post-treatment care in which cancer survivors are offered follow-up care according to their level of exposure to treatment and their likelihood of developing chronic complications. Taxonomic classification of survivors allows healthcare systems to have higher resources but at the same time, patient safety remains high. As an example, high-risk survivors (high-dose chemotherapy, pelvic radiation, or stem cell transplants) should be closely monitored by oncology teams. Such patients are more susceptible to late effects, such as dysfunction of organs, secondary malignancies or complex psychosocial problems and hence require frequent surveillance, diagnostics testing, and interventions. This pro-active strategy allows them to detect and control complications in the early stages of their development avoiding further advancement and enhancing the long-term results.

Conversely, the survivors of lower to moderate risk who have not received extensive therapies, or whose health has been stable in the context of primary care, can be safely provided at the primary care system with periodic involvement of the oncology expertise. Such shared-care model will relieve the oncology services of unnecessary burden, provide continuity in overall services, and make follow-up conveniently available to the patient near the home. Risk stratification is thus a compromise in patient safety and cost-effectiveness that guarantees specialized oncology resources are focused on the patients that require them the most without having others lose the watch. In addition, this model enhances sustainability of survivorship care particularly in the healthcare systems where survivor numbers are increasing. It enables patients to have more power, lowers the cost of healthcare, and can help in an equitable redistribution of care throughout the survivor population by personalizing the level of follow-up risk.

Core Activities

Precision palliative care and survivorship programs activities are extensive and are based on the multi-dimensional needs of cancer patients. Management of symptoms continues to be at the forefront and specific interventions have been identified in pain, fatigue, neuropathy,

nausea, cachexia, and sleep disturbance. Physical and occupational therapy are some of the rehabilitation services that play important roles in restoring the mobility, independence and stamina of an individual following intensive treatments.

In addition to physical recovery, these programs deal with cognitive and sexual health complications as they are helping patients with the so-called chemo-brain, memory lapses, sex dysfunction, or body image. Emphasis is put on fertility and endocrine health issues, with fertility preservation as well as hormonal dysfunction in response to gonadotoxic therapies being counseled. Moreover, psychosocial and financial counseling Assists in mental well-being, the caregiver stress management, the return-to-work integration, and alleviation of financial toxicity, which has been increasingly identified as a factor in the overall quality of life.

Metrics and Evidence

The scientific literature has begun to list the quantitative advantages of early palliative care integration. Research indicates that it improves quality of life, increases patient and caregiver satisfaction, decreases avoidable hospital admissions and hinders futile but aggressive end of life care. It also enhances communication between patients, families and clinicians in a way that assists to make sure that the care plans are aligned with patient preferences and values.

It can also be observed that survivorship programs have a lot of benefits when put into practice on a systematic basis. Long-term complication morbidity including cardiac dysfunction, endocrine failure, and secondary malignancies have been shown to be risk-stratified with reduced morbidity by survivorship care. Patients who receive such programs record favorable functional recovery, which facilitates easier reintegration into work and everyday functions. There is also an improvement in mental health outcomes, and depression, anxiety, and fear of recurrence are reduced. Significantly, survivorship care is economical since the intensive resources are used on the most at-risk populations, whereas the lower risk groups are safely assisted in the context of community or primary care.

10.3. PSYCHOSOCIAL SUPPORT AND DIGITAL HEALTH TOOLS

Psychosocial care is an indispensable element of holistic cancer treatment, which involves combating psychological, social, spiritual and financial issues that a patient and his or her family encounter. Existing theories like cognitive behavioral therapy, mindfulness and meaning-centered therapy have been used to evidence-based therapies to control anxiety,

depression and existential distress and access to services like housing, transportation and financial institutions is accessed through social work. Spiritual care and peer support groups are a source of emotional comfort and lessening the sense of isolation, structured caregiver programs can prevent burnout, which protects both the well-being of the caregiver and the patient. Financial navigation is becoming known as a necessity because the medication of cancer is a costly affair that may adversely affect adherence, mental well-being, and the prognosis. Screening psychosocial needs with reliable instruments such as the NCCN Distress Thermometer on a regular basis can be utilized so that the psychosocial needs are treated with seriousness as the physical symptoms are.

Digital health tools increase the psychosocial and supportive oncology care through the possibility to monitor in real-time, provide interventions tailored to individuals, and provide access to a wider audience. Remote symptom monitoring and electronic patient-reported outcomes (ePROs) enable the rapid assessment of toxicity or distress and enhance communication and, perhaps, survival. Telehealth and virtual multidisciplinary teams deliver high-quality care in underserved communities and can engage in shared decision-making. Wearables, mobile applications, and passive digital biomarkers are used to monitor activities, sleep, cognitive ability, and adherence to treatment, and AI-based clinical decision support forecasts complications and proactive care. Nonetheless, the technologies are associated with such challenges as the digital divide, data privacy issues, integrating workflows, algorithmic bias, and equity gaps. To implement effectively, the digital tools should be designed with consideration to the users, strong data governance, clinician training, and ongoing assessment to ensure they benefit care without making disparities worse.

Psychosocial Care

The treatment of cancer is not only a complicated case of biomedicine but also a deep psychosocial process, which impacts not only patients but also their families. Effective management of cancer needs to focus on the psychological, social, spiritual, and financial aspects of illness as these are the crucial factors that can affect the health outcomes and quality of life in general. Oncology psychosocial support is multi-faceted, and it has many interconnected elements:

- **Psychological therapies:** Cognitive behavioral therapy (CBT), mindfulness-based stress reduction and meaning-centered therapy are evidence-based interventions that are very important in assisting the patient to deal with the psychological effects of

cancer. These treatments are aimed at relieving anxiety, depression, insomnia and existential distress that often comes along with a serious illness. In addition to a positive impact on mental health, these interventions also increase treatment adherence, effective pain management, coping, and resilience to disease in general.

- **Social work services:** Cancer patients may face practical barriers, such as the difficulty in getting to the cancer centers, disability benefits, or job interruptions. Social workers in oncology are the key advocates, linking the patients to the community services, housing services and community support systems. Through his/her approach to these practical needs, the social worker assists in minimizing obstacles to care and enable the patient to devote more attention to his/her treatment and recovery.
- **Spiritual care:** A severe diagnosis is a serious diagnosis that can make patients and their families think about the meaning, mortality, and purpose. Emotional comfort, acceptance of the illness, and improvement of psychological well-being are achieved by access to spiritual resources such as chaplains or spiritual counselors and the emotional comfort they provide. Spiritual care is especially useful in end-of-life situations, where peace-building and reconciliation may dramatically enhance the living conditions of patients and their family members.
- **Peer support groups:** Interventions in the form of groups (engaging in-person or online) provide the patient with the chance to discuss experiences and coping mechanisms, as well as support each other. Membership in such groups helps alleviate feelings of isolation, makes shared fears and anxieties a regular occurrence and a feeling of belongingness to a group of people struggling with the same problems. Peer support tends to be a complement to professional care, enhancing emotional strength and social interrelationship.
- **Caregiver support and respite:** Family members are often overwhelmed with significant emotional, physical, and economic challenges when they support their loved ones during treatment. The prevention of burnout, protection of caregiver health, and the long-term sustenance of the caregiving role are impossible without structured caregiver programs, counseling services, and respite opportunities. Indirect benefits are extended to the patients through the support of the caregivers since properly supported caregivers have a better chance of delivering reliable and effective care.

- **Financial navigation:** The problem of increasing cost of cancer treatment is a cause of financial toxicity, a clinical problem impacting decreased adherence to treatment, care delays, and increased psychological distress. Financial navigators assist patients in obtaining the insurance coverage, grants, co-core payment assistance, and charitable funds to reduce the economic burden of cancer care. The benefits of spending money successfully both increase compliance and success but also lessen the level of stress, which allows the patient to focus on recovery and holistic health.

➢ **Why essential:** Psychosocial distress (depression, anxiety, and financial hardship) is a measurable consequence that has not been managed: patients with uncontrolled psychosocial distress report greater symptom burden, high health-care use, decreased chemotherapy or radiotherapy adherence, and lower survival. To overcome this, it is recommended in best practice practices to screen distress routinely and systematically with validated instruments, like the NCCN Distress Thermometer or Hospital Anxiety and Depression Scale, followed by immediate referral to psychological, social or palliative services. This forward-looking strategy may make psychosocial needs receive the same level of urgency as the physical symptoms.

Digital Health Tools

Digital innovations are transforming supportive oncology care into continuous, real-time and more individualized. These technologies increase the scope of practice of clinicians, patient empowerment, and data-driven decision-making, which is part of cancer management.

- **ePROs (electronic patient-reported outcomes) and Remote Symptom Monitoring**: Patients regularly report their symptoms, side effects, and quality-of-life measures via mobile apps, web portals, or tablets in clinics. These data are directly integrated into electronic health records and clinical workflows, alerting oncology teams to early signs of toxicity or distress. Clinical studies demonstrate that ePRO monitoring reduces emergency room visits, enhances communication between patients and providers, and in some cases improves overall survival.

- **Telemedicine and Virtual Multidisciplinary Teams (MDTs)**: Tele-oncology platforms allow patients in rural or underserved regions to access high-quality cancer care without traveling long distances. Virtual MDTs bring together oncologists, radiologists, pathologists, and psychosocial experts across locations, enabling

collaborative treatment planning. Telemedicine also allows family members to participate in consultations, enhancing shared decision-making.

- **Apps, Wearables, and Digital Biomarkers**:
    - **Wearables** (e.g., smartwatches, fitness trackers) provide continuous, objective measures of activity, heart rate, sleep quality, and mobility, which can be correlated with treatment tolerance and recovery.
    - **Mobile apps** deliver digital CBT modules, mindfulness exercises, medication reminders, nutrition tracking, and survivorship education tailored to the individual's cancer journey.
    - **Passive digital biomarkers**—such as changes in typing speed, mobility patterns, or speech—offer early detection of cognitive or functional decline, enabling timely interventions.
- **Decision Aids and Personalized Education**: Digital tools now present individualized risk–benefit scenarios in interactive formats, helping patients visualize treatment trade-offs and long-term implications. These decision aids support shared decision-making (SDM), aligning therapy choices with patient preferences, values, and goals.
- **Artificial Intelligence (AI) and Clinical Decision Support (CDS)**: AI-driven predictive models can identify patients at high risk for complications, such as unplanned hospitalization, severe side effects, or relapse of depression. When transparently integrated into workflows, AI enhances proactive care planning. However, ethical use requires rigorous validation across diverse populations to avoid algorithmic bias and inequitable outcomes.

Barriers and Safeguards

Although digital health tools have enormous potential to offer, their implementation and performance are undermined by a number of practical and ethical issues:

- **Digital inequality:** Digital access to health solutions is not equal. The least connected populations, those with low levels of digital literacy, or low technical capacity, might be locked out of the benefits of digital interventions. This digital divide has the potential to support health disparities thus placing vulnerable populations at the disadvantage.

Attempts to improve accessibility, including off-line capabilities or ease of use interfaces are essential to reduce this obstacle.

- **Data privacy and security:** Digital health tools are sensitive because they process personal health information that is highly sensitive and require a high level of data protection. It is required to comply with the set regulations, like HIPAA in the United States or GDPR in Europe, to protect privacy of patients and ensure trust. Violation or abuse of the information could devastate the trust of digital health programs.
- **Workflow integration:** implementing digital tools in clinical practice has the potential to destabilize workflows. Excessive transmission of alerts, notifications, or administrative tasks to clinicians, which is often called alert fatigue, may decrease compliance and decrease perceived usefulness of these systems. It should be able to integrate seamlessly with the current workflows in order to support sustainable adoption.
- **Algorithmic bias:** AI-based health technologies depend on data to train and in case of narrow, homogeneous or unrepresentative datasets, algorithms will fail some groups of people. This bias may enhance the presence of health inequities by providing non-optimal recommendations or interventions to underrepresented communities. Bias should be averted through constant surveillance and participatory data creation.
- **Equity issues:** Digital health technologies should be specifically created to reduce disparities and not intensify them, on top of being accessible and effective. Equity-based models can be characterized as interventions designed to meet the needs of disadvantaged groups, as well as the active monitoring of the results to make benefits distribution fair.

To resolve these, there are a number of strategies which have worked. Digital tools are made user-intuitive, relevant and practical, a process that involves user-centered design, which includes feedback of the patients, caregivers and clinicians. Sound data protection governance defines clear policies on the secure data handling, storage and sharing. Clearly-defined avenues of alerting about symptoms will aid in making sure that there is prompt clinical care and minimize risk. Also, the equity implications should be continuously evaluated in order to check whether the interventions actually decrease the disparities.

Lastly, a sustainable implementation requires clinician buy-in, which can be achieved by developing specific training, proving clinical value, and integration with current workflows. It

is important to involve all stakeholders during the development and deployment process to make the digital health tools effective, trusted and equitable.

10.4. THE FUTURE OF PERSONALIZED CANCER CARE AND EQUITY CHALLENGE

Precision oncology is turning next to a biopsychosocial and adaptive model of care that incorporates both molecular precision and the realities of the lives of patients. This approach does not use only genomic or proteomic indicators but also psychological resilience, emotional well-being, daily functioning, and social determinants, including housing, income, education, and access to healthcare. Understanding that biology interrelates with lifestyle, behavior, and environment, therapies are now designed with increasing attention to tumor biology, as well as, individual needs. To supplement this, learning health systems are based on continuous data feeds of electronic health records, patient-reported outcomes, wearables, and clinical encounters to construct feedback loops refining care in real time. Adaptive trial designs such as basket, umbrella and platform trials can be used to generate knowledge faster, whereas N-of-1 strategies can enable continuous personalization on a patient level. Cross-sector integration also reinforces this paradigm by converging oncology and primary care, mental health and nutrition, housing and employment services- making survivorship and palliative care not a specialty, but a part of living. Collectively, these advances are a shift toward non-dynamic one-size-fits-all cancer care to dynamic, personalized ecosystems.

Nevertheless, equitable personalization in precision oncology is not that easy to achieve. Availability of such modern technologies as genomic sequencing, immunotherapies, and digital health technologies is still held in high resource facilities, where rural, low-income, and underserved populations stand a chance of being left out. Algorithms and dataset biases can also alienate a minority or an underrepresented group and the cost of new therapies can be so high that it becomes financially toxic, necessitating patients to ration or forgo care. There is also cultural and language barrier, which diminishes shared decision-making and participation in supportive programs that add to disparities. In the future, equity will need to be designed deliberately, clinical trials and algorithms should be designed to encompass diverse populations, health systems need to measure and report outcomes that are disaggregated by race, gender and socioeconomic status. Diversification of access channels by subsidizing genetic testing, telemedicine, community health navigators, and non-physician task-sharing may decrease the number of specialists that are in short supply. Change such as insurance

coverage, survivorship and digital monitoring reimbursement and lessening out-of-pocket expenses matters, as well as community involvement to co-create culturally relevant and sustainable care. With such precision, oncology can truly become an inclusive system, with the state-of-the-art molecular understanding alongside the reality of every patient.

Biopsychosocial Precision

The next frontier in cancer treatment lies in integrating molecular precision with a biopsychosocial approach. While molecular precision focuses on detailed genomic, proteomic, and other biomarker-driven analyses to guide targeted therapies, a biopsychosocial framework expands the scope to consider psychological, behavioral, and social factors that significantly influence treatment outcomes. Psychological resilience, emotional well-being, and daily functioning are critical determinants of how patients tolerate and adhere to complex treatment regimens. Simultaneously, social determinants of health—including income, housing stability, education, and access to healthcare—directly shape the feasibility and effectiveness of precision therapies. By considering the patient's holistic life context, this approach ensures that clinical decisions are not solely based on tumor biology but are aligned with the patient's capacity to engage with and benefit from the prescribed care.

For instance, two patients with identical tumor profiles may require different treatment strategies based on their psychosocial circumstances. A patient with strong family support, financial security, and stable access to healthcare may tolerate aggressive multi-modality treatment and achieve optimal outcomes. Conversely, a patient with limited financial means, minimal social support, or unstable living conditions may benefit from a less intensive, more personalized treatment plan that balances efficacy with feasibility. This integrative methodology acknowledges the dynamic interaction between biology, behavior, lifestyle, and environment, emphasizing that successful precision oncology must address both the molecular characteristics of the disease and the real-world context in which the patient lives. Such a comprehensive approach promotes not only clinical effectiveness but also patient-centered, sustainable care.

Learning Health Systems

The concept of lifelong learning is starting to take over modern oncology in healthcare systems. Learning health systems (LHS) are intended to be self-improving and adaptive ecosystems where data produced in the course of standard clinical attention is constantly informative and improves future decisions. Electronic health records (EHRs), patient-reported outcomes

(PROs), wearable devices, and the knowledge gained during clinical encounters are the major sources of information, which serve as the inputs to real-time analytics that assists clinicians in refining treatment plans. This data richness can be systematically captured and analyzed to allow health systems to see patterns and identify emerging risks, and to tailor interventions to the changing needs of various patient groups in response to their needs. This feedback loop of iteration is used to make sure that care recommendations are not fixed but are optimized dynamically based on the most recent evidence and patient experiences.

As an illustration, health systems learning can utilize the PRO data to identify early signs of heightened toxicity in particular groups of patients, allowing a change in dosing schemes or supportive treatment plans. This responsiveness, in turn, makes it possible to make personal adjustments that enhance safety and effectiveness. In addition to the treatment of each patient, the insights may be quickly generalized to the system-level, normalizing the best practices and improving the quality of care, in general. By doing so, each patient engagement will be a chance to generate actionable knowledge, establishing a self-reinforcing oncology network where treating an individual patient will be informed by the system-wide learning. Learning health systems would help transform oncology into more responsive, accurate, and fair by mediating between bedside evidence generation and real-time clinical practice.

Adaptive Trials and N-of-1 Strategies

Although traditional randomized controlled trials (RCTs) have long been the standard of testing an innovative new cancer therapy, they tend to be less capable of capturing the variability inherent at the individual patient level. Basket trials, umbrella trials and platform trials: Adaptive trial designs are more flexible and responsive methods of producing clinical evidence. In basket trials, patients are recruited on the basis of common molecular mutations, but not on tumor site, and therapies are tested in different types of cancer that have in common a biological target. Umbrella trials on the other hand compare several treatment modalities in a single cancer type, and determine which type of intervention is best in various molecular subgroups. Platform trials extend this flexibility by simultaneously testing two or more interventions those using the same protocol, adding new therapies and eliminating unproductive ones. These designs increase the rate of discovery, streamline resource utilisation and are more representative of patient heterogeneity in a real world setting.

N-of-1 strategies, which supplement adaptive trials, are based on the individual patient as an experimental unit. In such studies, treatment regimens are constantly readjusted with respect

to on-going biomarker surveillance, symptom observation, and therapeutic outcome. This method enables clinicians to optimise therapies on the fly and hence, maximise efficacy and minimise toxicity to the individual patient. Notably, N-of-1 trials, as well, can be used to gain information about micro-subpopulations that are either underrepresented or ignored in a large-scale trial and that can inform future research and general clinical guidance. Through the integration of adaptive trial designs with N-of-1 designs, precision oncology can advance to strongly individualized care and simultaneously produce knowledge that is relevant to individual patients and the broader cancer community.

- ***Cross-Sector Integration***

There is a growing awareness in the modern management of cancer that patient outcomes are not simply a part of clinical intervention; instead, social, economic, and environmental interventions are essential to recovery, adherence, and longer-term survivorship. Cross-sector integration is an attempt to connect oncology care with such complementary sectors as primary care, rehabilitation, mental health, nutrition, social work, housing and employment support. Through the development of a synchronized network of services, patients enjoy holistic care that deals with both medical and non-medical determinants of health. As an example, a breast cancer survivor who is at risk of losing a job can use early contact with occupational rehabilitation programs, which would guarantee financial security and maintenance of care. Likewise, a lung cancer patient with unstable housing can have social services that offer safe and stable living circumstances and consequently, facilitate compliance therapeutic and follow-up care.

This interprofessional model facilitates the care of the whole person in which survivorship and palliative services are integrated within ordinary life as opposed to visiting the clinic. When non-medical stressors (such as financial difficulties, housing, or nutritional deficiencies) are kept to a minimum, patients are more resilient, psychologically healthy, and able to comply with complicated medical regimes. The cross-sector integration facilitates not only the enhancement of clinical outcomes but also the creation of a more equal and sustainable cancer care system by considering the larger context of the patients lives. Finally, this model does not only emphasize the treatment of disease as an isolated phenomenon but aims at enhancing the quality of life, long-term health, and functional recovery of the patients.

- **The Equity Challenges**

Lack of access to high accurateness apparatus, prejudiced algorithms, expensive treatment, and cultural or language issues cause significant inequalities in cancer care. Such challenges limit patient involvement in trials and their compliance with treatment regimens and, finally, clinical outcomes. Unserved populations then experience systemic disadvantage, so precision oncology becomes less available and discrepancies in survival and quality of life continue.

1. **Access to Precision Tools:** Some of the major recent advances in precision oncology, including genomics sequencing, immunotherapies, targeted medications, and digital health platforms, are largely limited to high-resource and urban medical institutions. The patients who live in rural or underserved communities or neighborhoods with low income often do not or cannot access these innovative interventions. These disparities are further enhanced by the absence of infrastructure, trained personnel and specialized facilities. Consequently, the patients in such environments might suffer late diagnosis, lack of treatment alternatives and lower survival rate. Precision oncology will not be a part of a universal standard of care unless intentional measures and initiatives to democratize access are implemented.
2. **Bias in Data and Algorithms:** Clinical decision-support systems and artificial intelligence (AI) have a tremendous opportunity to improve individualized cancer treatment. Most of these tools, however, are trained and trained on data sets that are imbalanced, with the minority communities, rural, and low socioeconomic groups being underrepresented. Such under-representation may cause systematic risk misclassification, incorrect predictions and less effective recommendations to underrepresented cohorts. Integrated into healthcare provision, these biases reinforce existing disparities by prioritizing the use of advanced tools to benefit the already represented populations in the data, as opposed to meeting the needs of marginalized populations.
3. **Financial Toxicity:** Precision oncology presents a serious obstacle to fair care because of its high cost. The expenses of genomic profiling, targeted therapies, regular monitoring, and supportive ancillary services can be excessive. Even insurance patients can have large out of pocket costs, leading to delayed care, rationing of care, or no therapy at all. Financial toxicity does not only decrease access to high-quality care but also increases stress, decreases compliance, and poor health outcomes. These economic

limitations must be tackled to make sure that precision oncology does not become an instrument of inequality against all groups but a source of meaningful returns.

4. **Cultural/Language Barriers:** Shared decision-making (SDM) is an essential component of effective cancer care and, therefore, it is based on effective and culturally competent communication. Low health literacy, low ability to use the dominant language of the health care system, or cultural distrust can result in patients being unable to comprehend complicated treatment choices or participate in care plans in their entirety. Such obstacles: these may diminish the involvement in clinical trials, restrict the use of survivorship and palliative care programs, and decrease the adherence to the recommended treatments. In the absence of culturally competent communication strategies, supportive programs, precision oncology might not come to or find a resonance with the populations that need it the most.

➢ **Moving Toward Equitable Personalization**

A clear emphasis on inclusivity, accessibility and fairness in cancer care on all dimensions is necessary to ensure equitable precision oncology is achieved. This includes putting in place measures to remove inequity in clinical research, care provision, and policy formulations, as well as proactively involving patients and communities in order to promote trust and intercultural sensitivity.

- **Design for Inclusion:** The clinical trial and data collection policies should be purposely structured to include patients who represent a wide range of populations based on race and ethnicity, geographical location and social economic status. This variety makes the findings to be general and relevant to other population subgroups. In addition to recruitment, predictive algorithms and models applied in precision oncology must be checked in these subgroups in particular to verify accuracy, avoid bias, and to ensure equity in treatment suggestions. Inclusive design also involves actively finding out impediments to participation, including logistical, financial or social ones, and working out specific approaches to address those.

- **Measure Equity:** The health systems must change their outlook on measuring outcomes in terms of simple aggregate outcomes including average survival rates or total toxicity. Rather, disaggregated reporting is necessary and that includes data stratified by gender, race, socioeconomic status, and geographic area. This method enables healthcare providers and organizations to detect the inequity in treatment

outcomes and prevent them. In addition, institutional incentives like funding, accreditation, or recognition can be associated with quantifiable equity-oriented interventions to promote systemic accountability and a long-term movement towards equitable care provision.

- **Close the Care Gaps with Widened Access:** As an important step to curb care disparities, it is essential to expand access to precision oncology. This may be done in a variety of ways: subsidized genomic testing ensures that patients do not get locked out of high-end diagnostics because of financial constraints; telemedicine can be extended into remote or underserved regions; community health navigators can simplify the complex care pathway; and the process of task-sharing with trained and skilled non-physicians can enhance capacity and scalability. Through these strategies, the health systems will be able to minimize the reliance on a small pool of professionals and to make more patients receive individualized treatment.

- **Policy/Reimbursement Reforms:** To have a fair measure of precision oncology, new policy and financing mechanisms are needed. Insurance coverage is to be extended to patient-reported outcome (PRO), survivorship care, rehabilitation, and digital health monitoring that have demonstrated to result in better clinical outcomes and patient satisfaction. Furthermore, reducing out-of-pocket payments are the key to preventing financial toxicity and providing equal care accessibility. Policymakers should take into account the models that can subsidize the high-cost interventions and implement preventive and supportive care as the part of the regular coverage, which can decrease disparities and encourage long-term health equity.

- **Community Engagement:** Culturally competent and trusted care is based on meaningful interaction with patients, caregivers and community organizations. Collaboration in the design of interventions with local stakeholders enhances chances that interventions are culturally relevant, acceptable, and can be sustained over time. Engagement of the community is also used to enhance the trust of patients in the healthcare systems, promoting adherence to treatment plans, and the delivery of care in ways that promote compatibility to the needs, values, and preferences of that community. Precision oncology can be brought to a more equal and patient-centered result by integrating communities into the design and implementation process.

REFERENCES

1. Colomer-Lahiguera, S., Gentizon, J., Christofis, M., Darnac, C., Serena, A., & Eicher, M. (2024, June). Achieving comprehensive, patient-centered cancer services: optimizing the role of advanced practice nurses at the core of precision health. In *Seminars in oncology nursing* (Vol. 40, No. 3, p. 151629). WB Saunders.
2. Adi-Wauran, E., Krishnapillai, S., Uleryk, E., Saeedi, S., & Bombard, Y. (2025). Patient-centred care in precision oncology: A systematic review. *Patient education and counseling*, 108753.
3. Madu, C., & Mofiyinfoluwa, A. V. (2025). Patient-centered care in precision medicine and end-of-life care in neuro-oncology: The role of nursing in enhancing quality of life and treatment outcomes.
4. Mao, J. J. (2020). Oncology acupuncture: precision medicine meets patient-centered care. *Medical Acupuncture*, *32*(6), 405-407.
5. Sedhom, R., Bates-Pappas, G. E., Feldman, J., Elk, R., Gupta, A., Fisch, M. J., & Soto-Perez-de-Celis, E. (2024). Tumor is not the only target: ensuring equitable person-centered supportive care in the era of precision medicine. *American Society of Clinical Oncology Educational Book*, *44*(3), e434026.
6. Baird, A. M., Westphalen, C. B., Blum, S., Nafria, B., Knott, T., Sargeant, I., ... & Wong-Rieger, D. (2023). How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action. *Health Science Reports*, *6*(6), e1349.
7. Anuyah, S., Singh, M. K., & Nyavor, H. (2024). Advancing clinical trial outcomes using deep learning and predictive modelling: Bridging precision medicine and patient-centered care. *arXiv preprint arXiv:2412.07050*.
8. Karimanal, H., & Bandaru, D. (2024). A review on integration of Precision Medicine in Oncology Practice. *Journal of Pharma Insights and Research*, *2*(3), 016-022.
9. El-Alti, L., Sandman, L., & Munthe, C. (2019). Person centered care and personalized medicine: irreconcilable opposites or potential companions?. *Health Care Analysis*, *27*(1), 45-59.
10. Marion, S., Ghazal, L., Roth, T., Shanahan, K., Thom, B., & Chino, F. (2024, October). Prioritizing patient-centered care in a world of increasingly advanced technologies and disconnected care. In *Seminars in radiation oncology* (Vol. 34, No. 4, pp. 452-462). WB Saunders.

11. Sharma, R., Kannourakis, G., Prithviraj, P., & Ahmed, N. (2022). Precision medicine: an optimal approach to patient care in renal cell carcinoma. *Frontiers in Medicine*, *9*, 766869.
12. Giordano, F. A., Welzel, G., Siefert, V., Jahnke, L., Ganslandt, T., Wenz, F., ... & Nicolay, N. H. (2020). Digital follow-up and the perspective of patient-centered care in oncology: what's the PROblem?. *Oncology*, *98*(6), 379-385.
13. Panagiotou, O. A., Högg, L. H., Hricak, H., Khleif, S. N., Levy, M. A., Magnus, D., ... & Cogle, C. R. (2020). Clinical application of computational methods in precision oncology: a review. *JAMA oncology*, *6*(8), 1282-1286.
14. Siegel, C. A. (2018). Refocusing IBD patient management: personalized, proactive, and patient-centered care. *Official journal of the American College of Gastroenterology| ACG*, *113*(10), 1440-1443.
15. Haque, A. (2025). Convergence of Minimally Invasive and Personalized Surgery: A New Era in Patient-Centered Care. *Asia Pacific Journal of Surgical Advances*, *2*(2), 81-83.

ABOUT THE EDITOR'S

Dr. Sanjeev Kumar is a Senior Resident in the Department of Biochemistry at ESIC MedicalCollege & Hospital, Bihta, Patna. He completed his M.D. in Biochemistry (Gold Medalist) andMBBS from IGIMS, Patna.He holds an Advanced Certification in Dermatology from the British Association of Dermatologists (NHS/HEE, UK) and a Master Diploma in Dermatology from MGBIMS, Delhi.Dr. Kumar also pursued a prestigious Post GraduateCertificate in AdvancedHealthcare Management jointly offered by IIM Nagpur and AIIMS Nagpur. Additionally, he has successfully completed the ICMR-certified Basic Course in Biomedical Researchand Clinical Laboratory Management under ISO 15189:2022 standards.With over seven years of diverse clinicaland academic experience, he has served as a General Duty Medical Officer (GDMO) & In-charge at DOS/East Central Railway and as a Nodal Medical Officer at Sadar Hospital, Jamui, Bihar. He is the first recipient from Bihar of the prestigious ICMR-STS Research Grant for his pioneering work on ELISA-based serodiagnosis. His research focuses on clinical biochemistry, immune-dermatology, biomarker discovery, molecular diagnostics, and AI-driven medical device innovation.

Dr Sanjana Bhagat, working as Assistant professor & HOD in the department of Biotechnology, Govt. Nagarjuna PG College of Science, Raipur, Chhattisgarh with 12 years of research and teachingexperience. Published Thirteen research articles in peer reviewed journals. Strong technical knowledge in Cell Biology, Immunology and Genetic Engineering. Thesis focus on molecular identification sickle cell disease haplotypes analysis. Good working knowledge of sickle haplotypes identification and bioremediation of environment pollutant. Many dissertation works supervised under her guidance. Expertized to work in research environment like environment biotechnology and molecular Biology.

Dr. Sumit Bhatt, an assistant professor and PhD Scholar in the department of oral and maxillofacial surgery at Rajasthan Dental College and hospital under Nirwan University Jaipur, completed his MDS (Gold Medalist) in 2022 and BDS (Topper) in 2016. He has earned 16 university awards, including the Pierre Fauchard Academy and International College of Dentistry honors. Recognized as the Best Undergraduate Student by Guident, Bitein, and Famdent journals, Dr. Bhatt won the Pepsodent quiz in 2013. He holds more than 25 patents and copyrights both national and international. Dr. Bhatt has authored more than 50 publications and also holds editorial board member's position in various journals.

Dr. Farah Deeba is an Assistant Professor of Pharmacology at the School of Pharmacy, Sharda University, Greater Noida. She holds a Ph.D. and M.Pharm in Pharmacology from Jamia Hamdard, a premier NIRF-ranked institution. With over seven years of teaching and four years of research experience, she has authored 15+ publications in reputed journals, including high-impact factor papers, and has participated in 50+ conferences nationally and internationally. Her work has earned her several awards, including the Highest Impact Factor Publication Award (2021), Best Poster Award (SNCI), and the Scholar Guidance Award (2023). She is actively involved in academic events, workshops, and industrial visits. Her research focuses on the endocannabinoid system in diabetes and therapeutic interventions.

NEXUS
KNOWLEDGE PUBLICATION
Imprint of AKT Multitask Consultancy

editor@nknpub.com
https://nknpub.com
Sarkanda Bilaspur, Chhattisgarh, India

ISBN:- 978-81-985724-3-1
9 788198 572431
MRP ₹499/-